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Glioblastoma Multiforme (GBM) makes up approximately 45% of all primary brain 
tumours. State of the art treatment at present involves concurrent and adjuvant 
temozolomide (TMZ) with radical radiotherapy which extends median survival from 12.1 
months (radical radiotherapy alone) to 14.6 months according to the study of the 
European Organization for Research and Treatment of Cancer (EORTC) Brain Tumour 
and Radiotherapy Groups and the National Cancer Institute of Canada (NCIC) Clinical 
Trials Group. Meanwhile, National Cancer Registry Ireland presented that GBM 
represents over 40% of all malignant brain tumours and had the worst five-year net 
survival (4%) compared to overall malignant brain cancer (five-year net survival, 19%) 
in Ireland. Long term survival of patients with GBM has not been significantly improved 
in the last 20 years. GBM tumours also have presented high level of resistance to normal 
treatments. Therefore, novel therapies to treat GBM are urgently needed. This study 
aimed to investigate efficient therapeutic methods by combining novel interventions, 
including cold atmospheric plasma (CAP), gold nanoparticles (AuNPs) and specific 
chemotherapeutic compounds to overcome the barriers of GBM treatment. Over the past 
decade CAP has emerged as a novel approach in health care area, especially cancer 
therapy. CAP generates chemically active species such as reactive oxygen species (ROS) 
and reactive nitrogen species (RNS) and has been demonstrated to act in synergy with a 
selection of traditional chemotherapeutic compounds which could reduce the effective 
concentrations of drugs needed at the tumour and may allow for targeted toxicity at sites 
exposed to the plasma field. AuNPs, well known as biocompatible drug delivery and 
diagnosis agents for cancer therapy, have been demonstrated to have synergistic anti-
cancer effects in combination with CAP treatment. 
In this project, for the first time, we investigated and described the detailed mechanism 
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behind the synergistic anti-cancer effects between AuNPs and CAP treatment. Chapter 2 
and Chapter 3 demonstrated that low dose treatment of CAP treatment was capable of 
promoting the uptake of AuNPs into glioblastoma U373MG cells via stimulated 
membrane repair clathrin-dependent endocytosis. The intracellular accumulation of 
AuNPs was tracked using atomic absorbance spectrometry (AAS) and simulated with 
numerical modelling to identify the enhanced uptake routine. AuNPs were tracked into 
early endosomes, late endosomes and finally lysosomes using specific fluorescent probes 
and confocal microscope. The lipid oxidation of cancer cells induced by CAP treatment 
was confirmed by various methods, including confocal microscopy, Thiobarbituric Acid 
Reactive Substances (TBARS) assay and flow cytometry. Meanwhile, the related 
endocytosis pathway was determined to be clathrin dependent using multiple clathrin and 
caveola specific inhibitors and clathrin siRNA.   
In Chapter 4, we performed the screening of 47 prodrug candidates for their cytotoxicity 
against U373MG cells in combination with CAP treatment. The selection of 
chemotherapeutic compounds provided by collaborators have been tested to determine 
dose response curves with or without CAP treatment using Alamar Blue assay, thus, to 
characterise their synergistic potential in combination with CAP. Two leading candidates 
which showed significant cytotoxicity with CAP, have been identified from 47 
compounds. Furthermore, the mechanism behind the synergistic cytotoxicity between 
one of the leading candidates, JW-04-061, and CAP treatment has been investigated. It 
has been demonstrated that reactive species, especially short-lived species, generated in 
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AAS  Atomic Absorbance Spectrometry 
AgNP Silver Nanoparticle 
AIC   5-aminoimidazole-4-carboxamide  
AKT  v-akt murine thymoma viral oncogene homolog  
ASK1   Apoptosis signalling regulating kinase 1 
ATP   Adenosine Triphosphate 
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CAP  Cold Atmospheric Plasma 
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CNS   Central nervous system  
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CT  Computed tomography  
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EEDF   The electron energy distribution function  
EGF Epidermal Growth Factor  
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EPR Enhanced permeation and retention  
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FAK   Anti-phospho-focal adhesion kinase  
FDA       The US Food and Drug Administration 
GBM Glioblastoma multiforme 
GSCs   Glioma stem-like cells  
GSH   Glutathione 
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GzmB   Cytotoxic protein Granzyme B 
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IR Ionizing radiation  
JNK  c-Jun N-terminal kinase  
LDH   Lactate dehydrogenase  
MAPK Mitogen-activated protein kinase 
MCM-41   Mobil Composition of Matter No. 41  
MCT Monocarboxylate transporters  
MDA   Malondialdehyde 
MGMT  Methylguanine methyltransferase  
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MRI  Magnetic resonance imaging 
MRS   Magnetic resonance spectroscopy  
MTIC   Monomethyl triazene 5- 3-methyltriazen-1-yl - imidazole-4-carboxamide 
NAC N-Acetyl Cysteine  
NADPH Nicotinamide adenine dinucleotide phosphate  
NCIC  Radiotherapy Groups and the National Cancer Institute of Canada 
NEU   Human epidermal growth factor receptor 2 
NP Nanoparticle 
NTAP   Non-thermal atmospheric plasma 
OES   Optical Emission Spectroscopy  
ON  Oligonucleotide 
p21  21-kDa protein  
P53   Protein 53  
PAM   Plasma activated medium  
PBS   Phosphate buffer solution  
pDNA  Plasmid DNA  
PEG   Polyethylene glycol  
PEGylated   Polyethylene glycol-coated 
PEI  Polyethylenimine  
PHAs   Polyhydroxyalkanoates 
PI   Propidium iodide  
PI3K Phosphatidylinositol 3-kinase  
PIP3 Phosphatidylinositol-3,4,5-trisphosphate  
PLGA   Poly- lactide-co-glycolic acid   
POD    Peroxidase  
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PSLs   pH-sensitive liposomes  
PTEN   Phosphatase and tensin homolog 
PVA  Polyvinyl alcohol  
rhTNF   Recombinant human Tumour Necrosis Factor  
RNS  Reactive Nitrogen Species 
ROS  Reactive Oxygen Species 
RS   Reactive species  
RT   Radiotherapy 
S.E.M  Standard error of the mean 
SBA-15   Santa Barbara Amorphous-15 
siRNA   Small interfering RNA 
SPR  Surface plasmon resonance  
SPS   Second positive system 
TBA Thiobarbituric acid 
TBARS  Thiobarbituric Acid Reactive Substances  
TMZ  Temozolomide  
TP53   Tumour suppressor protein 53 
TPPMS   Triphenylphosphine monosulfonate  
TRX  Thioredoxins  
TSLs   Thermo-sensitive liposomes  
WHO World Health Organization   
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CHAPTER 1. INTRODUCTION 
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1.1  Brain Cancer 
As technology improves, the survival rates of certain types of cancer, such as lung and 
breast cancer, have changed dramatically during recent years. However, only small 
improvements were made in brain cancer treatment. Brain cancers are divided in two 
types, primary brain cancer and secondary brain cancer (Young et al., 2015). Primary 
brain cancer originates in brain cells, forms in the central nervous system (CNS) and 
usually does not metastasize to the outside of the CNS. Secondary brain malignancy is 
formed by tumours cells metastasized from outside of CNS, such as lung cancer and 
breast cancer (Young et al., 2015). Although secondary brain cancer is more common, 
primary brain cancer is more deadly, which is the third leading cause of cancer deaths in 
age 15-34 adults and the most common cause of neoplasm deaths in children (Mladenov 
et al., 2007). Primary brain cancer can be classified as gliomas and nongliomas according 
to the origination (as described in Table 1 below). 
Table 1. Main types of primary brain cancer 
Gliomas Astrocytomas, Oligodendrogliomas, Ependymomas 
Nongliomas  Menigiomas, Medulloblastomas 
 
Gliomas are developed from glial cells, including astrocytes, oligodendrocytes and 
ependymal cells or mixed of the above (Parsons et al., 2008). Glial cells are non-neuronal 
cells in CNS and the peripheral nervous system which mainly provide protection and 
support for neurons (Jessen and Mirsky, 1980). Most common types of nongliomas 
include meningiomas, tumours that are developed in the meninges (Marta, Correa and 
Teixeira, 2011), and medulloblastomas, primitive neuroectodermal tumour that is raised 




Astrocytomas are the most common type (representing approximately 50%) in the above 
primary brain cancer. According to the World Health Organization (WHO), astrocytomas 
are classified into 4 types, including pilocytic astrocytoma (Grade 1), low-grade 
astrocytoma (Grade 2), anaplastic astrocytoma (Grade 3), glioblastoma (Grade 4) (Young 
et al., 2015). Grade 1 pilocytic astrocytomas glow slowing and typically can be cured by 
surgical excision (Louis et al., 2016). Low-grade astrocytomas, also known as diffuse 
astrocytomas, have higher possibility to recur and may further progress to higher grade 
astrocytomas, thus regarded as malignant tumours (Louis et al., 2016).  WHO grade 3 
and 4 astrocytomas grow much faster compared to the previous tumours mentioned above, 
when surgical excision is more difficult to be performed completely (Young et al., 2015). 
Thus, radiation therapy and chemotherapy are typically applied to control the progress of 
malignancy and extend survival. 
1.2  Glioblastoma Multiforme 
Glioblastoma, also known as glioblastoma multiforme (GBM), is the most invasive brain 
malignancy and the most common primary brain cancer among the previous tumours 
mentioned in section 1.1, accounts for 60-75% of astrocytic tumours and 15% of 
intracranial tumours in adults (Young et al., 2015). The term glioblastoma multiforme 
was first defined by Harvey Cushing and Percival Bailey in 1926, as the name implies, 
GBM is developed from glial cells, and presents highly various morphologies, as well as 
variable levels of cellular and nuclear polymorphism, which also is able to induce 
multiple symptoms, including cysts, haemorrhage and necrosis (Møller et al., 2013). 
Even “multiforme” is currently not used in WHO classification, GBM is still commonly 
accepted in the literature as abbreviation synonymous with glioblastoma. 
The most common symptoms of GBM include changes to personality, headaches, 
localized neurological problems, memory loss, mood or concentration, nausea, seizure 
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and vomiting (Alifieris and Trafalis, 2015). However, the type of symptoms induced has 
no specificity and mainly depends on the location of the neoplasm. Computed 
tomography (CT), Magnetic resonance imaging (MRI), Magnetic resonance spectroscopy 
(MRS) are commonly used to view suspected GBM. Craniotomy with tumour resection, 
stereotactic biopsy and pathology are typically required for definitive diagnosis. 
Furthermore, based on histological confirmation and genetic analysis, GBM can be 
divided into primary and secondary subtype. Primary GBM directly originates from glial 
cells (de novo), and develops faster, presenting much worse prognosis compared to 
secondary GBM. Secondary GBM is progressed from lower-grade (WHO Grade 2) 
astrocytoma which has been previously clinical identified. It should be noted that, as 
mentioned in section 1.1, all primary and secondary subtypes of GBM originate in brain 
cells, which are all primary brain cancer. Due to the difference between primary and 
secondary GBM, it is crucial to distinguish these two subtypes, especially identify 
primary glioblastoma to determine tumour therapy and prognosis. Although, primary and 
secondary GBM cannot be differentiate morphologically, clinical statistic presented that 
primary GBM was frequently diagnosed in patients older than 60 years, whereas 
secondary GBM more commonly occurred in patients younger than 45 years. The genetic 
make-up of primary and secondary GBM can be distinguished. The genetic alternation in 
primary GBM more commonly (40-50%) presents as over expression of Epidermal 
Growth Factor Receptor (EGFR), whereas tumour suppressor protein (TP53) mutations 
were usually (~60%) identified in secondary GBM (Riemenschneider et al., 2010).  
However, the current common chemotherapy agents showed little efficacy in the 
treatment of primary GBM which develops faster and has worse prognosis compared to 
secondary GBM (Clarke, Butowski and Chang, 2010; Tabunoki et al., 2012). Therefore, 
efficient novel therapy for primary GBM is urgently needed. The following sections will 
12 
 
focus on primary GBM treatment. U373MG glioma cell line was used for investigation 
of the treatment against primary GBM in this project. In the following sections, the term 
‘GBM’ was used to present primary GBM.  
Surgery typically is applied after diagnosis of GBM to remove the tumour as much as 
possible, followed by aggressive treatment, including radiotherapy or chemotherapy or 
combining of them (Gallego, 2015). TMZ is commonly used in chemotherapy, which is 
considered having relatively efficient killing effect to GBM cells compared with other 
drugs, therefore is used in standard treatment following maximal surgical resection (75 
mg/m2 TMZ daily, together with 60 Gy radiotherapy for 6 weeks) (Hart et al., 2013; 
Khosla, 2016). However, even when aggressive treatment was applied after operation, 
the neoplasm usually will recur and the prognosis is very dismal (Gallego, 2015). The 
length of survival is 12-15 month following diagnosis in most cases, and only less than 
3%-5% of patients survived longer than 5 years. The median survival without treatment 
is merely 3-4 months (Omuro and DeAngelis, 2013; Gallego, 2015). 
The largest cause of treatment failure is the strong resistance of GBM tumours to 
conventional therapies, including radiotherapy and chemotherapy. Tumour hypoxia is 
that tumour cells alter their metabolism to survival under oxygen deficit situation. As 
tumours grow, the insufficient blood supply and rapid proliferating of tumour cells limit 
the oxygen diffusing further into core area of the tumour. Therefore, to survive and 
proliferate under low oxygen condition, those hypoxic tumour cells dramatically changed 
their signalling pathway and following behaviour, which can lead to the resistance to 
radiotherapy compared to well-oxygenated cells (Gilkes, Semenza and Wirtz, 2014). 
Hypoxia is well known to exhibit in portions of GBM tumours. Spontaneous necrosis was 
frequently found in GBM tumours and considered as result of hypoxia (Brat et al., 2004). 
In 1994, Rampling et al. proved that hypoxic regions are present in glioblastomas via 
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directly measuring the oxygen level (varies from 9.5% to 68.5%, pO2) in tumours from 
10 patients (Rampling et al., 1994). Oxygen plays the key role in the cytotoxicity of 
ionizing radiation. The free electron of the free radical in DNA caused by ionizing 
radiation, can aggressively react with oxygen then causes covalent modification of DNA 
leading to damage of tumour cells and alteration of the sensitivity of tumour cells to other 
DNA damaging agents.  
However, under hypoxic conditions, the radical in DNA can be ‘neutralized’ when 
obtained hydrogen from non-protein sulfhydryls in tumour cells, which gives 
glioblastomas strong resistance to ionizing radiation (Brown, 1999). The alteration of 
signalling pathways in the absence of oxygen, such as hypoxia-inducible factor (HIF-1) 
and following pathways, also have been indicated that induce resistance to radiotherapy. 
At present, TMZ has been approved by the US Food and Drug Administration (FDA) and 
used as standard chemotherapy in GBM treatment. TMZ can alkylate the guanine base of 
DNA, thus leading to cell damage (Figure 1). Meanwhile, this alkylating agent can be 
effectively transported through the blood brain barrier (BBB) and get into GBM cells. As 
seen in Figure 1, TMZ acts a prodrug which is stable at acidic pH but labile above pH 7 
and spontaneously breaks down to form monomethyl triazene 5-(3-methyltriazen-1-yl)- 
imidazole-4-carboxamide (MTIC) (Zhang et al., 2011). MTIC then reacts with water to 
release 5-aminoimidazole-4-carboxamide (AIC) and the highly reactive 
methyldiazonium cation which methylates DNA (Tisdale, 1987; Zhang et al., 2011). 
Although the extracellular pH level in the environment of cancer cells is lower than that 
around normal cells whereas the acidic products/protons generated during rapid 
metabolism of cancer cells are actively transported to the extracellular space via Na+/H+ 
exchangers, Na+HCO3– transporters, Cl–/HCO3– exchangers and monocarboxylate 
transporters (MCT), etc. (Hjelmeland et al., 2011). The average intracellular pH level of 
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brain tumours was found to be 7.31, slightly higher than normal brain cells (7.24) (Hao, 
Xu and Li, 2018). In this case, GBM cells possess a more alkaline pH compared with 
healthy tissue, therefore favouring TMZ activation preferentially within tumour tissue 
DNA (Rottenberg et al., 1984; Zhang et al., 2011).  
 
Figure 1. Structure and activation route of prodrug temozolomide (Zhang et al., 2011). 
However, it has been demonstrated that glioblastomas also present resistance to TMZ 
treatment (Mirimanoff et al., 2007; Hegi et al., 2008). The enzyme, methylguanine 
methyltransferase (MGMT), can attach to damaged DNA and obtain the alkyl group from 
guanine. The alkylated MGMT then will be detached and finally be degraded via 
ubiquitin/proteasomal system (Zhang et al., 2011). The expression level of MGMT is 
increased in GBM cells, thus resulting in resistance to TMZ treatment. Meanwhile, it has 
been found that TMZ has little or no effect on prognosis in up to half GBM 
(FERNANDES et al., 2017). 
Various radiosensitizers, such as oxygen diffusion-enhancing compound trans sodium 
crocetinate, have been investigated in preclinical and clinical trials with limited success 
(Gainer et al., 2017). More powerful techniques, molecular targeted therapy (such as HIF-
1 inhibitors) and hypoxia-selective drugs, etc. were investigated to beat glioblastomas 
(HARADA, 2011). However, the limitations of conventional treatment in GMB therapy 
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haven’t been overcome and novel efficient therapeutic methods with low side effects are 
still urgently needed. 
1.3  Plasma 
Plasma is one of the four fundamental states of matter which is a form of ionized gas, 
usually, and accounts for most of the known Universe’s matter. Its early stage of 
biomedical applications is focus on the heat and high temperature of thermal plasma for 
the purpose of tissue removal, sterilization, and cauterization (Fridman et al., 2008). 
1.3.1 Clinical Application of Hot Plasmas 
Hot plasmas, also known as high temperature/thermal plasmas, have been widely used 
for sterilization, blood coagulation, tissue ablation and tumour therapy, etc. The high 
temperature and kinetic energy generated by thermal plasmas device are utilized to 
coagulate, cut or ablate tissue surfaces (Heinlin et al., 2010; Gibson and Suslov, 2012). 
In the mid-1970s, Glover et al. first reported a convenient thermal plasma device with a 
nozzle that was capable of generating high power density of plasma flow by a low gas 
flow, which was able to both coagulate and cut tissue and showed that plasma scalpel is 
effective in cauterizing blood vessels and causes less damage compared with 
steel/electrosurgical scalpels (Link, Incropera and Glover, 1976). This design rapidly 
gained ground in surgical operation and has been developed further to invent the 
PlasmaJet system. 
The PlasmaJet system has been used in clinical surgery since 2004, using small scale, 
high-thermal and high-kinetic argon plasma jet to effectively ablate, coagulate a tissue 
surface (Roman et al., 2013). The PlasmaJet causes slight thermal tissue damage (seldom 
more than 600 μm) with the formation of a filmy coagulum (Deb et al., 2010). It has 
shown safety and high performance in plastic surgery, hepatic surgery, gastroenterology, 
orthopedics and thoracic surgery (Nezhat and Kho, 2009). More recently, PlasmaJet and 
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other thermal plasma devices have been investigated as safe and effective modalities for 
treatment of tumours which are untreatable by surgery (Sagawa et al., 2003; Roman et 
al., 2013). For instance, using PlasmaJet in ablation of endometrioma showed 
encouraging recurrence and pregnancy rates compared with the best reported results of 
endometrioma cystectomy, may be due to the fact that the surgeon can select appropriate 
degree of completeness of treatment and keep enough normal endometrial tissues by the 
plasma operation (Roman et al., 2013). Meanwhile, electrically neutral thermal argon 
plasma technology has been demonstrated that can maximize cancer cell killing effects 
and decrease tumour burden in several cases of epithelial ovarian cancer (Renaud and 
Sebastianelli, 2013). In gynecological oncology cases, PlasmaJet also is used to minimize 
the damage to the underlying tissue when removing secondary tumour from the sensitive 
or vital structures, such as ureter, bowel and liver (Madhuri et al., 2010). 
1.3.2 Cold Atmospheric Plasma 
Technological advances have allowed researchers to generate cold atmospheric plasma 
which possesses ambient temperatures and approximately 1.0 atmospheric pressure, 
compared to hot plasma. Even though hot and cold plasma are both generated by adding 
energy to a gas, releasing electrons from nuclei of atoms, electrons in cold plasma can be 
at several million K whereas the nucleus of atoms are at room temperature 
(thermodynamic disequilibrium state).  These are known as cold (or non-thermal/low 
temperature) atmospheric plasmas. The application of cold atmospheric plasma allows 
direct treatment of cells or live tissues with ionised gases without risking thermal injury. 
Cold atmospheric plasma (CAP) has been investigated as a promising technique for 
therapies in various fields. Known biomedical applications of CAP include cancer 
therapy (Keidar et al., 2011), sterilization (Zelzer et al., 2012), wound healing (Isbary et 
al., 2012) blood coagulation (Kalghatgi et al., 2007) and viral destruction (Shi et al., 
17 
 
2012). CAP has also been investigated as a novel method to enhance cell transfection 
(Leduc et al., 2009) and promote cell proliferation (Kalghatgi et al., 2010). 
CAP generates a unique physical and chemical environment activating short- and long-
lived reactive nitrogen species (RNS, e.g.  peroxinitrite (ONOO-), nitric oxide radicals 
(NO)) and reactive oxygen species (ROS, e.g. hydroxyl radicals (OH), oxygen atoms (O), 
oxygen negative ions (O2-)), photons as well as generation of heat, pressure gradients, 
charged particles, and electrostatic and electromagnetic fields (Stoffels, Kieft and Sladek, 
2003; Kong, Keidar and Ostrikov, 2011; Babington et al., 2015), many of which are 
known to induce  biological effects. For example, peroxinitrite (ONOO-), which also 
occurs naturally (Babington et al., 2015), can initiate lipid peroxidation reactions and help 
to protect against infection during inflammation (Patel et al., 1999) whereas ROS can 
cause damage to DNA and induce apoptosis by activating the cell death receptors in the 
TNF/NGF-family (Stoffels, Sakiyama and Graves, 2008). These high flux of ROS also 
have significant effect in inactivating fungi, virus and bacteria (Fridman et al., 2008; 
Kong et al., 2009; Park et al., 2014). 
Figure 2. The dielectric barrier discharge (DBD) plasma source (Lu et al., 2014). 
CAP can be generated by several different principles such as dielectric barrier discharge 
(DBD) plasma sources, atmospheric pressure plasma jet and corona discharge plasma 
sources (Weltmann et al., 2008; Hähnel, Von Woedtke and Weltmann, 2010; Ehlbeck et 
al., 2011; Wu et al., 2011; Park et al., 2012; Haertel et al., 2014; Babington et al., 2015).  
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Different gases such as air, argon, helium, oxygen and nitrogen can be used which alter 
the physical and chemical properties of the CAP (Babington et al., 2015). Cold 
atmospheric plasmas can be divided into three types in accordance with the interaction 
with target cells / tissues: direct plasmas, indirect plasmas and hybrid plasmas (Kong et 
al., 2009). 
The dielectric barrier discharge (DBD) plasma source is known as the most widely used 
direct plasma. The electrical discharge is generated between two electrodes separated by 
a dielectric barrier. The dielectric cannot pass direct current and prevents the rise of arcing 
after breakdown (Kuchenbecker et al., 2009). The prototype DIT-120, DBD plasma 
source used in this project, consists of two circular aluminium plate electrodes over 
perspex dielectric layers, a high voltage transformer and a voltage variac (Figure 2). The 
applied voltage to the electrode is obtained from the voltage transformer (Lu et al., 2014; 
Pankaj et al., 2014). The two electrodes are separated by a dielectric barrier and the 
discharge is generated between these two electrodes to ionize gas and create plasma 
(Babington et al., 2015). The treated sample has direct contact with all agents in DBD. 
The main difference between indirect plasmas and direct plasma is that the plasmas 
generated between two electrodes are then mixed into a gas flow to treat samples remotely 
in indirect plasmas devices. This technology is also called the atmospheric pressure 
plasma jet, Figure 3 (Cullen and Milosavljević, 2015), and has developed various devices 
from large ‘plasma torches’ to very narrow ‘micro plasma jet’ (Laroussi, 2002; Kieft, 
Laan and Stoffels, 2004; Sladek and Stoffels, 2005; H. W. Lee et al., 2009; Kong et al., 
2009; Babington et al., 2015) . Corona discharge plasma source is also known as ‘barrier 
coronal discharges (BCD)’, BCD introduce a grounded wire mesh electrode and combine 
the current-free property of indirect plasmas and the production technique of direct 
plasmas (Morfill et al., 2009). As seen in Figure 4, the BCD device can be safely applied 
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on human body for disinfection. 
Figure 3. kINPen® MEDTM plasma source.  
Photograph of kINPen® MEDTM plasma source (right) with the schematic of the entire 
system (left). It’s a commercially available plasma jet with pure argon as a carrier gas 
(Cullen and Milosavljević, 2015). 
Figure 4. ‘HandPlaSter’, a prototype of corona discharge plasma source (Morfill et al., 
2009). 
Cold atmospheric plasmas have been proved to have various effects on mammalian cells, 
such as stimulating proliferation or inducing proliferation arrest, necrosis and apoptosis. 
All these responses are dependent on the type and dose of CAP and the type of cell being 
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treated (Kim et al., 2010; Kalghatgi et al., 2011). At present, it is promising that there are 
a great variety of CAP generating prototypes and commercial cold atmospheric plasma 
devices. With different devices, by alternation of gas types, voltage, frequent and current 
of energy input, etc., the dose and location of applied CAP can be precisely and easily 
controlled to induce specific reaction to targeted area (Adhikari et al., 2020). Most 
importantly, cancer cells are generally sensitive to low doses of CAP and can 
subsequently undergo apoptosis. These doses often do not produce any measurable 
cytotoxic effect on corresponding normal cells (Ahn et al., 2011; Keidar et al., 2011; Siu 
et al., 2015). As described above, the wide range and high amounts of reactive oxygen 
species and reactive nitrogen species (ROS/RNS) generated by plasma were proposed to 
play the major role in the selective cytotoxicity (Walk et al., 2013). It also showed that 
CAP can likely induce cancer cells to produce more of their own ROS/RNS (Keidar et 
al., 2011). However, the exact mechanism of CAP is not fully understood. Previous 
research has proposed several mechanisms for the selective toxicity of cold atmospheric 
plasmas, including membrane disruption, mitochondrial dysfunction, DNA damage, 
deregulation of signal pathways, protein up/down regulation, cell cycle arrest and finally 
apoptosis/necrosis/ autophagy. 
CAP have been demonstrated to induce the S-nitrosylation of  SH-groups in proteins and 
thereby cause inactivation of proteins function (Ishaq, Evans and Ostrikov, 2014). In 
addition, ROS can cause lipid peroxidation by interacting with unsaturated fatty acid. It 
has been found that CAP treatment could cause the loss of cancer cell membrane integrity, 
induce the leakage of cellular content (Siu et al., 2015) and promote the transmission of 
ROS/RNS into cells by  S-nitrosylation, lipid peroxidation and creating rifts in the 
membrane (Halliwell, 1991; Rao, Hale and Ormrod, 1995; Bestwick et al., 2001; 
Babington et al., 2015). Nina Recek et. al have studied the differential effects of CAP on 
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cell membrane of normal human astrocytes and human glioblastoma cells by atomic force 
microscopy (Recek et al., 2015). CAP didn’t harm E6/E7 cells but only caused temporary 
disappearance of microvilli structure on cell membrane, whereas plasma treatment  
caused selective apoptotic effect on the GBM cells along with granular elevations and 
bigger clusters were observed on the surface of GBM cells (Recek et al., 2015). These 
different effects on cell membrane may indicate the potential mechanisms of selective 
toxicity of CAP (Recek et al., 2015). In the meantime, the cold atmospheric plasma 
treatment has been shown to cause enhanced mitochondrial transmembrane permeability 
and possible release of proapoptotic factors by depolarizing the mitochondrial membrane 
potential via generation of free radicals. And the plasma-induced cell apoptosis has been 
proved to be mediated partially by mitochondria-dependent caspase cascade (Ahn et al., 
2011). 
After CAP treatment, it was found that cellular DNA was damaged with increasing 
intracellular levels of ROS (Babington et al., 2015). In addition, plasma treatment has 
been proved to selectively induce the deregulation of several genes in cancer cells. These 
genes are intimately associated with multiple pathways, including cell adhesion, cell 
proliferation, growth regulation and cell death. Some of these pathways are involved in 
cancer processes and their deregulation may be the potential reason of tumour ablation 
while treating CAP. Notably, the genes related with oxidative stress and apoptotic 
pathways were significantly deregulated in tumour cells by plasma treatment, which 
could potentially help explain the plasma-induced apoptosis mechanism (Keidar et al., 
2011). 
At present stage, the short-lived and long-lived reactive species generated by cold 
atmospheric plasma are considered playing key role in selective cytotoxicity to cancer 
cells. In the following section, the interaction between reactive species and tumour cells 
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will be detailed introduced. 
1.4 The Intracellular Reactive Species and Signalling Pathway 
Affected by CAP 
Reactive oxygen species (ROS) are a group of highly reactive molecules that have been 
identified as important regulators of many signaling pathway. Moderate levels of ROS 
are generated during normal cellular metabolism progress and participate in cellular 
signalling and several cellular functions by reversibly oxidizing/modifying protein 
structure (Ray, Huang and Tsuji, 2012; Perillo et al., 2020). Meanwhile, uncontrolled 
ROS have long been known as initiating tumourigenesis, which can cause oxidative 
damage to lipid, proteins and DNA or disrupt oxidative signalling to promote cancer-
causing mutations and cell proliferation (Perillo et al., 2020). Some epidemiological 
evidence exists for this, including the observation that a diet high in natural anti-oxidants 
is generally associated with lower incidence of various cancers. Thereby, antioxidant food 
and supplements have been considered as weapon to prevent cancer for a long term. 
As understanding deepens, ROS were found to be a double-edged sword to cancer cells. 
Evidence shows that higher level of ROS were generated in cancer cells, compared to 
normal cells, due to higher metabolic activities and more rapid proliferation of 
transformed cells (Schumacker, 2006). Hence, the cellular antioxidant system works 
under heavier load to protect tumour cells from oxidative stress, suggesting it may be 
possible to selectively eliminate them with inducers of tumour ROS (Trachootham, 
Alexandre and Huang, 2009). 
One hypothesis for the increased production of ROS in tumour cells is the difference in 
metabolism between normal and cancer cells. Cancer cells require more biomass 
synthesis per unit time due to the unregulated and relatively rapid cell growth and 
proliferation (Harris et al., 2015). It has been found a phenomenon called “the Warburg 
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effect” that cancer cells rely primarily on glycolysis and lactic acid fermentation to 
generate energy, whereas most other nucleated cells generate adenosine triphosphate 
(ATP) by oxidative phosphorylation (Vander Heiden, Cantley and Thompson, 2009). To 
deal with higher intracellular ROS levels, tumour cells synthesise nicotinamide adenine 
dinucleotide phosphate (NADPH). NADPH is utilized as a reducing equivalent to reduce 
thioredoxins (TRX), peptides that in turn reduce oxidized proteins such as peroxiredoxins, 
a family of hydrogen peroxide-scavenging enzymes (Sabharwal and Schumacker, 2014). 
NADPH is also involved in the generation of the antioxidant glutathione (GSH), an 
important tripeptide in antioxidant systems (Harris et al., 2015). Despite the increased 
expression of antioxidant systems, cancer cells generally have a higher baseline 
intracellular ROS which strains the antioxidant capacity of tumour cells to deal with 
additional oxidative stressors (Harris et al., 2015). With the excessive intracellular levels 
of ROS, lipids, proteins and DNA can be damaged in cancer cells, leading to lipid 
peroxidation-initiated oxidative stress, inhibition of phosphatases, alternation of 
cytoplasmic and nuclear signaling, disruption of epigenetic modulators, etc., and 
eventually apoptosis, autophagy or ferroptosis of cancer cells (Perillo et al., 2020). 
Therefore, the reactive species generated by CAP can be selective toxic to tumour cells 
which can be exploited for efficient, specific and low side effects anticancer strategies. It 
has been shown that CAP treatment regulates possible signalling cascades implicated in 
cancer cell death, such as stress kinases pathways and growth signalling pathways, etc. 
Meanwhile, it also has been found that the interaction of CAP with proteins and 
interrupting of cell cycle play important roles in CAP-induced selective cell death, as 
detailed below. 
1.4.1 Stress Kinase Pathways 
Mitogen-activated protein kinase (MAPK or MAP kinase) is involved in the regulation 
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of various cellular functions, including apoptosis, differentiation, gene expression, 
mitosis and proliferation. c-Jun N-terminal kinase (JNK) is also involved in multiple 
pathways which are responsive to apoptosis, differentiation and stress stimulation, 
including ROS, ultraviolet radiation, heat and osmotic shock. (Tobiume et al., 2001).  
Elevated accumulation of intracellular ROS was found to activate p38α MAPK/JNK by 
the activity of Apoptosis signalling regulating kinase 1 (ASK1) (Elenitoba-Johnson et al., 
2003; S. P. Li et al., 2003). ASK1 is one of the regulators of pathways involving p38α 
MAPK and JNK. Then p38α MAPK results in the activation of several tumour 
suppressors, including protein 53 (P53) (Bulavin and Fornace, 2004), Cdc25 
phosphatases (Manke et al., 2005) and pro-apoptotic members of B-cell lymphoma 2 
(Bcl2) family (Ishaq, Evans and Ostrikov, 2014), leading to caspases-dependent 
apoptosis of cancer cells (Figure 5). Inhibitory members of Bcl-2 family are capable of 
inhibiting the release of cytochrome c from mitochondria and in turn lead to the inhibition 
of caspases in the apoptosis pathway (Küpper et al., 2014). P53 is able to downregulate 
the production of anti-apoptotic Bcl-2 members  promote phosphorylation of the 
inhibitory Bcl-2, then stimulate caspases pathway (Ling et al., 2002) (Figure 5). 
Phosphorylation of inhibitory Bcl-2 members has been observed after CAP treatment in 
a study using Hela and lung cancer cells (Ahn et al., 2014).  
Figure 5. CAP affected stress kinase pathway.  
Excessive intracellular ROS generated by plasma can stimulate TNF pathway and inhibit 
CBR1 and GSTP1, leading to the activation of downstream JNK or p38α MAPK, which 
finally induces caspase-dependent tumour cell apoptosis. 
Similarly, the signalling cascade of the stress-activated protein kinase JNK is important 
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and involved in cellular environment adaptiveness and several physiological processes, 
including inflammation, proliferation and apoptosis (Ishaq, Evans and Ostrikov, 2014). 
The augmented level of intracellular ROS also has been indicated that may activate JNKs 
by blocking stress-response proteins such as Glutathione S-transferase pi 1 (GSTP1) and 
carbonyl reductase 1 (CBR1), leading to tumour cells suppression and growth arrest by 
stabilizing p53 and stimulating the caspase cascade (Ishaq, Evans and Ostrikov, 2014) 
(Figure 5). There’s evidence that pre-treatment of HeLa cells with antioxidants, JNK and 
p38 inhibitors, and JNK and p38 siRNA inhibits mitochondrial membrane depolarization 
and reduced plasma-induced cancer cell death (Ahn et al., 2014).  
The exact mechanisms for activation of JNK and P38 is not fully clear, although in a 
study using melanoma cells, upregulation of TNFR1 and TNFα was observed when 
incubated with CAP. This was accompanied by an increase in active caspases and could 
be reversed using TNFR1 blocking antibodies. Interestingly, increased expression of 
TNFR1 and TNFα was only observed in malignant melanoma cells and not in 
melanocytes (Ishaq et al., 2014). 
1.4.2 Growth Signalling Pathways 
CAP can directly interact with growth signalling pathways. For example, the 21-kDa 
protein (p21), known as a tumour suppressor encoded by gene WAF1/CIP1, was found 
to inhibit the activities of cyclin-dependent kinase which is required for progression of 
the cell cycle (Wade Harper et al., 1993). The expression of p21 provided another 
pathway to inhibit tumour growth whilst normal p53 function is lost in half of all tumours. 
It has been found that excessive level of intracellular ROS induces the expression of p21 
as a consequence of oxidative damage, which is independent of p53 (Russo et al., 1995). 
Secondary GBM often shows p53 mutation whereas primary GBM mainly contain EGFR 
amplification as the principal mutation and rarely present p53 genetic alteration 
26 
 
(Watanabe et al., 1996). The EGFRvIII, a ligand-independent constitutively active 
mutant of EGFR which is often associated in primary GBM, is keeping activating the 
phosphatidylinositol 3-kinase (PI3K)/v-akt murine thymoma viral oncogene homolog 
(AKT) signaling pathway, thus promotes the survival of primary GBM cells (Li et al., 
2004; Tabunoki et al., 2012). PI3K/AKT pathway is known as a oncogenic signalling 
disturbed in many human tumours, which plays an important role in tumour development 
and affect the response of cancer cells to tumour treatment (Fresno Vara et al., 2004). 
PI3K binds to the growth factor receptors on cell membrane while the receptor is 
activated, and then converted to phosphatidylinositol-3,4,5-trisphosphate (PIP3). PIP3 
induces the activation of several signalling proteins, including PKB/AKT, subsequently 
leading to survival, growth and proliferation of cells via various signalling pathways 
(Fresno Vara et al., 2004). AKT phosphorylates and inhibits p21 by sequestering it in the 
cytoplasm (Zhou et al., 2001). Therefore, excessive intracellular ROS generated by 
plasma can potentially activate p21, counteract the PI3K/AKT pathway and control 
tumour cell growth (Ishaq, Evans and Ostrikov, 2014) (Figure 6).  
Figure 6. Cold plasma affected growth signalling pathway.  
The induced generation of ROS can counteract PI3K/AKT pathway and induce growth 
arrest of cancer cells via activation of p21, PTEN and INK4a/ARF. 
Intracellular ROS is also capable of inhibiting PI3K/AKT by activating several other 
tumour suppressors, including phosphatase and tensin homolog (PTEN) and INK4a/ARF 
(Ishaq, Evans and Ostrikov, 2014). PTEN downregulates the level of PIP3 by 
dephosphorylating it and inhibits the phosphorylation/activity of AKT(Stambolic et al., 
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1998). INK4a/ARF encodes two proteins p16 and p14 respectively, which are required 
for the activation of PTEN (Maehama and Dixon, 1999; Uhrbom et al., 2002). 
1.4.3 Protein Interactions 
CAP can directly modify cellular enzymes and structural proteins. For instance, CAP are 
able to enhance lipase activity (Li et al., 2011), inactivate lysozyme in aqueous solution 
(Takai et al., 2012), decrease peroxidase (POD) activity in fruits and vegetables (Pankaj, 
Misra and Cullen, 2013), and inactivate lactate dehydrogenase (LDH) in the phosphate 
buffer solution (PBS) (Zhang et al., 2015). The changes of protein activity could be 
mainly due to the interaction between protein and the long-lived reactive species (RS) 
generated by CAP. These long-lived RS, such as ozone (O3) and hydrogen peroxide 
(H2O2) can modify many amino acids (Cataldo, 2005)  and denature proteins by oxidizing 
them (Nordberg and Arnér, 2001). Therefore, the modification of amino acids can lead 
to the secondary structure changes or protein-protein cross-linkage. The structure changes 
in the active centre will significantly affect protein activity and protein-protein cross-
linkage may cause the molecular aggregation between proteins and then decrease the 
amount of viable exposed active sites (Zhang et al., 2015). Especially, cysteine was found 
to be the most sensitive of the 20 amino acids to oxidizer. The oxidation of thiol group 
on the cysteine residue can affect the function of proteins, including several antioxidant 
small molecules or enzymes, including thioredoxin, peroxiredoxin and glutathione 
peroxidase, which further reduces the capacity of the antioxidant system of targeted 
cancer cells and facilitates the cytotoxicity of extracellular ROS generated by CAP 
treatment (Yan et al., 2015). 
1.5 Nanoparticles in Cancer Therapy 
Cancer treatment can be affected by a combination of physical, chemical and biological 
technologies. Due to the considerable variation between types and status of tumours and 
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individual patients, the efficiency of cancer therapy is difficult to guarantee and 
commonly associated with side effects and off-target toxicity can be daunting (Chen et 
al., 2017). However, recent technological advances have led to the development of new 
nanotechnological approaches for cancer therapies, which promise high-precision ways 
to beat cancer. Nanotechnology can be combined with chemotherapy to facilitate targeted 
delivery into cancer tissue with high specificity and efficacy (Ferrari, 2005). 
Nanoplatforms allow more accurate, non-invasive and real-time cancer diagnosis and 
monitoring during therapy using magnetic resonance imaging, ultrasonography, etc. 
(Alexis et al., 2008; Baetke, Lammers and Kiessling, 2015; Zaimy et al., 2017) Adjuvant 
nanotechnological devices are used in cancer interventions such as radiotherapy (Wu et 
al., 2016), photodynamic therapy (Clement et al., 2017) and sonodynamic therapy (H. 
Xu et al., 2016), which are capable of achieving considerably higher precision of 
treatment and reduced side effects. After decades of developing the understanding of 
nanotechnology, cancer-related nano-treatments have undergone extensive preclinical 
and clinical-trial studies and shown promising results (Chen et al., 2017). Bregoli et al. 
have summarised the current state of the art of nanomedicines undergoing clinical trial 
and clinically-approved nanomedicines for cancer therapies (Bregoli et al., 2016). 
The traditional definition of a nanotechnological device for cancer treatment is that the 
essential components of the device or the device itself are artificial, and have at least one 
dimension in the 1-100 nm range (Whitesides, 2003; Ferrari, 2005). It has been suggested 
that there should be less emphasis on the exact definition of size which could be extended 
to a range of 1–1,000 nm, and define the approaches to bionanotechnology according to 
their function and purpose (Ferrari, 2005). According this definition, nanotechnologies 
used in cancer treatment include drug-delivery, therapeutic nanovectors, nano-sensitizers, 
diagnostic agents and macroscopic devices with essential nanocomponents such as 
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microarrays/ ‘nanoarrays’, nanocantilever arrays and silicon nanowires for highly-
specific and highly-efficient molecular detection and diagnostic (Ferrari, 2005). The 
recent advances and use of these emerging nanotechnological treatments for cancer is 
briefly reviewed in this section with an emphasis on nanotechnologies used for drug-
delivery.  
The applications of nanoparticles in pharmacology have been investigated over the last 
three decades and a new generation of vehicles for delivery of biomedical compounds 
has emerged (Couvreur and Vauthier, 2006). Nano-scale carriers have been exploited for 
drug delivery, drug targeting, histological engineering, tissue targeting and labelling 
(Kong, Keidar and Ostrikov, 2011). The evolution of nanotechnology enables researchers 
to synthesize a wide variety of nanoparticles with distinct functions and characteristics. 
Such nanomaterials can be functionalised with molecular and imaging probes or bioactive 
compounds which can be conjugated, linked, coated or adsorbed to them, in order to 
implement specific functions (Kong, Keidar and Ostrikov, 2011). 
For cancer therapy, nanoparticles have been demonstrated to provide site-specific 
delivery by incorporation of various targeted ligands to bind to the desired site or utilizing 
stimuli-responsive strategies. Targeted ligands can include various compounds (e.g. 
antibodies, peptides, hormones, receptor ligands, nucleic acids and lipid derivatives) 
(Eckmann et al., 2014). Functionalized nanoparticles are capable of responding to one or 
more physical, chemical, biochemical or environmental stimuli, including osmotic 
pressure, hydrodynamic pressure, vapor pressure, mechanical force, magnetics, 
sonophoresis, iontophoresis, hydration, electricity, pH, salt concentration, hydrolysis, 
enzyme, temperature, light and hypoxia, etc. (Bennet and Kim, 2014) In addition, 
nanocarriers can prolong circulation time and are incapable of diffusing across non-
fenestrated endothelium, thus enabling accumulation in the tumour tissues, resulting in 
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enhanced permeation and retention (EPR). Notably, however, it has been pointed out that 
precise prognosis should be based on comprehensive characterisation of an individual 
tumour, rather than broadly on the EPR effect (Chen et al., 2017). 
The term nanoparticle can encompass a variety of materials, including liposomes, 
nanogels and polymer-based nanoparticles, silicon and silica nanoparticles, dendrimers, 
metal-based nanoparticles, and combinations of the above. This section reviews the recent 
developments of nanoparticles for effective cancer treatment and provides related content 
that can be used for reference. 
1.5.1 Liposomes 
Liposome platforms have attracted considerable attention from the academic and clinical 
arenas and have become one of the most studied biomaterial nanoparticles, due to the fact 
that liposomes can significantly improve the efficiency of a drug by increasing its 
solubility, overcoming resistance, controlling its targeted release and modifying its 
biocompatibility, bioavailability and safety profile. There have been several clinically 
approved liposome-based nanomedicines for cancer therapies, such as Doxil, Myocet, 
Mepact, Dauno Xome, Depocyt, Marqibo and MEPACT (Bregoli et al., 2016). Moreover, 
advances in liposome research have led to the emergence of hundreds, even thousands, 
of different functional liposomes for various tumours, which have been tested in 
preclinical research and clinical trials (Ferrari, 2005; Bregoli et al., 2016). According to 
their number of bilayer membranes, liposomes are grouped into unilamellar and 
multilamellar vesicles (Zununi Vahed et al., 2017). Unilamellar vesicles have a single 
lipid bilayer, while multilamellar vesicles consist of several unilamellar vesicles 
surrounded by lipid bilayers. On the another hand, according to the formulation, 
liposomes can be grouped into several types, including PEGylated stealth liposomes 
(Couvreur and Vauthier, 2006), immunoliposomes (Tila et al., 2015), lipoplexes (Lonez, 
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Vandenbranden and Ruysschaert, 2008), fusogenic liposomes (Yuba et al., 2010), 
stimuli-responsive liposomes (Zununi Vahed et al., 2017) and combinations of the above. 
(Couvreur and Vauthier, 2006) 
Nanoparticles, including liposomes, can be rapidly cleared from the bloodstream by the 
mononuclear phagocytic system (MPS), significantly decreasing in-vivo circulation half-
life and the delivery efficiency of drugs (Bregoli et al., 2016). Therefore, for a longer 
circulation time, it is critical to protect liposomes from MPS detection. Doxil, the first 
clinical approved nanomedicine for cancer therapy, is made of polyethylene glycol-
coated (PEGylated) liposomes containing anti-cancer drug doxorubicin (Bregoli et al., 
2016). Coating liposomes with polyethylene glycol, which is a class of biocompatible, 
inert and hydrophilic polymer, results in significant increases of the circulation half-life, 
from several hours to around 45 h, achieving sustained and prolonged drug delivery, and 
promoting tumour accumulation of liposomes (Couvreur and Vauthier, 2006). PEGylated 
stealth liposomes have been widely applied in the clinic and are easily functionalised with 
other functional features, such as stimuli-responses and ligand targeting (Tila et al., 2015). 
Alternatively, sustained release of a drug from MPS cells, more complex liposomal 
formulations (e.g. small size, net neutral charge, incorporation of cholesterols and lipids), 
or drug release into specific areas, such as the cerebrospinal fluid, non-PEGylated 
liposomes have been demonstrated to result in an increase in the tumour exposure to the 
drug (Bregoli et al., 2016). 
Attaching targeting ligands to the liposome surface is now a well-established and widely 
used feature in liposome design. Liposomes functionalised with antibodies, also known 
as immunoliposomes, can carry a drug dose and selectively bind to a chosen tumour site, 
whilst antibody fragments, glycoproteins, peptides, vitamins and oligonucleotide 
aptamers can also be used as targeting ligands (Zalipsky et al., 1996; Park et al., 1997; 
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Mastrobattista, Koning and Storm, 1999; Gunawan and Auguste, 2010; Tila et al., 2015). 
Gene therapies have been considered as a novel and promising method for cancer 
treatment. Lipoplexes (cationic liposomes) have been investigated as an attractive gene 
delivery system that are simple to synthesize and control, have high delivery efficiency 
and can enhance the stability of nucleic acid therapeutics (Tila et al., 2015). Cationic 
lipids used in lipoplexes are comprised of a cationic head and hydrophobic domain and 
have the capacity to form particulate complexes in the liposomal membrane by interacting 
with nucleic acids therapeutics (negatively charged), including plasmid DNA (pDNA), 
small interfering RNA (siRNA) or micro-RNA (Tila et al., 2015). 
Fusogenic liposomes are able to fuse with cellular membranes and directly release 
encapsulated drugs into the cytoplasm or targeted cell organelles, significantly enhancing 
the cellular uptake of drugs, avoiding lysosomal degradation, and counteracting the drug 
resistance of cancer cells (Kunisawa et al., 2005; Tila et al., 2015). Membrane fusion is 
achieved by the specific interactions between the membrane receptors and the liposomes 
or the membrane-associated proteins or peptides that are contained within the liposomes. 
Moreover, negatively charged phospholipids promote the fusion in the presence of 
calcium in some types of fusogenic liposomes (Malaekeh-Nikouei et al., 2008; Yuba et 
al., 2010; Watarai et al., 2014). The formation of lipid bilayers and incorporation of 
special lipids (e.g. dioleoyl phosphatidylethanolamine (DOPE)) also promote the 
membrane fusion reaction and enhance the release of the encapsulated drugs (Tila et al., 
2015). 
Functional liposomes have been used for the improvement of circulation time and 
stability of drugs, specifically targeting cancer cells, and promoting drug delivery. More 
recently, the maturation of stimuli-responsive liposome technologies has yielded precise 
control of drug release, which provides greater individualised treatment with lower 
33 
 
undesirable side effects (Deshpande, Biswas and Torchilin, 2013). Several types of drug 
release triggers have been used in liposome-based delivery systems, including 
temperature, pH level, enzymes, light, ultrasound, electromagnetic waves and magnetic 
fields. (Zununi Vahed et al., 2017) 
Tumor cells are efficient at maintaining plasmalemmal pH gradients, whereas the protons 
generated during the metabolism of cancer cells are exported to the extracellular space 
efficiently and the extracellular bicarbonate is taken up by cancer cells, following re-
export of CO2, for increasing intracellular pH (Chiche et al., 2012). Therefore, the 
extracellular pH level in the environment of cancer cells is lower than that around normal 
cells (pH 6.2-6.8 vs pH 7.35-7.45). Additionally, in endosomal vesicles, the pH is lower 
than 5 (Moussa, Martins and Husseini, 2015). pH-sensitive liposomes (PSLs) are stable 
at the neutral pH of blood and healthy tissues, but are designed to become destabilized 
and release encapsulated drugs in the vicinity of cancer cells and/or in endosomes 
(Karanth and Murthy, 2007). The most developed class of PSLs are designed to be 
triggered after endocytosis and several mechanisms may be involved: direct release of 
drugs into the cytosol due to the fusion of the endosome and liposome membranes which 
is induced via pH changes; drug leakage into the cytosol because of the pH-induced 
destabilization of liposomal membranes which will cause the destabilization of 
endosomal membranes; release of drugs inside the endosomes due to the pH-induced 
destabilisation of the liposomes, followed by the diffusion of the molecules into the 
cytosol (Moussa, Martins and Husseini, 2015). There are several classes of materials used 
in the formulation of different PSLs, including polymorphic lipids combined with 
amphiphilic compounds that contain an acidic group, lipid derivatives that have pH-
sensitive chemical bond (e.g. N-acylated aminophospholipid derivatives and 
plasmalogens), reconstituted fusion proteins or peptides that are pH-sensitive and able to 
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destabilise the membrane of liposomes in acidic environments, and pH-titratable 
polymers, which change conformations at low pH, as recently reviewed by Moussa et al. 
(Moussa, Martins and Husseini, 2015) 
Thermo-sensitive liposomes (TSLs) are sensitive to temperature, due to their specific 
chemical composition. For example, some types of liposomes consist of lipids (e.g. 
dipalmitoyl phosphatidylcholine) that begin to melt when the temperature exceeds their 
thermal threshold, whereupon the surface of the liposomes becomes porous and the 
encapsulated drug is released (Moussa, Martins and Husseini, 2015). The increase of local 
temperature, known as hyperthermia, can be induced via pathological status or external 
triggers such as light, ultrasound, microwave or magnetic fields (Moussa, Martins and 
Husseini, 2015; Tila et al., 2015). Optimisation of the hyperthermic effect allows precise 
control over the amplitude and location of the temperature rise in targeted cancer tissues. 
Therefore, TSLs which are stable at the temperature of the human body (37°C on average), 
can be triggered to release the encapsulated molecules at targeted sites by hyperthermia 
(about 39-43°C) to achieve greater therapeutic effect and reduced side effects (Ta and 
Porter, 2013; Moussa, Martins and Husseini, 2015). 
Moreover, liposomes can be designed to be sensitive to certain enzymes that only have 
high activity at the tumour site, such as lipases, cancer-associated proteases and 
phospholipases (de la Rica, Aili and Stevens, 2012; Arouri et al., 2013; Moussa, Martins 
and Husseini, 2015). There are several classes of enzyme-sensitive liposomes, chemically 
modified with different molecules (e.g. lipopolymers (Arouri et al., 2013), small peptides 
and phosphorylated synthetic estrogen, etc.(Bibi et al., 2012)) that can specifically 
respond to certain enzyme levels above a threshold. 
Some types of liposomes are capable of absorbing the energy of certain external triggers 
(e.g. light, ultrasound, electromagnetic waves or magnetic fields, etc.) and subsequently 
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converting it to heat, causing a localised hyperthermia that effects the liposomes and 
induces the release of drugs (Moussa, Martins and Husseini, 2015). These external 
triggers also can be used to directly affect the liposomes. For instance, light can induce 
changes in the form of photosensitive lipids, which are chemically modified, and change 
the membrane permeability (Anderson and Thompson, 1992). Ultrasound is able to 
induce the rupture of microbubbles at target sites, known as transient cavitation. The 
collapse of microbubbles produces enormous localised heat and pressure waves, which 
can cause the disruption of the liposomal and/or cell membranes, consequently allowing 
the release and permeation of drugs (Hernot and Klibanov, 2008). 
Additionally, liposomal platforms which are capable of co-delivering combinatorial 
drugs bring a paradigm shift in tumour therapy (Hu, Aryal and Zhang, 2010). Several 
classes of liposome-based drug combinations have been reported, including the co-
delivery of chemotherapeutic drugs, the co-delivery of chemosensitizers and 
chemotherapies, and the co-delivery of siRNA and chemotherapies (Mayer et al., 2006; 
Saad, Garbuzenko and Minko, 2008; Hu and Zhang, 2010). The combination of drugs 
can achieve greater synergistic activity by loading them into liposomes at optimised 
molar ratios and selecting appropriate encapsulation schemes (Hu, Aryal and Zhang, 
2010). For example, multiple hydrophilic drugs can be encapsulated in liposomes; 
lipophilic drugs can be partitioned into the membrane of liposomes; and negatively 
charged oligonucleotide drugs (e.g. siRNA) are able to bind to the positively charged 
liposomal surface (Hu, Aryal and Zhang, 2010). 
1.5.2 Nanogels and Polymeric Nanoparticles 
Polymeric nanoparticles are nano-sized colloidal particles and have been extensively 
explored for drug delivery for cancer therapies. Among the various materials, designs and 
synthesis methods, the polymeric nanoparticles studied most commonly consist of a 
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hydrophobic polymer-based core containing anticancer drugs and a hydrophilic outer 
shell, which ultimately enabled longer persistence and systemic circulation time in the 
bloodstream, leading to further accumulation of nanoparticles in cancer tissue (Masood, 
2016). Alternatively, there has also been increasing interest in using nanosized 
hydrophilic cross-linked polymer networks, also termed as nanogels, for drug delivery 
(Sivaram et al., 2015; Chan and Almutairi, 2016). 
Polyhydroxyalkanoates (PHAs) (Li and Loh, 2017), cyclodextrins (CDs) (Duchene, 
Cavalli and Gref, 2016) and poly-(lactide-co-glycolic acid) (PLGA) (Katiyar et al., 2016) 
are the most commonly used polymer materials for the core fabrication (Masood, 2016). 
Meanwhile, nontoxic hydrophilic outer shells provide outstanding blood biocompatibility, 
such as , polyvinyl alcohol (PVA), PEG and monomethoxy poly-(ethylene glycol) 
(mPEG), which has also been widely applied in surface modification of other kinds of 
nanoparticles, such as liposomes and gold nanoparticles (Masood, 2016). The reader is 
referred to (Duchene, Cavalli and Gref, 2016; Masood, 2016; Li and Loh, 2017) for an 
in-depth investigation and discussion of recent advanced PHAs, CDs and PLGA-based 
polymeric nanoparticles used for cancer treatment. 
Nanogels are hydrophilic nanosized cross-linked polymer networks, also called hydrogel 
nanoparticles (Lux et al., 2013; Sivaram et al., 2015; Chan and Almutairi, 2016). In the 
last decade, there has been increasing interest in the applications of nanogels as drug 
carriers and imaging agents (Maya et al., 2013; Sultana et al., 2013; Sivaram et al., 2015). 
Nanogels have unique utilities and properties including: 
1. high biocompatibility on account of the high water content and living tissue-like 
physical properties and they are easily biodistributed by intravenous injection (Chan 
and Almutairi, 2016; Soni and Yadav, 2016). 
2. the ability to selectively respond to stimulation, including changes of pH, ionic 
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content, biomolecules, magnetic field, light and temperature, which is important in 
specific drug delivery and responsive imaging (Stuart et al., 2010; Eckmann et al., 
2014). 
3. highly efficient loading capacity of a wide range of drugs due to the prolonged 
residence time provided by muco-adhesive polymers (Sivaram et al., 2015). 
The release of the drugs and other molecules is easy to control by varying the nanogel 
properties, for example by incorporating stimulus-responsive crosslinkers or changing 
crosslinking density (Sivaram et al., 2015). 
Nanogels are capable of generating appropriately sized complexes with molecules and 
keeping their configuration and activity, and even encapsulating fragile compounds to 
increase their stability (Bae et al., 2008; Sasaki et al., 2010; Singh, Gill and Gill, 2013; 
Sivaram et al., 2015). Like other nanomaterials, nanogels have nanoscale physical 
properties, such as size (20~200 nm) and large surface area (Maya et al., 2013; Soni and 
Yadav, 2016). Meanwhile, the production of nanogels enables versatile formulation and 
it is facile to chemically modify nanogels for specific purposes, including triggered drug 
release and targeted drug delivery (Vinogradov, Bronich and Kabanov, 2002; Maya et al., 
2013). These properties of nanogels make them promising for applications in anti-skin 
disease, anti-inflammatory, ocular, transdermal and protein/peptide drug delivery and 
therapy, cancer drug delivery and imaging (Sivaram et al., 2015). 
For cancer therapy, nanogels demonstrate site-specific delivery by incorporating various 
targeted ligands to bind to a desired site, or utilising the stimuli-responsive ability 
(Eckmann et al., 2014). Targeting ligands can include various compounds, such as 
antibodies, peptides, hormones, receptor ligands, nucleic acids and lipid derivatives, etc. 
In addition, nanogel carriers have prolonged circulation time and are incapable of 
diffusing across non-fenestrated endothelium, and thus are able to accumulate in tumour 
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tissues. For instance, Liang et, al. described a novel self-assembled nanogel consisting of 
hyaluronic acid-epigallocatechin gallate conjugates (HA–EGCG), cytotoxic protein 
Granzyme B (GzmB) and linear polyethylenimine (PEI) (Liang et al., 2016). HA is 
known to have the ability of targeting CD44, which is overexpressed in many cancer cells 
types and EGCG is used to facilitate the formation of stable nanogels. After endocytosis, 
PEI is able to change the pH in endosomes and rupture the membrane to release drugs 
into the cytosol (Boussif et al., 1995). It has been observed that this nanogel  efficiently 
kills CD44-overexpressing cancer cells and shows little toxic effect to normal cells (Liang 
et al., 2016).  
After accumulating in tumour tissues via the EPR effect, pH-responsive nanogels are 
triggered to release drugs either in the extracellular fluids (pH 6.8) or, after cellular uptake, 
in the acidic endosomes and lysosomes (pH 4.5-6.5) in cancer cells (Manchun, Dass and 
Sriamornsak, 2012; Manchun et al., 2015). In recent research, hybrid nanogels have been 
applied to photothermal cancer therapy. Hui Wang et al. fabricated drug loaded core-shell 
hybrid nanogels that have the function of both tumour imaging, local hyperthermia, 
temperature sensing and triggered drug release (Wang et al., 2014). These multifunctional 
nanoparticles have high photoluminescence, photostability, magnetic/NIR-heat 
conversion ability and drug accumulation potential due to the composite structure 
consisting of fluorescent carbon dots, a porous carbon shell and superparamagnetic iron 
oxide nanocrystals. Meanwhile, the hydrogel shell can control the release of drug and 
fluorescence intensity by varying environmental temperature, which is based on the 
thermo-responsive poly (N-isopropylacrylamide-co-acrylamide) (Wang et al., 2014). 
Therefore, NIR light and magnetic field are able to induce localised heating and trigger 
the release of drugs. In addition, they demonstrated that these hybrid nanogels are capable 
of overcoming cellular barriers to exert effects in mouse melanoma B16-F10 cells (Wang 
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et al., 2014). 
1.5.3 Silicon and Silica Nanoparticles 
As emerging nanomaterials, nanosized porous silicon (silicon-based nanoparticles) and 
silicon oxide (silica)-based nanoparticles have attracted great attention for cancer 
treatment applications. Compared to other types of nanoparticles, silicon and silica based 
nanoparticles have uniquely mesoporous structures, strong hydrophobicity and other 
distinct material characteristics which make them a promising nanomaterial for cancer 
therapy applications (Feng et al., 2016). Due to the biocompatibility, porous 
structures/volume and high active surface area of silicon-based nanoparticles, they have 
been demonstrated to be one of the outstanding candidate nanovectors for targeted drug 
delivery, diagnosis and sensitisations of sonodynamic, photodynamic and thermal 
therapies, etc. (Ferrari, 2005; Stojanovic et al., 2016) Silicon is one of the most 
fundamental trace materials in the human body, and silicon-based nanoparticles are 
completely degradable in the living organism. The generated free silicon atoms can be 
converted to a nontoxic bioavailable form and be excreted efficiently, which illustrates 
the biocompatibility of silicon-based nanoparticle (Stojanovic et al., 2016). It was 
observed using Raman spectroscopy that silicon nanoparticles can be completely 
biodegraded in breast cancer cells after 13-days incubation (Tolstik et al., 2016). The 
surface modifications of silicon-based nanoparticles for stabilisation, targeted delivery, 
controlled drug release or immunotherapy can be accomplished due to the porous 
structures/volume and high surface area (Stojanovic et al., 2016). Meanwhile, the pores 
inside silicon-based nanoparticles and their structure allow high-efficiency loading of 
varied compounds for cancer treatment, including both hydrophilic and hydrophobic 
compounds (Salonen et al., 2005; Kinsella et al., 2011; Kaasalainen et al., 2015; 
Stojanovic et al., 2016). 
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Coating silicon nanoparticles with PEG (Putnam, 2008) or serum albumin (Xia et al., 
2013) is capable of increasing the solubility and stability of silicon nanoparticles in 
aqueous environments and results in a much longer circulation time and EPR, similar to 
other nanoparticles. Simultaneously, silicon nanoparticles can target tumour tissue and 
enter cancer cells by recognising the receptors on the cell membrane and anchoring via 
multiple functionalised components, such as carbohydrates, antibodies and peptides 
(Godin et al., 2011; Secret et al., 2014; Stojanovic et al., 2016). A variety of silicon 
nanoparticle-delivered drugs have been examined, such as methotrexate, SFN (Wang et 
al., 2015), indomethacin (Liu et al., 2013), PTX (Liu et al., 2015), DOX (Xu et al., 2015) 
and siRNA (Osminkina et al., 2012), etc. 
Silicon oxide, also known as silica, is well-known as a bio-safe and widely applied natural 
material. Due to the large internal surface area, controllable porous structure and other 
material properties of silica-based nanoparticles, they have been investigated as imaging 
agents, drug vectors and sensitisers as well as silicon-based nanoparticles (Feng et al., 
2016). The most commonly studied structures of silica nanoparticles for drug delivery 
are mesoporous silica based nanoparticles based on Mobil Composition of Matter No. 41 
(MCM-41) and/or Santa Barbara Amorphous-15 (SBA-15) (Feng et al., 2016). By 
altering the temperature, solution composition and concentrations of the synthesis system, 
the size, shape, surface area and pore size of the hexagonal porous MCM-41 structure can 
be easily controlled. SBA-15 type silica nanoparticles are synthesized using a polymeric 
template, which is able to provide mesostructural ordering properties for silica 
nanoparticles (Zhao et al., 1998). MCM-41 type and SBA-15 type have both been 
extensively explored for targeted drug delivery (Feng et al., 2016). Controlled-release 
drug delivery systems based on silica nanoparticles have also attracted increasing 
attention. The stimuli used for triggered drug release from silica nanoparticles include pH 
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(Casasús et al., 2004), temperature (Yang et al., 2014), redox potential (Giri et al., 2005), 
enzyme (Radhakrishnan et al., 2015) and light (Tang et al., 2015), etc. For instance, 
Chang et al. fabricated a pH-sensitive drug delivery system by modifying the surface of 
silica nanoparticles with polydopamine. The anti-cancer drug desipramine contained in 
pH-triggered silica nanoparticles can be released in low-pH cellular conditions (Chang et 
al., 2016). Compared to free desipramine, pH-sensitive silica nanoparticles showed 
significantly higher toxicity and inhibitory effects to cancer cells. Lipid-coated silica 
nanoparticles, a lipid bilayer surrounding silica nanoparticles containing anti-cancer 
drugs, have been investigated recently, and less drug leakage, slower rate of drug release, 
and more substantial in vivo therapeutic effects where observed (Meng et al., 2015; Choi 
et al., 2016; Liu et al., 2016) . 
1.5.4 Dendrimers 
Dendrimers are 3-dimensional, highly branched monodispersed nanoscale 
macromolecules (Sharma et al., 2017). Generally, dendrimers consist of an initiator core, 
branches which emanate from the core and functional end groups on the outermost layer 
(Gupta et al., 2010). Dendrimers have been considered as a promising nanomaterial for 
targeted delivery and diagnostic imaging agents, due to their unique properties, such as 
the monodispersity, internal cavities and modifiable functional end groups (Sharma et al., 
2017). The cavity in the hydrophobic core and the multivalent surface allow dendrimers 
to effectively load hydrophobic and hydrophilic compounds, respectively (Hu, Aryal and 
Zhang, 2010). Varied dendrimer-based MRI, X-ray and CT contrast agents have been 
developed by linking contrast agents to dendrimers with design formulations (Sharma et 
al., 2017). In addition to diagnostic agents, functionalized and ligand-anchored 
dendrimers have shown outstanding ability to target drug delivery. The ligands that have 
been used with dendrimers include folic acid (Hilgenbrink and Low, 2005), biotin (Yang 
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et al., 2009), N-acetyl-glucosamine (Vannucci et al., 2014) and riboflavin, etc. (Sharma 
et al., 2017) Due to the definition of dendrimers, the formulations of dendrimers are 
various, such as PAMAM (Buczkowski et al., 2011), polyglycerol (Lee and Ooya, 2012), 
PPI (Jain et al., 2015), polyester (Morgan et al., 2006) and nucleic acid (Taghdisi et al., 
2016), etc. (Sharma et al., 2017) For instance, Taghdisi et al. fabricated an aptamer-base 
DNA dendrimer containing the anti-cancer drug epirubicin, and targeted drug delivery 
and considerable in vivo tumour inhibiting effects were observed (Taghdisi et al., 2016). 
Several major types of nanovectors, including liposomes, polymeric, metal-based, silicon 
and silica-based nanoparticles, and dendrimers which have been applied in clinical or 
preclinical trials for targeted delivery of anti-cancer drugs, have been briefly introduced 
above. Moreover, oceans of novel nanoparticles are currently under study and the 
systematically combination of varied nanomaterial will provide a very large number of 
options for selecting highly specific and highly efficient therapeutic nanovectors 
according to individual patient. On the other hands, to develop more selective and less 
toxic cancer therapies, nanoparticles have been applied to combine several therapeutic 
interventions, including photodynamic (Chatterjee, Fong and Zhang, 2008; Roblero-
Bartolon and Ramon-Gallegos, 2015; Agostinis P, Berg K, Cengel K., 2017), 
sonodynamic (H. Xu et al., 2016; Rengeng et al., 2017) and radiotherapy (Hainfeld et al., 
2010), etc., as sensitisers or imaging agent or both. The following sections will review 
the recent advance in the combination of nanoparticles with existing anti-cancer 
interventions. 
1.5.5 Metal-based Nanoparticles 
Metal-based nanoparticles used for drug delivery include gold (Cooper, Bekah and 
Nadeau, 2014), iron oxide (Sharma et al., 2015), zinc oxide (Rasmussen et al., 2010) and 
titanium oxide (Bakhshizadeh et al., 2017) based nanoparticles. For instance, Sun et al. 
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fabricated iron oxide nanoparticles conjugated with anti-cancer drug methotrexate and 
targeting ligand chlorotoxin, and enhanced cytotoxicity was observed both in vitro and in 
vivo (Sun et al., 2008). Meanwhile, due to the superparamagnetic properties of iron oxide 
nanoparticles, they can also be used as MRI contrast agents for diagnosing and 
monitoring the effects of tumour treatment at the same time (Sun et al., 2008). To enhance 
the loading capacity of metal-based nanoparticles, polymer (Bakhshizadeh et al., 2017), 
lipid (Kong et al., 2012) or other customized shells have been used to coat the metal cores, 
which also provide high stability and biocompatibility. For instance, Bakhshizadeh et al. 
assembled core-shell molecularly imprinted polymer for drug delivery by coating 
titanium oxide nano-cores with diacrylated polycaprolctone as cross-linkers and 
methacrylic acid or 4-vinylpyridin as the functional modification, and superior loading 
capacity, higher amount of drug release and considerable cytotoxicity in vitro were 
observed (Bakhshizadeh et al., 2017). 
On the other hand, metal-based nanoparticles, including copper, copper oxide (Studer et 
al., 2010; Akhtar et al., 2016), titanium oxide (Park et al., 2008), silver (Foldbjerg et al., 
2009) have been demonstrated to be able to induce the generation of reactive oxygen 
species inside cells and ultimately lead to oxidative stress, DNA damage and apoptosis 
of targeted cells, which provide the therapeutic potential as anti-cancer agents themselves. 
Among those nanoparticles, gold nanoparticles (AuNPs) are the most studied metal-based 
nanoparticles for anti-cancer drug delivery and have been demonstrated to be promising 
and effective imaging labels and contrast agents on account of their strong surface 
plasmon resonance (SPR) effect. Electromagnetic radiation of specific resonant 
frequencies can induce a coherent oscillation of the free electrons on the nanoparticle 
surface, when the diameter (1-100 nm) of the metal nanoparticles is less than the 
wavelength of light. The oscillation is called the SPR. The SPR can cause an intensely 
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enhanced absorption and scattering of electromagnetic radiation in resonance with the 
metal nanoparticles (Jain, ElSayed and El-Sayed, 2007). Furthermore, AuNPs have high 
stability and can be easily manufactured in controllable size, shape and functionalised by 
bioconjugations and biomodifications, which make them an outstanding nanomaterial for 
drug delivery. AuNPs are facile to be bio-conjugated and bio-modified on account of the 
strong binding affinity towards amines, disulphides and thiols of their surface. This strong 
affinity allows AuNPs to conjugate a variety of peptides, proteins, DNA and other 
biomedical compounds (Niemeyer, 2001; Katz and Willner, 2004; Jain, ElSayed and El-
Sayed, 2007). Cancer specific antibodies (such as anti-FAK antibody and anti-EGFR 
antibody), biomolecules (which can be eagerly taken up by cancer cells) and viruses etc. 
can be conjugated to AuNPs to selectively target cancer cells (El-Sayed, Huang and El-
Sayed, 2005; Jain, ElSayed and El-Sayed, 2007; Kim et al., 2008; Cheng et al., 2014). 
Therefore, antibody-conjugated gold nanoparticles are widely used in cancer diagnosis 
and therapy. It is also known that AuNPs with strong surface-plasmon-enhanced 
absorption can convert the absorbed light into localized heat expeditiously and therefore 
can be utilised for selective photothermal cancer therapy (El-Sayed, Huang and El-Sayed, 
2006). 
AuNPs are generally considered relatively nontoxic to normal cells (Connor et al., 2005; 
Shukla et al., 2005; Alkilany and Murphy, 2010; Villiers et al., 2010), but non-
functionalized AuNPs have been reported to show selective cytotoxicity to certain cell 
lines, especially cancer cells. Hirak K. Patra and colleagues found that citrate-capped 
AuNPs (13 nm in diameter) can specifically induce death in the human carcinoma lung 
cell line (A549), while leaving two other cell lines, baby hamster kidney and human 
hepatocellular liver carcinoma, unaffected at the same dosage (Patra et al., 2007). AuNPs 
have been implicated in detrimental  effects on various important cellular components, 
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such as mitochondria and membrane, damage to DNA, generation of reactive chemical 
species, hindrance of cell function and ultimately induction of cell death (Alkilany and 
Murphy, 2010). Triphenylphosphine monosulfonate (TPPMS) capped AuNPs (1.4 nm in 
diameter) were found to be toxic to HeLa cervical carcinoma epithelial cells (IC50 = 48 
μM）as a result of oxidative stress and mitochondrial damage leading to necrosis (Pan et 
al., 2009). Metal nanoparticles can capture electrons from O2, owing to their high 
surface/volume ratio and the specific electronic configuration of surface atoms (Nel et al., 
2006). Jia et Al. reported that AuNPs (13 nm in diameter) can catalyse the production of 
nitric oxide (NO) from endogenous S-nitroso adducts with thiol groups (RSNOs) in blood 
serum, resulting in the formation of Au-thiolate on the surface. It is known that NO can 
effectively interact with superoxide to generate a toxic peroxinitrite (ONOO-) (Jia et al., 
2009). 
Cellular responses to AuNPs depend on their chemical/physical properties, such as 
surface charge, size and shape (Alkilany and Murphy, 2010). For instance, Goodman and 
colleagues found that cationic (aminated) AuNPs (size 2 nm) are able to cause membrane 
disruption and cell death, while anionic (carboxylated) AuNPs with similar size and shape 
show no toxicity to cells. It suggests that the binding of the AuNPs to the negatively 
charged cell membrane can be a potential mechanism of the cytotoxicity of cationic 
AuNPs (Goodman et al., 2004). 
Recent nanoparticles-cancer research has led to the development of special functional 
nanosized gold-based particles that conjugate drugs, antibodies or bioactive ligands 
which are designed to target or kill cancer cell (Service, 2005; Kong, Keidar and Ostrikov, 
2011; Cheng et al., 2014). Branch et al. reported aurimmune CYT-6091, constructed by 
concurrently binding polyethylene glycol (PEG) and recombinant human Tumour 
Necrosis Factor (rhTNF) to AuNPs. It was tested in a phase I dose escalation clinical trial. 
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It was demonstrated that the rhTNF plays a role in targeting and killing cancer cells 
(Libutti et al., 2010). Anil Kumar et al. successfully investigated a kind of peptide 
functionalized AuNPs which consists of a therapeutic peptide, PMI and neuropilin-
1(Nrp-1) receptor-targeted peptide on ultrasmall AuNPs (2 nm). Since nrp-1 is highly 
expressed by a variety of human cancer cell lines and PMI is a potent inhibitor of 
suppressive protein, p53, these AuNPs can target cancer cells and show strong anti-cancer 
activity (Kumar et al., 2012).  
1.5.6 Combination of Gold Nanoparticles and CAP Treatment 
The combination of CAP treatment and nanoparticles, especially gold nanoparticles, has 
been a new approach in the therapies of cancer. There are few studies reported that CAP 
treatment has anti-cancer synergy with various types of nanoparticles, including iron 
nanoparticles (Jalili, Irani and Mirfakhraie, 2016), iron oxide-based magnetic 
nanoparticles (Li et al., 2019), silver nanoparticles (Manaloto et al., 2020), paclitaxel 
loaded core-shell magnetic nanoparticles (Yu et al., 2018). However, the related studies 
were mainly focused on the combination therapy between CAP treatment and AuNPs due 
to the unique properties and various advantages of AuNPs. 
Kim et al. first reported their study about synergistic effect between CAP and antibody-
conjugated AuNPs on G361 human melanoma skin cell (Kim et al., 2008). The authors 
achieved five-fold enhancement in G361 cell death over the case of the CAP alone by 
using CAP with AuNPs conjugated to anti-phospho-focal adhesion kinase (FAK) 
antibodies (Kim et al., 2008). In this study, melanoma cancer cells were placed 2 mm 
from the touch-safe CAP source and treated for 40s. The CAP temperature remained less 
than 38℃ even after radiating for 10 min (Kim et al., 2008). FAK was more expressed 
in melanoma cells than in normal cells and crucial for melanoma cells’ survival, growth 
and metastasis. So anti-FAK antibody-conjugated AuNPs (FAK-AuNPs) can target 
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melanoma cells and enter into cytoplasm to bind to FAK (Kim et al., 2008). In the 
research, there were three groups cultured in: (1) only medium (control); (2) medium 
containing AuNPs; (3) medium containing FAK-AuNPs. FAK-AuNPs (30 nm) and 
AuNPs (30 nm) did not show to toxicity to G361 compared with the control group. After 
these groups of cells were exposed to CAP for 40s, the cell death rate was 74% (FAK-
AuNPs), 36% (AuNPs) and 14% (control) (Kim et al., 2008). It seems that CAP 
stimulated nanoparticles induced deactivation of FAK and led to increased cell death rate. 
This study first demonstrated that a low-dose CAP treatment can combine AuNPs located 
inside cells to effectively kill cancer cells. The synergy of CAP and AuNPs suggested a 
promising novel method to against cancer which is low-dose, safe, selective and effective 
(Kim et al., 2008).  
More recently, using CAP plus various cancer specific antibody-conjugated AuNPs has 
been reported that has significant cancer selective lethal effect, such as anti-epidermal 
growth factor receptor (EGFR) antibody conjugated AuNPs (AuNPs-EGFR). EGFR has 
been demonstrated to be overexpressed in multiple cancer types and can promote solid 
tumor growth (Nicholson, Gee and Harper, 2001). It was shown that AuNPs coated with 
EGFR binding immunoglobulins can bind selectively to EGFR on cancer cells membrane 
and inactivate them with CAP stimulating, consequently causing the destruction of cancer 
cell membrane and cell death while leaving normal cells significantly less affected (Choi 
et al., 2012).  
A similar approach was taken by the same authors (Choi BB et al.) using anti-human 
epidermal growth factor receptor 2 (NEU) antibody labelled AuNPs and CAP to treat 
melanoma cells. The NEU protein is usually over-expressed in melanoma cells and the 
anti-NEU antibody labelled AuNPs can preferentially target melanoma cells rather than 
other normal cells (Choi et al., 2015). It was shown that the NEU protein was selectively 
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destroyed, leading a downstream effector after the synergistic treatment. These effects 
finally caused significantly higher death rate of melanoma cells compared with other 
control groups (Choi et al., 2015).  
Unconjugated AuNPs also display synergistic effects when used in combination with 
CAP against cancer. Chen et al. studied the synergistic effect of non-attached AuNPs and 
CAP on human brain glioblastoma U87 cell line, which takes a larger CAP lethal dose 
than other brain glioblastoma cancer cell lines and is resistant to AuNPs (Cheng et al., 
2014). The synergy can induce up to 30% more cell death with an optimal concentration 
of AuNPs compared to control groups (Cheng et al., 2014). The unconjugated AuNPs in 
the cell culture medium may potentially promote the absorption of extracellular ROS and 
RNS generated by CAP into cells (Cheng et al., 2014). The absorption may help 
accumulation of intracellular ROS and RNS and theoretically leads to oxidative stress, 
which further affects the cellular pathways and causes damage to the DNA, lipids and 
proteins. This strengthened effect on CAP treatment varies with the concentration, 
incubation time of AuNPs and cancer cell lines (Cheng et al., 2014). The exact 
mechanism has yet to be studied further.  
In the study by Irani S et al. higher concentration of AuNPs showed stronger cytotoxicity 
to Human colorectal cancer cells (HCT-116). The authors used highest concentration of 
AuNPs (375 ppm) and CAP (exposure time: 60, 90, 120 and 180 s) to treat HCT-116 
cells, longer CAP treatment time led to more apoptotic cell death synergistically 
combined with AuNPs treatment (Irani et al., 2015).  The endocytosis of AuNPs plays an 
important role in their application, and indicated that CAP may promote the uptake of 
AuNPs into cancer cells. X. Cheng et al. found that CAP induced the formation of small 
pores on cell membrane of Glioblastoma cells (U87) and made the membrane become 
uneven, while leaving immortalized normal human astrocytes (E6/E7) unaffected. The 
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cancer cell morphology was changed by CAP treatment which may explain the 
accelerated uptake of AuNPs by CAP (Cheng et al., 2015).  
The combination of low doses of AuNPs and CAP was indicated to inhibit PI3K/AKT 
pathway in cancer cells (Kaushik et al., 2016). AKT activation has been demonstrated to 
obstruct the function of p53 protein and inhibit the activity of caspase-9 (Cardone et al., 
1998; Jeong et al., 2005). Caspase cleavage plays a crucial role in apoptosis (Jia et al., 
2015) and is known as reliable marker of apoptotic cell death with PARP cleavage 
together (Kaushik et al., 2016). Moreover, CASP9, p53, and CASP3 mRNA expression 
were observed that were enhanced by the co-treatment with AuNPs and CAP (Kaushik 
et al., 2016). Epithelial-mesenchymal transition (EMT) is known as a cellular mechanism 
that contributes to  normal embryonic development and generally is responsible for the 
initiation of metastasis in solid tumors (Roizen, 2012; Kaushik et al., 2016). It has also 
been indicated that EMT can stimulate the cancer stem cells (CSCs) potential of cancer 
cells. CSCs are the only cells that can initiate and drive tumor growth, resulting metastasis, 
tumor recurrence and clinical relapse (Mani et al., 2008; Morel et al., 2008). A growing 
amount of evidence indicates that these cells are resistant to radiation therapy and 
chemotherapy. Hence, it is highly promising that co-treatment with AuNPs and CAP can 
effectively block EMT and inhibit CSCs. It has also been found that low dose of AuNPs 
combined with CAP induce the increase of epithelial markers, such as E-cadherin, with 
decrease in mesenchymal markers, such as N-cadherin (Kaushik et al., 2016). Co-
treatment also can enhance the expression levels of some EMT-associated transcription 
proteins, such as N-Cad, Zeb-1 and Slug which can block cell cycle and are related with 
the loss of N-Cadherin (Kajita, McClinic and Wade, 2004; Vega et al., 2004; Kaushik et 
al., 2016). Besides, it has been shown that co-treatment with AuNPs and CAP can 
significantly reduce the population of glioma stem-like cells (GSCs) in vivo and vitro 
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model and thus avoid drug resistance, recurrence and metastasis (Kaushik et al., 2016). 
However, the effects of combination therapy of CAP treatment and AuNPs can vary due 
to the wide range of different AuNPs, CAP-generating devices and cell lines. More 
importantly, the exact and detailed mechanism behind the synergistic cytotoxicity, 
especially, accelerated uptake of AuNPs into cancer cells by CAP, has yet been to be 
discovered. Therefore, considering all the advantage of AuNPs and the unsolved research 
questions, this project used AuNPs to investigate the synergistic anti-cancer effects 
combined with CAP treatment. 
1.6 Combination of Chemotherapy with CAP Treatment 
A number of studies have investigated the possible additive, or synergic effect of CAP 
with traditional chemotherapeutic agents. The chemical and physical effects (i.e. 
production of reactive oxygen and nitrogen species, generation of heat and 
electromagnetic fields) of CAP treatment induced cell permeability (Leduc et al., 2009), 
disruption of cell membrane (Chen, Cheng and Cheng, 2018), enhanced endocytosis (He 
et al., 2018) and cell apoptosis (Tanaka et al., 2015). Therefore, the cancer cells treated 
by CAP could increase their uptake of chemotherapeutic agents and present higher 
sensitivity to chemotherapy. Additive or synergic effects have been described in a number 
of studies and  several mechanisms of action are beginning to emerge (Brullé et al., 2012; 
Kaushik et al., 2015; Conway et al., 2016; Zhu et al., 2016). For instance, Conway GE 
et. al first reported the enhanced ROS-, JNK-, and caspase-independent mechanism of 
cell inactivation in human glioma cell line U373MG by the combination of CAP with 
TMZ (Conway et al., 2016). CAP was observed to overcome chemoresistance of the 
GBM cell line LN18 which has unfavourable MGMT status and displays resistance to 
TMZ. Pre-treatment with CAP induced cytotoxicity and restored cell cycle arrest in G2/M 
Phase when co-treated with TMZ (Köritzer et al., 2013). In a myeloma cell line model, 
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CAP was found to increase bortezomib sensitivity and induce myeloma cell apoptosis (D. 
Xu et al., 2016). Interestingly, low frequency, low intensity alternating current electrical 
stimulation has also been shown to enhance chemotherapeutic efficacy in MDR1 drug 
resistant brain, lung, prostate, ovary, fibrosarcoma and tumour cells (Janigro et al., 2006).  
Due to the alterations of metabolism of cancer cells, a specific microenvironment with 
high reactive species level is created both inside of cancer cells and in the tumour tissues. 
The increased reactive species level provide an attractive target for developing anticancer 
therapy, especially as it seems a common feature among various types of cancer 
(Marzenell et al., 2013). Several anticancer drugs targeting this feature have been 
developed to further increase reactive species level in cancer cells beyond their tolerable 
allowance to trigger cancer cell death, including fenretinide (Sun et al., 1999), nitric 
oxide-donating aspirin (Gao, Liu and Rigas, 2005), imexone (Hersh et al., 1992), 
motexafin gadolinium (Evens et al., 2005), menadione (Beck et al., 2009), β-lapachone 
(Y. Li et al., 2003) and others (Trachootham, Alexandre and Huang, 2009). However, 
those drugs also can increase the reactive species level in healthy cells, which may induce 
secondary malignancies as a dangerous side effect (Marzenell et al., 2013). Therefore, 
prodrugs, which were developed in an alternative strategy against the specific high 
reactive species level in tumours, are only activated to be cytotoxic after exposure to rich 
reactive species, which should lack this side effect and be more specific.  
The majority of prodrugs were developed to be activated in cells by oxidation induced by 
ROS. CAP has been demonstrated to generate ROS and RNS in specific area and treat 
tumour tissues with controllable dose (Welz et al., 2015), therefore it can be a promising 
intervention for combination therapy with ROS-activated pro-drugs, especially, 
increasing the therapeutic efficiency of pro-drugs.  
In this project, we have acquired four types of prodrug candidates, including ferrocene-
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based prodrugs provided by Prof. Andriy Mokhir (Marzenell et al., 2013) and Prof. 
Gérard Jaouen (Jaouen, Vessières and Top, 2015), matrix metalloproteinase pro-
inhibitors and thiazolidinone-based prodrugs provided by Prof. Seth M. Cohen (Perez et 
al., 2015), and pyrazolopyrimidines derivatives provided by Prof. John Stephens (Kelada 
et al., 2018). 
As seen from Appendix V Supplementary Table S1 and S3, ferrocene (C5H5FeC5H5) 
consists of two cyclopentadienyl rings and a central iron atom. Ferrocene itself has high 
stability but reacts with reactive oxygen species which induces alternations of their 
derivatives. Prof. Gérard Jaouen and his group have investigated and reported a series of 
compounds based on ferrocene derivatives, [3] ferrocenophane and ferrocifen derivatives. 
[3] ferrocenophane consists of a central iron atom and two cyclopentadienyl rings linked 
by a three-carbon atom bridge. Ferrocifen is also known as ferrocene derivative 
hydroxyferrocifen. So, based on those ferrocene derivatives and analogues, Prof. 
Jaouen’s group has developed a series of compounds which are capable of being activated 
in cancer cells by their relative high ROS level with the formation of alkylating agents 
and other cytotoxic agents, which inhibit the cellular antioxidative system and induce 
antiproliferative effects against cancer cells (Plazuk et al., 2009; Görmen et al., 2010; 
Top et al., 2013; Jaouen, Vessières and Top, 2015). A series of compounds that have been 
tested and approved to be antiproliferative against MDA‐MB‐231 breast cancer cell line 
were provided to us for investigating the combination treatment with CAP against GBM 
U373MG cell line. Meanwhile, we also received two aminoferrocene-based prodrugs 
from Prof. Andriy Mokhir which are active against primary chronic lymphocytic 
leukemia cells and found to not affect mononuclear cells and representative bacterial cells 
(Marzenell et al., 2013). And those aminoferrocene-based prodrugs also contain boronic 
acid ester residue, which has been well-developed as oxidation trigger group, therefore 
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will be cleaved in the presence of ROS, leading to the formation of two types of anti-
cancer agents: redox-active iron-containing species (aminoferrocenes and iron(II) ions) 
that induce the catalytic generation of ROS and a quinone methide that inhibits the 
cellular antioxidative system (Marzenell et al., 2013).  
The matrix metalloproteinase pro-inhibitors provided by Prof. Cohen contain boronic 
acid esters or benzylic ether as ROS trigger groups which can liberate the active 
compounds while being oxidised by high level of ROS (Rouffet and Cohen, 2011). The 
pro-inhibitors were designed to inhibit matrix metalloproteinase at high ROS level 
therefore could apply for the treatment of ischemic injury whereas increasing level of 
ROS and ROS activated matrix metalloproteinases break down the blood brain barrier 
(Major Jourden and Cohen, 2010; Rouffet and Cohen, 2011). Therefore, they were not 
designed for cancer treatment, but it is interesting to treat brain cancer cells with those 
matrix metalloproteinase pro-inhibitors in combination with CAP treatment. Meanwhile, 
Prof. Cohen provided few thiazolidinone-based prodrugs, in which thiazolidinone group 
can reveal carboxylic acid groups after activation by hydrogen peroxide (Perez et al., 
2015). 
The last group of compounds were provided by Prof. John Stephens, which are 
pyrazolopyrimidine derivates, not usually considered as prodrugs, but have found use as 
various bioactive molecules in the battle against cancer, infections, obesity and cystic 
fibrosis (Kelada et al., 2018). It also has been reported that pyrazolopyrimidines 
derivatives present notable inhibiting effects to the activity or function of several kinases, 
including the PI3 kinase, glycogen synthase kinase -3 (GSK-3) and others, which are 
involved in and even play key roles in a variety of cellular activities including cell 
differentiation, motility, cell growth, proliferation, survival and intracellular trafficking, 
and therefore involved in cancer cells (Peat et al., 2004; Folkes et al., 2008; Venkatesan 
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et al., 2010; Martina Ferrari et al., 2015). Therefore, it is promising to find novel drugs 
in pyrazolopyrimidine derivates for cancer treatment which may possess synergistic anti-
cancer effects in combination with CAP treatment. 
1.7 Aims & Objectives 
GBM neoplasms usually recur and the prognosis is highly dismal. The length of survival 
is commonly 12-15 month, whereas 5-year survival rate is only less than 3%-5% (Gallego, 
2015). Meanwhile, even with aggressive treatment, application of radiosensitizer or many 
chemotherapeutic agents, high amount of GBM tumours present high resistance to 
conventional therapies, and the therapeutic effects of chemotherapeutics are limited when 
they are blocked by the blood-brain barrier.  Novel therapies are urgently needed and the 
understanding of molecular signalling processes of GBM also needs to be further 
investigated. The aim of this project is to investigate novel therapies for glioblastomas by 
combining cold atmospheric plasma, gold nanoparticles and chemotherapy, to enhance 
the knowledge of the reaction of GBM to cold atmospheric plasma and provide the basis 
to further develop efficient novel clinical treatment for GBM tumour. More specifically, 
we aimed to investigate the synergistic anti-cancer effects between low dose CAP 
treatment, AuNPs and discover new prodrug candidates that possess strong synergy with 
CAP treatment. Our research questions are ‘How does low dose CAP treatment accelerate 
the uptake of non-toxic AuNPs into GBM U373MG cells and lead to synergistic 
cytotoxicity?’ and ‘Identify potential leading prodrug candidates that can be activated and 
induce synergistic anti-cancer effects in combination with low dose CAP treatment.’ 
There are 4 Chapters in this PhD thesis. In Chapter 1, the objective is completing a 
literature review, which has been presented above in section 1.1-1.6, to introduce brain 
cancer, especially GBM, therapeutic cold and hot plasma, the intracellular reactive 
species and related signalling pathways, nanoparticles in cancer therapy and 
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chemotherapy agents, especially, prodrugs that have potential synergistic anti-cancer 
effects combined with CAP treatment. The literature review has been published as a book 
chapter. In Chapter 2, the objective was identifying the synergistic cytotoxicity of CAP 
treatment and AuNPs against U373MG cells and investigating the mechanism of CAP-
accelerated uptake of AuNPs, which leads to the synergistic cytotoxicity. For deliverables: 
(1) The study was published (He et al., 2018); (2) We preliminary determined the 
mechanism of the synergistic effects between CAP and AuNPs. The further studies about 
signalling pathway and detailed mechanism of CAP-accelerated uptake is being carrying 
out and is presented in Chapter 3. In Chapter 3, the objective was determining the possible 
endocytosis pathways activated by low dose CAP treatment. For deliverables: (1) The 
study described above was published (He et al., 2020); (2) For the first time, we 
discovered the membrane repairing clathrin-dependent endocytosis was activated after 
being treated with CAP, whereas it increases the accumulation of AuNPs inside cells and 
eventually leads to cell death. This mechanism of RONS-induced endocytosis will also 
be of relevance to other cancer therapies that induce an increase in extracellular RONS. 
In Chapter 4, the objective was screening all prodrug candidates and identify possible 
leading candidates that have significant synergy with CAP treatment. For deliverables: 
(1) Screening of all 47 prodrug candidates was carried out and the alamar blue assay was 
used for all compounds to determin their dose response curves against U373MG cells 
with or with CAP treatment;  (2) The manuscript is in preparation and will be submitted 
for publication soon; (3) We have indentified two leading candidates and the possible 
mechanism of the activation of prodrug JW-04-061 by CAP treatment.
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CHAPTER 2. COLD ATMOSPHERIC PLASMA 
PROMOTE THE UPTAKE AND ACCUMULATION 
OF GOLD NANOPARTICLES IN U373MG CELLS 
 
Part of this Chapter has been published. 
He, Z., Liu, K., Manaloto, E., Casey, A., Cribaro, G.P., Byrne, H.J., Tian, F., Barcia, C., 
Conway, G.E., Cullen, P.J. and Curtin, J.F., 2018. Cold atmospheric plasma induces 
ATP-dependent endocytosis of nanoparticles and synergistic u373mg cancer cell 





2.1  Introduction 
Gold nanoparticles (AuNPs) can be used as diagnostic agents, radiosensitizers and drug 
delivery vehicles, due to their specific physical and chemical properties, such as strong 
surface plasmon resonance effect, high stability and low cytotoxicity (Jain, ElSayed and 
El-Sayed, 2007; Cheng et al., 2011; Joh et al., 2013). AuNPs can be readily manufactured 
in various controllable shapes, sizes and monodispersity. Though non-functionalized 
AuNPs can show selective cytotoxicity to certain cell lines, especially cancer cells (Patra 
et al., 2007), AuNPs are generally considered nontoxic to normal cells (Connor et al., 
2005; Alkilany and Murphy, 2010). Cytotoxicity of AuNPs is size dependent, small 
AuNPs elicit higher cytotoxicity than larger AuNP. AuNPs of ~20 nm diameter elicit 
relatively low cytotoxicity in both normal and cancer cells (Pan et al., 2007) and are 
optimal for traversing the blood brain barrier to enter the brain (Shilo et al., 2015). The 
surface chemistry of AuNPs enables bio-conjugation and bio-modification, for example, 
conjugation of antibodies to assist in targeting or conjugation of chemotherapeutic or 
detection agents (Cheng et al., 2011; Joh et al., 2013). These properties underpin the 
emergence of gold nanoparticles as promising therapeutic and diagnostic administration 
systems to treat neoplasms. 
Plasma, a form of ionized gas, is one of the four fundamental states of matter and by far 
the most common form of matter in the universe. Initially, biomedical applications of 
plasma concentrated on heat and high temperature, i.e. thermal plasmas, for tissue 
removal, sterilization, and cauterization (Fridman et al., 2008). Technological advances 
have allowed researchers to generate plasmas at ambient temperatures and at 
approximately 1.0 atmospheric pressure, allowing safer application to biological samples 
and tissues without risking thermal injury. These are known as non-thermal atmospheric 
plasma (NTAP) or Cold Atmospheric Plasma (CAP). CAP has been investigated as a 
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promising technique for various biomedical applications including tumour therapies, 
sterilization, wound healing and local viral and microbial infection control (Isbary et al., 
2012; Shi et al., 2012; Zelzer et al., 2012; Yan et al., 2015). CAP generates a unique 
physical and chemical environment for exposure of biological tissues, eliciting effects 
such as activation of short and long lived reactive nitrogen species (RNS, e.g. N2+, NO3 
and NO, etc.) and reactive oxygen species (ROS, e.g. OH•, O and O2•, etc.), photons as 
well as generation of heat, pressure gradients, charged particles, and electrostatic and 
electromagnetic fields (Kong, Keidar and Ostrikov, 2011; Babington et al., 2015), many 
of which are known to induce effective death pathways in cancer cells (Yan et al., 2015). 
Synergistic anti-cancer effects between AuNPs and CAP have emerged as a promising 
potential approach in cancer therapy studies. Kim et al. first reported that cytotoxicity of 
CAP to melanoma cells was significantly increased (near five-fold) by combining with 
antibody-conjugated AuNPs (Kim et al., 2008). Zhu et al. showed that CAP coupled with 
drug loaded core-shell AuNPs led to a significant enhancement in growth inhibition of 
breast cancer cells compared with control groups (Zhu et al., 2016). Other studies have 
also suggested that AuNPs have synergistic cytotoxicity when combined with CAP in 
cancer treatment (Cheng et al., 2014; Irani et al., 2015). However, the effects of CAP and 
AuNPs can vary due to the wide range of different AuNP, CAP-generating devices and 
cell lines. 
The current research uses an experimental dielectric barrier discharge (DBD) plasma 
device, DIT 120, with a maximum voltage output of 120 kV at 50 Hz generated between 
two 15 cm diameter aluminium disk electrodes (Figure 7a, b) (Ziuzina et al., 2013; 
Patange et al., 2017). We have previously characterised biological activities in cancer 
cells that are dependent and independent of reactive species generation using this system 
(Boehm et al., 2016; Conway et al., 2016). We wished to explore the mechanism of CAP 
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and AuNPs induced cytotoxicity in cancer cells using our system. Using various 
analytical chemistry, biochemistry and microscopy to characterise the effects of CAP on 
AuNP, we provide evidence that direct exposure to CAP induces increased AuNPs 
endocytosis and trafficking to lysosomes, which could be the mechanism of the 
synergistic cytotoxic effects observed in GBM U373MG cells.  
Figure 7. CAP demonstrates no significant effect on AuNPs (≤100μg/ml) within 
culture medium or water. 
(a) Schematic of the DIT120 Plasma Device used in this study. (b) A photograph showing 
plasma generation (blue) and treatment on cell samples. (c) 20nm AuNPs were diluted to 
different concentrations with cell culture medium or water. The mixed solutions were 
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treated with CAP (75 kV, 30 s), incubated for 24h, then measured the sizes by Zetasizer. 
(d) AuNPs were diluted in cell culture medium or water to 100μg/ml and treated with 
CAP at 75 kV for 0, 30 s. Zeta potential was then measured by Zetasizer. (e) STEM of 
AuNP, from left to right: mixed with water; mixed with culture media; mixed with culture 
medium then exposed to CAP for 75 kV, 30 s, AuNPs concentrations are 100μg/ml. For 
Fig. 1c and d, Zetasizer measurements were repeated in six replicates. Statistical analysis 
was carried out using one-way ANOVA with Bonferroni’s multiple comparisons post-test. 
2.2  Materials &Methods 
2.2.1 Cell Culture. 
The human brain glioblastoma cancer cell line U-251 MG (formerly known as U-373 
MG) (ECACC 09063001) were obtained from Dr Michael Carty (Trinity College Dublin).  
The stock held as U-373MG in ECACC was found to be identical by STR-PCR profiling 
to U-251, so now has been re-named as ‘U-251 MG (formerly known as U-373 MG)’. 
The new deposit of U-373 MG is named as U-373 MG (Uppsala) (ECACC catalogue 
number 08061901). However, the U-373MG cell line used in this project is considered 
as a subclone of U-251 and has been demonstrated to display variations in phenotypic 
marker expression as well as differences in growth characteristics, which may explain 
that various laboratories reported different results from U-373MG and U251 cell lines 
(Torsvik et al., 2014). Therefore, we used term U373MG in this thesis and only added 
explanation in all Method Sections to distinguish it from the U-251 and U-373MG 
(Uppsala) cell lines. Cells were cultured in Dulbecco’s Modified Eagle’s Media-high 
glucose (Sigma-Aldrich) supplemented with 10% foetal bovine serum (Sigma-Aldrich) 
and 1% penicillin and streptomycin mixture (Thermo Fisher Scientific) in TC flask T25, 
standard for adherent cells (Sarstedt). The cultures were maintained under a condition of 
5% (v/v) CO2 and 37 ℃ in a humidified incubator. Culture medium was changed every 
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2 days until reaching around 80% confluency. Cells were then brought into suspension 
using 0.25% trypsin solution (Thermo Fisher Scientific) and subcultured in new flasks. 
2.2.2 CAP Configuration and Treatment. 
The CAP-DBD device used (Figure 7a, b) is an experimental atmospheric low 
temperature plasma generator (Conway et al., 2016). It consists of two aluminium disc-
electrodes (diameter 15 cm) with a polypropylene sheet in the middle, which is used as 
dielectric barrier and holder for the reactor and cell samples. The thickness of the 
dielectric barrier is 1.2mm, and the distance between the two electrodes was 26.6 mm. 
Samples were placed in a sealed reactor and treated inside or outside the plasma 
discharging area. The CAP was generated between two disc-electrodes when the high 
voltage was applied. Voltage was monitored using an InfiniVision 2000 X-Series 
Oscilloscope (Agilent Technologies Inc., Santa Clara, CA, USA). TC dish 35 standard 
(35x10mm, Sarstedt) was used as the cell container for CAP treatment. U373MG cells 
were seeded into the dishes at a density of 1×105 cells/ml and incubated overnight to 
allow a proper adherence (70-80% confluency). For direct treatment, culture medium was 
removed from the dishes before the CAP treatment, then the cell culture dishes were put 
between the two electrodes and treated at 75 kV for 0-40 s. The fresh culture medium 
containing 100 μg/ml AuNPs or inhibitors was added after exposing to CAP. For CAP-
activated culture medium, the fresh culture medium were contained in TC dish 35, 
standard and treated with CAP at 75 kV for 30 s and stored overnight to remove short-
lived reactive species. AuNPs were added into CAP-activated medium to 100 μg/ml. The 
CAP-untreated cells were then incubated with CAP-activated medium containing AuNPs 
for 24 and 48 h. The indirect CAP treatment was used to determine the role of direct 
physical effects. To indirectly treat cells with CAP, the sample was treated in the reactor 
without the dish lid on it, and culture medium was removed before the treatment. The cell 
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culture dish was placed on the corner of the reactor, outside the plasma discharging area. 
During the treatment (75 kV, 30 s), the reactor was sealed in a high barrier polypropylene 
bag (B2630; Cryovac Sealed Air Ltd, Dunkan, SC, USA) to keep the CAP inside the 
reactor, and to make sure the cells were only affected by the short-lived and long-lived 
reactive species generated in air (Han et al., 2016). Fresh culture medium containing 100 
μg/ml AuNPs was then added after indirect CAP treatment. 
2.2.3 Gold Nanoparticles Synthesis and Characterization. 
20 nm AuNPs used in this study are synthesised by trisodium citrate (Na3C6H5O) 
reduction of auric acid (HAuCl4). The typical method of AuNPs synthesis as follows. 
HAuCl4 was dissolved in water at a concentration of 0.25 mM in a clean glass flask and 
heated with magnetic stirring and brought to boiling. The corresponding amount of 5% 
(w/v) sodium citrate solution was quickly added to final 3.5:1 molar ratio of citrate to 
Au3+ while being keep heating and stirring. The reaction was completed until the colour 
of solution was changed from dark purple to wine red and keep stable. The gold colloid 
was then centrifuged at 10000 g for 10 min to concentrate the AuNPs stock solution to 
2500 μg/ml. The size, absorbance curve and zeta potential of AuNPs was then determined 
by UV-Vis spectrometer (Shimadzu, UV-1800), Zetasizer (Malvern, Nano ZS) and 
scanning transmission electron microscopy (STEM). The AuNPs stock solution was 
diluted in water or culture medium to corresponding concentration as indicated in the 
relevant figures. 
2.2.4 Cell Viability Assays. 
Cell viability was analysed using the Alamar blue assay (Thermo Fisher Scientific), 
which used a redox indicator that can generate fluorescent signal by the metabolic 
reduction. U373MG cells were plated into 96-well plates (Sarstedt) at a density of 1×104 
cells/well (100 μl culture medium per well) and were incubated overnight to allow a 
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proper adherence. The cells were then directly treated with CAP at 75 kV for 0- 30 s at 
70-80% confluency, and culture medium containing 0-100 μg/ml AuNPs was added post 
CAP treatment. Forty-eight hours late, the cells were rinsed once with phosphate buffered 
saline (Sigma-Aldrich), incubated for 3 h at 37 ℃ with a 10% Alamar blue/90% culture 
medium solution. The fluorescence was then measured (excitation, 530 nm; emission, 
595 nm) by a Victor 3V 1420 microplate reader (Perkin Elmer). 
2.2.5 Atomic Absorption Spectroscopy.  
U373MG cells were seeded into 60 mm dishes (Sarstedt) at a density of 1×105 cells/ml 
and incubated for 2 days to achieving 90-100% confluency. The culture medium was 
removed, and cells were directly exposed to CAP at 75 kV for corresponding time. The 
fresh culture medium containing 100 μg/ml AuNPs or 0.1% (w/v) NaN3 was then 
replaced and incubated for 0.5-48 h at 37 ℃ or 4 ℃ as indicated. After treatment, cells 
were washed thrice with phosphate buffered saline to remove the AuNPs outside cells. 
Cells were then dissociated and collected from the culture dish using prewarmed (37 ℃) 
0.25% trypsin solution. The cell suspension was counted using hemocytometer, then 
transferred to 15 ml tube (Sarstedt) to measure the gold atomic absorbance in AAS. To 
verify the Au amount of the samples, five-point standard curve were first established 
using 1-5 ppm standard gold colloid. The concentrations of AuNPs in samples were then 
calibrated by the standard curve as described elsewhere (Trono et al., 2009). 
2.2.6 Inhibitor Studies. 
To determine the uptake of AuNPs, NaN3 was used as metabolic inhibitor to inhibit the 
energy-dependent endocytosis. 20% (w/v) NaN3 stock solution was prepared in 
phosphate buffered saline. The cells were pre-incubated with 0.1% (w/v) NaN3 in 
prewarmed (37 ℃) culture medium for 1h. The culture medium was then removed during 
CAP treatment, then fresh medium containing 0.1% (w/v) NaN3 and 100 μg/ml AuNPs 
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was added into the cell culture and incubated at 37 ℃ as indicated. 4 ℃ incubation was 
used to inhibit endocytosis as a standard experiment. Cells were incubated at 4 ℃ for 1h 
before the CAP treatment, pre-chilled culture medium containing 100 μg/ml AuNPs was 
then replaced post CAP treatment and incubated at 4 ℃ for 0.5-6 h as indicated. N-Acetyl 
Cysteine (NAC) was used as antioxidant to remove long-lived reactive species. 4 M NAC 
stock solution was prepared in water. The cells were pre-incubated with 4 mM NAC in 
culture medium for 1 h at 37 ℃. The culture medium was then removed during CAP 
treatment. Afterward, cells were incubated in fresh medium with 4 mM NAC and 100 
μg/ml AuNPs for 24 and 48 h. 
2.2.7 Fluorescent Dyes and Cell Imaging. 
Lysosomes was demonstrated using the LysoTracker™ Green DND-26 (Thermo Fisher 
Scientific). Cells were seeded in 35 mm glass-bottom dishes (Greiner Bio-One) at a 
density of 1×105 cells/ml overnight and treated with CAP for 0-40 s at 70-80% confluency, 
the fresh medium containing 0-100 μg/ml AuNPs was then replaced and incubated for 
24h or 48 h at 37 ℃ as indicated. After treatment, the cells were rinsed thrice with 
phosphate buffered saline and incubated with prewarmed (37 ℃) LysoTracker-
containing (50 nM) medium for 5 min at 37 ℃. Cells were then washed once with 
phosphate buffered saline and loaded with fresh phosphate buffered saline and observed 
using Zeiss LSM 510 confocal laser scanning microscope fitted with the corresponding 
filter settings as follows. LysoTracker™ Green DND-26, excitation wavelength: 488 nm, 
emission filter: 505-530 nm; AuNPs, excitation wavelength: 633 nm, reflection filter: 
649-799 nm. Plan-Apochromat 63x/1.4 Oil Ph3 was used as objective for all samples. To 
determine the level of AuNPs reflection, around 50 cells were randomly imaged for each 
treatment condition and the levels of reflection was analysed using the ImageJ and 
compared with other groups. 
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2.2.8 Statistical Analysis. 
All data points were from at least triplicate independent samples and are presented and/or 
pooled as mean ± S.E.M unless indicated otherwise. Curve fitting and statistical analysis 
were carried out using Prism 6 (GraphPad Software). The Alpha for all tests is 0.05 and 
two-tailed P values were used. One-way ANOVA and two-way ANOVA was used to 
verify the significance between data points as indicated in figures (*P<0.05, **P<0.01, 
***P<0.001, ****p<0.0001). 
2.3  Results 
2.3.1 The effects of CAP on the physical properties of AuNP.  
CAP has been used to fabricate metal nanoparticles (e.g. gold and silver) without adding 
reducing agents (Tseng et al., 2009). Moreover, AuNPs are known to agglomerate upon 
stresses such as repeated centrifugation, dilution, dialysis, and upon contact with 
biological medium (Articles and Results, 2012). We first explored whether exposure of 
20 nm AuNPs to our experimental plasma device DIT 120 altered their physical 
parameters (size, shape, surface (zeta) potential, or extent of agglomeration) in water and 
biological cell culture medium. A concentration range of AuNPs (20 nm, 50-200 μg/ml) 
in water or culture medium was treated with CAP (75 kV, 30s), or untreated and incubated 
for 24 hours prior to analysis. As evident in Figure 7c, agglomeration was evident at 
higher concentrations (>100 μg/ml) in culture medium and no agglomeration of AuNPs 
was evident even at 200 μg/ml in water. CAP did not induce any significant change in 
particle size and there is no evidence of agglomeration either in water or in culture 
medium (Figure 7c, P=0.1160 in medium group, >0.9999 in water group). We also 
confirmed that dilution of AuNPs in culture medium to 100 μg/ml and exposure to CAP 
(75 kV, 30 s) has no significant change in relation to other physical properties such as 
zeta potential (Figure 7d, P>0.05) or optical absorption (see Figure S1 in the Appendix 
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III). Moreover, no discernible change in physical parameters was evident using Scanning 
Transmission Electron Microscopy, nanoparticles remaining spherical with an average 
diameter of 20 nm and displaying similar degrees of dispersion across the surface of the 
gird (Figure 7e). As AuNPs were not observed to agglomerate in culture medium for 
concentrations AuNPs ≤ 100 μg/ml and no changes in physical parameters were detected 
in response to CAP, culture medium containing up to 100 μg/ml AuNPs were used in 
subsequent experiments exploring uptake kinetics of AuNP. 
2.3.2 Synergistic cytotoxicity when CAP and AuNPs are combined.  
Figure 8. Cytotoxic synergy observed between CAP and AuNP.  
(a) U373MG cells were treated with different concentrations of AuNPs (0-800 μg/ml). 
After incubation for 48 h, cell viability was analysed using the Alamar Blue assay. The 
cell viabilities were divided into two phases (red and green) and non-linear regression 
was carried out. The 95% confidence bands are displayed using dotted lines. Significant 
differences in the slope (p<0.05) are evident using non-toxic AuNPs concentrations (0-
12.5 μg/ml) which was further confirmed using Pearson’s Correlation test (p<0.05). All 
experiments were repeated in five replicates. (b) After CAP treatment (75 kV, 0, 30s) 
U373MG cells were incubated with 100 μg/ml AuNPs for 24 h, 48 h, then observed under 
optical microscope. 
In our previous study, U373MG cells were exposed to CAP for between 3 and 300 s at 
75 kV and the IC50 value of CAP treatment was determined to be 74.26 s (95% confidence 
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range of 47.24–116.8 s) (Conway et al., 2016). The toxicity measured in U373MG cells 
exposed to 30 s CAP is low (18.52%, SEM=5.41%) (see Table S1 in the Appendix III). 
Figure 8a shows the results of non-linear regression analysis used to calculate IC50 values 
and confidence ranges for cells treated with AuNPs alone and AuNPs combined with 
CAP (75 kV, 30 s) (see Table S1 in the Appendix III). The IC50 value for AuNPs alone 
was 2125 μg/ml (95% confidence range: 1294-3491 μg/ml) (Inverse IC50=~0.471 μl/μg), 
which is in agreement with other reports that ~20 nm spherical gold nanoparticles have 
very low cytotoxicity to healthy or cancerous cells (Connor et al., 2005; Pan et al., 2007). 
The IC50 value for AuNPs combined with CAP was 81.71 μg/ml (95% confidence range: 
53.83-124.16 μg/ml) (Inverse IC50=~12.238 μl/μg), ~26 times more toxic by comparing 
their inverse IC50. The dose response curve was divided into two phases of toxicity 
(Figure 8a) to demonstrate synergy between CAP and AuNP. In the first phase, using low 
concentrations of AuNPs (0-12.5 μg/ml), a sharp and significant drop in viability was 
observed only when cells were incubated with both CAP and increasing AuNPs 
concentrations. The 95% confidence intervals of the slope of CAP and AuNPs treated 
cells during first phase (-63.57 to -33.43) was significantly different to AuNPs only 
treated cells (-5.573 to 12.71). We believe this provides evidence that CAP and AuNPs 
have a synergistic cytotoxicity to U373MG cells and the uptake of AuNPs could reach to 
a threshold with increase concentration of AuNP. 
Morphological assessment using bright-field microscopy confirmed the accumulation of 
AuNPs in cells, but this was significantly greater when cells were pretreated with CAP 
(Figure 8b). We therefore hypothesised that CAP can accelerate the uptake and 
accumulation of AuNPs into U373MG cells, thereby causing higher cytotoxicity. To 
explore the mechanism of synergistic cytotoxicity of CAP and AuNPs, we used 100 μg/ml 
AuNPs which is close to the IC50 value, at which no discernible physical changes to 
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AuNPs was observed. 
2.3.3 Role of active (ATP-dependent) and passive (ATP-independent) transport 
mechanisms.  
To confirm the hypothesis that CAP affects enhanced AuNPs uptake, and to investigate 
the mechanisms, Atomic Absorption Spectroscopy (AAS) was used to quantify the total 
amount of gold in cells. Intracellular AuNPs accumulated over time and followed a 
similar overall non-linear relationship for cells with or without exposure to CAP. We 
observed that CAP significantly increased both the initial rate of uptake and total amount 
of AuNPs accumulated in cells (Figure 9a).  
To confirm whether active transport or passive diffusion mechanisms were involved, we 
used the mitochondrial decoupler, NaN3, to identify endocytosis, in which ATP is the rate 
limiting component. Meanwhile, cold temperature incubation (4 ℃) was used to inhibit 
all energy-dependent uptake in cells. NaN3 inhibited AuNPs uptake by about 50% when 
compared with controls (Figure 9a). Interestingly, NaN3 treatment inhibited the uptake of 
AuNPs in both CAP-treated cells and untreated cells. No significant difference was 
observed between these two groups between 4 and 48 hours (Figure 9a), indicating that 
CAP-stimulated uptake of AuNPs is mainly ATP-dependent. On the other hand, NaN3 
can act as a RONS scavenger, which may lead to different conclusions. In Chapter 3, 
AuNPs have been demonstrated to be uptake into cells mainly via endocytosis when the 
cell membrane remains intact. We have demonstrated that the membrane lipids were 
partly peroxidised by the membrane got repaired rapidly and remains intact. Therefore, 
we can confirm that NaN3 mainly inhibited the ATP-dependent endocytosis pathway. 
Cells were then incubated at 4 ℃ for 0.5, 1, 4, 6 h (cell viability was affected at longer 
time points). As expected, uptake of AuNPs was significantly inhibited compared with 
controls (Figure 9a). Together, we believe this provides evidence that an active transport 
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mechanism, most likely endocytosis, is the major route of uptake of AuNPs in cells, 
which occurred between 0 and 16 hours after incubation with AuNP, and which was 
stimulated by CAP exposure. We could not rule out other transport mechanisms playing 
a minor role. For example, we observed a small fraction (i.e. 10%) of CAP-stimulated 
AuNPs accumulation in cells that was not inhibited in either NaN3 or 4 ℃-incubated cells. 
This second, minor CAP-dependent uptake mechanism occurs within 1-hour exposure to 
NaN3 (Figure 9b) and 4 hours of exposure to 4 ℃-incubated cells (Figure 9c). Plasma-
activated culture medium (PAM) containing AuNPs was used to treat cells to determine 
the role of long-lived reactive species (Judée et al., 2016). As seen in Figure 9d, the uptake 
of AuNPs in PAM showed no significant difference when compared with the control after 
24 and 48 h incubation.  
Figure 9. AAS analysis demonstrate the accelerated uptake of AuNPs into cells. 
(a) After CAP treatment (75 kV, 0, 30s), U373MG cells were treated with 100 μg/ml 
AuNPs together with 1% NaN3 or without to inhibit endocytosis, then incubated at 37 ℃ 
or 4 ℃ as indicated before calculating the average amount of Au per cell using AAS. The 
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uptake curves were assessed by non-linear regression analyses. All experiments were 
repeated in six replicates. (b) The short-time effects of CAP with or without 1% NaN3 
were compared. (c) The uptake of AuNPs incubated at 4 ℃ for 0.5, 1, 4, 6 h. (d) The role 
of long-lived ROS generated by CAP on endocytosis in U373MG cells was determined by 
using Plasma activated medium (PAM; 75 kV, 30 s, stored overnight) in place of CAP. 
For Figure 9b-d, all experiments were repeated in six replicates. The statistical 
significances were assessed by two-way ANOVA with Tukey’s multiple comparison post-
test (*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001). 
2.3.4 Subcellular localization of AuNPs endocytosed in response to CAP treatment.  
Despite the accuracy of using AAS to quantify to total amount of Au in a sample, one 
limitation with the technique is the difficulty in differentiating between AuNPs that are 
loosely associated with the plasma membrane compared with intracellular AuNP. To 
verify the uptake of intracellular AuNP, investigate the subcellular location and quantify 
the rate of uptake, we used confocal microscopy (Figure 10). Unlabelled, citrate-capped 
AuNPs were visualised using reflection of laser light from the colloid gold (red dots) and 
lysosomes were counterstained using LysoTracker Green, as shown in Figure 10a. The 
absorption spectrum of 20nm AuNPs confirmed that the absorption peak is around 520 
nm, and that there is minimal absorbance above 600 nm (see Figure S1 in the Appendix 
III). The reflection filter setting for AuNPs was set at 649-799 nm and the emission filter 
for LysoTracker Green was set at 505-530 nm. This allowed us to confirm that the green 
fluorescence signal is from LysoTracker Green (excited with argon laser) and red 
reflection is from AuNPs (reflected light from HeNe laser). A significant fraction of 
intracellular colocalization was evident (yellow), indicating that the lysosomal 
compartment was the major destination of AuNPs following CAP-stimulated uptake 
(Figure 10a). Interestingly, some AuNPs were not located in lysosomes, suggesting that 
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these AuNPs remained in early endosomes or had entered the cytosol, either by passive 
diffusion, transport mechanisms through the cell membrane or released from lysosomes 
subsequent to endocytosis. Significantly higher levels of intracellular AuNPs in cells 
were observed following CAP treatment (Figure 10b), in agreement with our AAS data. 
Moreover, varying the dose of CAP confirmed a significant, strong and positive 
correlation exists between exposure to CAP and subsequent AuNPs uptake (Figure 10c), 
Pearson’s correlation, r=0.9359, P=0.0193. 
Z-stacked images were obtained to ensure that only intracellular AuNPs were quantified. 
Stacked, deconvoluted confocal images were next reconstructed using rendering software 
(Imaris 8.0. Bitplane) to generate 3 dimensional reconstructions of individual cells. The 
presence of AuNPs (red) inside lysosomes (green) was confirmed by rotating and 
sectioning the cells around the three spatial axes and projecting sections from the x, y and 
z planes of the reconstructions (Figure 11a, b. Taken together, our data confirm that CAP 
induces synergistic cytotoxicity while-stimulating the uptake of citrate capped 20nm 
AuNPs through a predominantly endocytic mechanism, leading to trafficking of the 





















(a) After CAP treatment (75 kV, 0, 30 s), U373MG cells were incubated with 100 μg/ml 
AuNPs for 24 h. Cell lysosomes were stained using 50 nM LysoTracker™ Green DND-
26. The reflection of AuNPs was measured by confocal microscopy. (b) After CAP 
treatment (75 kV, 0, 30 s), U373MG cells were incubated with 100 μg/ml AuNPs for 24 
h, 48 h. Cells were then measured by confocal microscopy, the level of reflection of 
AuNPs was quantified using ImageJ. The statistical significance was assessed by two-
way ANOVA with Tukey’s multiple comparison post-test (*P<0.05, **P<0.01, 
***P<0.001, ****p<0.0001), n≥20. (c) After exposure to CAP for increasing time (75 
kV, 0-40 s), U373MG cells were incubated with 100 μg/ml AuNPs for 24 h. Cells were 
then measured by confocal microscopy, the level (Integrated Density) of reflection of 
AuNPs was quantified using the software, ImageJ. Statistical analysis was carried out 
using Pearson’s correlation, r=0.9359, *P (two-tailed) =0.0193, n≥20.  
2.3.5 Role of physical and chemical effects of CAP on AuNPs uptake.  
Our data indicated that long-lived reactive species present in plasma activated medium 
(PAM) did not play a major role in enhanced uptake of AuNPs (Figure 9d). We wished 
to further investigate effects of CAP on AuNPs endocytosis. Due to the set-up of the DBD 
plasma device, samples can either be placed directly in the plasma discharging area 
(direct exposure) or outside the plasma-discharging area (indirect exposure). Plasma 
sources for direct or indirect plasma treatment were previously distinguished by Fridman 
et, al. (Fridman et al., 2008) and more recently by Von Woedtke et, al. (2013) (von 
Woedtke et al., 2013). In indirect plasma treatment, the electrodes are part of the plasma-
generating device, only and there is no significant electrical contact to the targeted 
structures, whereas in direct plasma treatment, the biological samples serve as one of the 
two electrodes. In both cases, samples are contained within a sealed reactor. Direct 
exposure results in direct interaction with UV, electric fields, electron beams, charged 
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particles, whereas indirect exposure does not result in any interaction with these physical 
species. However, the sealed reactor system still allows the exposure of reactive species 
to cells. It has been demonstrated that ozone concentration and reactive oxygen species 
generated are not significantly different during direct or indirect CAP exposure (Ziuzina 
et al., 2013; Han et al., 2016). We investigated the difference between direct and indirect 
CAP treatment on AuNPs uptake to differentiate between direct physical effects and 
chemical (oxidation) effects. Our results demonstrated that AuNPs uptake was 
significantly higher when cells were treated with indirect CAP exposure compared with 
untreated cells, suggesting that chemical effects were important in promoting endocytosis 
(Figure 11c, d). The enhanced AuNPs uptake was consistently slightly lower compared 
with direct CAP exposure although we were not able to determine a significant difference, 
suggesting that any physical effects only play a minor role in the increased uptake of 
AuNP. We used N-Acetyl Cysteine (NAC), a synthetic precursor of intracellular cysteine 
and glutathione (GSH) that replenishes intracellular GSH and scavenges reactive species 
as a redox buffer (Deneke, 2001) to remove long-lived ROS in situ during CAP treatment. 
This was ineffective in significantly reducing AuNPs uptake enhanced by CAP (Figure 
11c, d), suggesting that either the oxidising environment generated by CAP overwhelms 
GSH and other intracellular anti-oxidant defences, or that NAC-insensitive chemicals 
produced by both direct and indirect contained CAP fields are the primary cause of 













Figure 11. AuNPs are incorporated within lysosomes in glioma cells. 
(a) 3D reconstruction of the CAP-treated glioma cells visualized with dichroic channel 
(grey), incorporating AuNPs (red) within lysosomes (LysoTracker green). U373MG cells 
were incubated with 100 μg/ml AuNPs for 24 h, after CAP treatment (75 kV, 0, 30 s) and 
a significant increase of AuNPs was observed in the entire cells but being part located 
inside lysosomes. High magnifications in bottom panel show lysosomes evidenced with 
green isosurface. Vertical and horizontal clipping planes reveal red AuNPs nanoparticles 
inside lysosomes. Boxes at the bottom indicate the orientation of the clipping planes (b) 
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Analogous 3D reconstruction of CAP-untreated cells, demonstrated low incorporation of 
AuNPs inside the cells. High magnification at the bottom panel shows lysosomes rendered 
with green isosurface. Horizontal clipping plane revealed no red material inside 
lysosomes. (c, d) The role of short and long-lived reactive species generated by CAP on 
endocytosis in U373MG cells was determined by pretreating cells with 4 mM anti-oxidant 
N-Acetyl Cysteine (NAC) for 1 h before CAP treatment (75 kV, 30 s) or by indirect CAP 
treatment (see detail in Method). The level of reflection of AuNPs was quantified using 
the ImageJ after incubated for 24 (c) or 48 hours (d). The statistical significance was 
assessed by two-way ANOVA with Tukey ’s multiple comparison post-test (*P<0.05, 
**P<0.01, ***P<0.001), n≥20..  
2.4  Discussion 
AuNPs have been developed as promising theranostic agents for brain cancer therapy in 
diverse applications, such as in vivo tumour imaging, inducing radiosensitization and 
targeted delivery of chemotherapeutics across blood-brain barrier (BBB) to brain cancer 
cells (Joh et al., 2013; Setua et al., 2014). As an emerging platform for drug delivery, the 
toxic effect of AuNPs to normal cells can be minimized or eliminated by altering the size. 
(Pan et al., 2007) However, the proportion of AuNPs that penetrate the BBB is usually 
no more than 1% (Dykman and Khlebtsov, 2012). To date, efforts to enhance AuNPs 
crossing of the BBB have been mainly focused on targeting AuNPs to the surface 
receptors of endothelial cells (Kumar, Zhang and Liang, 2013) and the limited success 
means that there is still need for further studying the mechanisms of crossing BBB and 
blood-tumour barriers, etc. The permeability, targeting capacity and uptake of AuNPs 
into targeted cancer cells are the key to successful clinical application of AuNP. CAP 
treatment has been extensively investigated in cancer therapy, due to its promising 
selective capacity of killing a wide range of cancer cells (Yan et al., 2015), such as 
77 
 
carcinomas, glioblastomas, melanomas and hematopoietic malignancies (Kim et al., 2008; 
H. J. Lee et al., 2009; Yan et al., 2012). In recent years, CAP has been successfully and 
safely used in a prospective clinical trial for head and neck cancer treatment and chronic 
wound healing, demonstrating significant benefits and no side-effects. Meanwhile, the 
synergistic anti-cancer effects between AuNPs and CAP were reported in several 
previous studies (Kim et al., 2008; Cheng et al., 2014; Irani et al., 2015; Kaushik et al., 
2016; Zhu et al., 2016). 
Although cancer cells are generally reported to be favourably sensitive to CAP induced 
cytotoxicity when compared with normal cells or tissues (Babington et al., 2015), 
U373MG GBM cells have significantly higher resistance to CAP treatment compared to 
other cancer cell lines (Conway et al., 2016). GBM cells also show high aggressiveness 
and resistance to radiation therapy and most chemotherapies (Candolfi et al., 2007). There 
is evidence in the literature that AuNPs have synergistic cytotoxicity combined with CAP, 
although the mechanisms remain to be elucidated. Therefore, we chose to study the 
mechanism of CAP, combined with AuNP, as a possible future chemotherapy delivery 
vehicle. In this study, we confirmed that combining CAP with AuNPs increased around 
25-fold of U373MG cell death compared to AuNPs only. We also demonstrated that CAP 
treatments accelerate the endocytosis of U373MG cells by temporarily increaseing 
membrane permeabilisation or turnover, thereby increasing uptake and cytotoxicity of 
AuNP. These effects will be useful to induce higher selective cytotoxicity against cancer 
cells while increasing drug delivery efficiency and/or imaging diagnostics for cancer 
therapy. 
In this study, we used 20 nm citrate capped AuNPs, which not only have optimal BBB 
permeability and low toxicity, but also can rapidly enter cells, mostly by receptor-
mediated endocytosis (Gao, Shi and Freund, 2005; Pan et al., 2007; Shilo et al., 2015). 
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Therefore, 20 nm AuNPs can be the optimal candidate for drug delivery across BBB. We 
were able to confirm that the observation of the uptake of 20 nm citrate capped AuNPs 
are consistent with endocytosis and a large proportion of them were trapped in lysosomes 
in both CAP-treated and untreated U373MG cells (Figure 9, 4 and 5). We confirmed that 
CAP did not discernibly alter the physical properties of AuNP, although we did see 
evidence that CAP could stimulate low levels of non-active uptake through an ATP-
independent mechanism, which may indicate some level of surface modification or other 
physical change to AuNPs and/or cell membranes. Although we were unable to detect 
physical changes to AuNPs exposed to CAP, significant alterations in cell membranes 
after exposure to CAP were previously observed by others (Recek et al., 2015). Our 
observation that synergistic cytotoxicity occurs in parallel with enhanced uptake suggests 
the two processes are linked in U373MG cells. Although, there have been no studies 
reported to date on the relative sensitivity of normal and GBM cells to CAP-induced 
endocytosis, it has been demonstrated that the significant alterations in cell membrane of 
GBM cells induced by CAP treatment is maintained, whereas the membrane alteration in 
normal human astrocytes E6/E7 is weaker and reversible (Recek et al., 2015). More 
detailed mechanisms regulating the uptake of nanoparticles in normal and GBM cells will 
be investigated in a follow-on study. A controllable, directable CAP treatment, which is 
directly applied to diseased tissue, also is expected to be included to present the in vivo 
experiment in the follow-on study. At this stage, we provided a likely hypothesis as 
follows. 
It is possible that enhanced uptake of AuNPs may underpin the synergistic cytotoxicity 
observed, in combination with other effects such as the higher load of reactive species 
carried by CAP-treated AuNP. For example, it has been reported that AuNPs are capable 
of trapping reactive species and extending their half-life, and thus helping the delivery of 
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CAP generated reactive species into cancer cells (Kong, Keidar and Ostrikov, 2011). It 
is also likely that the enhanced accumulation of AuNPs is caused by one of three effects 
attributed to CAP, i.e. reactive species, direct physical effects and cellular mechanism 
(mainly endocytosis). 
Considering the potential role of reactive species, hydrogen peroxide (H2O2) was found 
to be capable of facilitating the endocytosis of polyethylenimine /oligonucleotide 
(PEI/ON) complexes, involving a cytoplasmic [Ca2+]-independent activation of 
calcium/calmodulin-dependent protein kinase II (CaMKII), which stimulates 
cytoskeleton contractions and transportation (Ma, Sun and Wang, 2014). It was also 
found that the ROS generated in mitochondria mediate the hypoxia-induced endocytosis 
in alveolar epithelial cells (Dada et al., 2003). It is considered that CAP is capable of 
influencing cell behaviour by generating intracellular ROS and RNS (Conway et al., 
2016). These studies imply that the CAP-generated intracellular ROS could have an 
impact on the enhanced endocytosis. Meanwhile, reactive species are capable of inducing 
membrane damage and increasing the permeability of cell membrane (Djordjević, 2004). 
The reactive species generated in the cytoplasm or in the medium can induce lipid 
peroxidation in membranes by oxidizing the polyunsaturated fatty acids. Reactive species 
are also able to attack membrane proteins, causing the membrane damage (Djordjević, 
2004). It has been found that the membrane lesions are capable of activating rapid 
endocytosis to remove damage parts and preserve and repair the integrity of cell 
membrane (Idone et al., 2008). Therefore, it is possible that the chemical and physical 
membrane damage caused by CAP could activate the membrane repair response, thus 
accelerating the endocytosis of AuNPs. Although we found that long-lived reactive 
species have little effect on the uptake of AuNPs (Figure 9d), the short-lived, highly 




Considering the direct physical effects, which are mainly electrical factors in DBD CAP 
treatment, Jinno, M et, al. has described the roles of chemical (reactive species) and 
electrical effects of CAP in the CAP gene transfection in L-929, mouse fibroblast cells 
(Jinno et al., 2016). It was found that reactive species alone do not work, but need to be 
combined with electrical effects. Electroporation effects, which can last for a few minutes, 
were also found to play a role in gene transfection (Jinno et al., 2016). Computational 
modelling was used to determine that large pore formation in spherical cell membranes 
(i.e. 15-25 nm) can be induced in strong electric fields in silico (Krassowska and Filev, 
2007), a notion which has since been confirmed for 20 nm AuNPs in vitro (Zu et al., 
2014). Meanwhile, it was observed that the treatment of CAP in GBM cells results in an 
uneven membrane and development of membrane pores (Cheng et al., 2015). Nina Recek 
et. al. have studied the differential effects of CAP on cell membranes of normal human 
astrocytes (E6/E7) and GBM cells by atomic force microscopy. CAP treatment causes a 
temporary disappearance of microvilli in E6/E7, and unrecoverable partial cell 
membranes and cell components damage of GBM cells. The temporary pores created in 
membranes and membrane damage could be the ATP-independent mechanism that 
stimulates low levels of non-active uptake of AuNPs during the first few hours after 
treatment with NaN3 or under low-temperature incubation (Figure 9b, c). Moreover, it is 
also known that CAP is capable of temporarily changing the polarity/potential of the 
membrane, which also could play a role in stimulating endocytosis (Dong, Liu and Xiong, 
2017). As seen in Figure 11c, d, the indirect treatment, which removes the direct physical 
effects caused by CAP, showed only slightly decreased accumulation of AuNPs and no 
significant difference evident compared with direct treatment. It confirmed that the 
temporary direct physical influence caused by DBD CAP treatment plays only a minor 
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role in the increased uptake of AuNP. 
It is considered that the endocyosis of cells can be stimulated by CAP via reactive species 
and other mechanisms such as membrane damage, as indicated above (Idone et al., 2008; 
Ma, Sun and Wang, 2014; Jinno et al., 2016). In gene transfection, the clathrin-dependent 
endocytosis stimulated by CAP was found to be dominant in the uptake, while 
synergistically combining with electrical effects (Jinno et al., 2016). We observed two 
phases to the enhanced uptake of AuNP. Over the first one hour, we observed both 
increased endocytosis and possibly also increased passive diffusion through damaged or 
otherwise permeable membranes (Figure 9b, c). We then observed a second phase, 
between 4 and 18 hours, where AuNPs uptake was further accelerated by CAP primarily 
though endocytosis with no evidence for further passive mechanisms before reaching a 
maximum accumulated threshold (Figure 9a). 
Taken together, we report that the synergistic cytotoxicity of AuNPs and CAP is a result 
of enhanced endocytosis and trafficking to the lysosomal compartment as well as 
temporarily increased membrane permeability, due to CAP treatment. This contributes 
understanding to the mechanisms of synergistic cytotoxic effects between CAP and 
nanotechnologies and identifies strategies that may be employed for the release of drugs 




CHAPTER 3. COLD ATMOSPHERIC PLASMA 
STIMULATES CLATHRIN-DEPENDENT ENDOCYTOSIS 
TO REPAIR OXIDISED MEMBRANE AND ENHANCE 
UPTAKE OF NANOMATERIAL IN GLIOBLASTOMA 
MULTIFORME CELLS 
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3.1  Introduction 
Cold atmospheric plasma (CAP) is increasingly studied in a growing number of clinical 
trials for cancer treatment (Fridman et al., 2008; Guerrero-Preston et al., 2014) and 
research is ongoing to explore the combination of CAP with other therapies, including 
nanoparticles, radiotherapy and chemotherapy (Kim et al., 2008; Collet et al., 2014; He 
et al., 2020).  
Gold nanoparticles (AuNPs) are known to be weakly-toxic to human cells and be readily 
manufactured and designed for targeting delivery of various therapeutic compounds into 
cells. Citrate-capped cationic AuNPs may adsorb serum proteins onto their surface and 
thereby stimulate receptor-mediated endocytosis(Alkilany and Murphy, 2010). Without 
special surface functionalisation, AuNPs enter cells and become trapped in vesicles 
(Chithrani, Ghazani and Chan, 2006; Alkilany and Murphy, 2010; Freese et al., 2012) or 
enter the nucleus, depending on their size/shape (Tsoli et al., 2005; Ryan et al., 2007). 
Meanwhile, AuNPs with functionalised surface chemistries/ligands can directly penetrate 
the membrane and enter the cytoplasm (Verma et al., 2008).  
Recently, AuNPs have emerged as a promising reagent, combined with CAP, for anti-
cancer therapy (Kim et al., 2008; Irani et al., 2015; Zhu et al., 2016). CAP generates a 
unique physical and chemical environment, including generating short- and long-lived 
reactive nitrogen species (RNS, e.g. excited N2, N2+, ONOO- and NO•, etc.) and reactive 
oxygen species (ROS, e.g. •OH, O, •O2- and O3, etc.), photons as well as heat, pressure 
gradients, charged particles, and electrostatic and electromagnetic fields, many of which 
are known to induce biological effects (Stoffels, Kieft and Sladek, 2003; Kong, Keidar 
and Ostrikov, 2011; Babington et al., 2015). Parallels to this can be found in phagocytes 
of the immune system. Enzymatic production of RONS along with various hypohalous 
acids, especially hypochlorite, play a significant role in respiratory bursts, also known as 
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oxidative bursts, which are used in the clearance of tumour cells by phagocytic immune 
cells including neutrophils, macrophages and monocytes (Reuter et al., 2010). Anti-
cancer cytotoxicity induced by respiratory bursts has been shown to induce spontaneous 
regression in mouse tumour models (Chao et al., 1994; Hicks et al., 2006; Zivkovic et al., 
2007).  
Reactive species can induce a free radical chain reaction in membrane lipids leading to 
lipid peroxidation, oxidative degradation of the lipids, disruption of membrane function 
and induced injury and disorder in cells. Peroxidated lipid products can induce further 
propagation of free radical reactions (Halliwell et al., 1992). Several ROS and RNS 
generated by CAP can induce cell injures via lipid peroxidation (Leopold and Loscalzo, 
2009), for instance, hydroxyl radicals (•OH) react with various cellular components, 
including membrane lipid (Adibhatla and Hatcher, 2008) while superoxide (•O2- ) can 
form peroxynitrite (ONOO-), which is able to initiate lipid peroxidation, after reacting 
with nitric oxide (NO) (Adibhatla and Hatcher, 2008). RNS, such as NO2 and ONOOH, 
also interact with lipids to form nitrated lipids, which have been demonstrated to play 
roles in vascular and inflammatory cellular signalling pathways (Leopold and Loscalzo, 
2009).  
Independent application of AuNPs and CAP for cancer therapy has been widely 
investigated. Recent studies have shown that combination of AuNPs and CAP is 
emerging as a novel and promising therapeutic approach against malignant tumours, 
resulting in synergistic anti-cancer effects. Synergistic cytotoxicity has been 
demonstrated for various AuNPs when combined with CAP against several cancer cell 
lines including melanoma (Kim et al., 2008), breast cancer (Zhu et al., 2016), 
glioblastoma (Cheng et al., 2014), alveolar basal epithelial cancer (Kim et al., 2017) and 
colorectal cancer cells (Irani et al., 2015).  
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In our previous study, we demonstrated CAP in combination with AuNPs shows 
promising synergistic cytotoxicity to U373MG Glioblastoma multiforme (GBM) cells 
and ATP-dependent uptake mechanism (He et al., 2018). Kim et al. demonstrated that 
epidermal growth factor-conjugated AuNPs combined with CAP induced DNA damage 
and selective apoptosis of A549 human cancer cells after uptake via receptor-mediated 
endocytosis (Kim et al., 2017). Shi et al found that CAP treatment can induce iron-
dependent oxidative stress to stimulate fluid-phase endocytosis in in mesothelioma cells 
(Shi et al., 2017). 
 However, the precise route of uptake requires further investigation. Herein, we 
demonstrate, for the first time, that synergistic effects of nonfunctionalised AuNPs 
combined with CAP is via clathrin-mediated endocytosis pathway and is triggered as part 
of the CAP-induced membrane repair process in GBM cells. Numerical modelling of the 
uptake of AuNPs, confirmed that CAP treatment stimulated a new uptake route separate 
from normal cellular processes and in response to lipid peroxidation. Meanwhile, our use 
of CAP as an alternative novel tool to trigger and understand membrane oxidative damage 
and repair mechanisms is outlined.  
3.2  Methods 
3.2.1 Cell Culture and Gold Nanoparticle Treatment.  
U-251 MG (formerly known as U-373 MG) (ECACC 09063001), human brain 
glioblastoma cancer cells (Obtained from Dr Michael Carty, Trinity College Dublin) were 
cultured in DMEM-high glucose medium (Merck, Arklow, Ireland) supplemented with 
10% FBS (Merck) and maintained in a 37 ℃ incubator within a humidified 5% (v/v) CO2 
atmosphere. Gold nanoparticles were synthesised by trisodium citrate reduction of auric 
acid. 20nm sphere citrate-capped AuNPs were used to treat cells whose properties were 
determined in a previous study (He et al., 2018). The gold colloid was concentrated to 
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2500 μg/ml then diluted in culture medium to 100 μg/ml. 
3.2.2 CAP Configuration and Treatment.  
The current research uses an experimental atmospheric dielectric barrier discharge (DBD) 
plasma reactor, which has been described and characterised in detail (Moiseev et al., 2014; 
Conway et al., 2016). Unless otherwise stated, all U373MG cells were treated within 
containers, which were placed in between two electrodes, at a voltage level of 75 kV for 
30 s. The culture medium was removed prior to CAP treatment then replaced with fresh 
culture medium afterwards.   
3.2.3 H2DCFDA Assay and Optical Emission Spectroscopy (OES) and Ozone 
measurement. 
H2DCFDA (Thermo Fisher Scientific, Ballycoolin, Ireland) was used to detect ROS 
induced by CAP treatment. U373MG cells were seeded into the TC dish 35 standard 
(Sarstedt, Belfast, UK) at a density of 2×105 cells/ml and incubated overnight to allow 
adherence. After washing twice with PBS, cells were incubated with 25 μM H2DCFDA 
in serum-free medium for 30 min at 37 ℃. Cells were then washed with PBS twice, 
culture medium once and treated with CAP at 75 kV for 30s. The fluorescence of 
H2DCFDA was measured using flow cytometry 30 minutes later. 
Optical emission spectroscopy was carried out using an Edmund Optics CCD 
spectrometer with a spectral resolution of between 0.6 nm to 1.8 nm. The spectra was 
measured using BWSpecTM software with a spectral range between 200 and 850 nm and 
was acquired every 7.5 s with an integration time of 1500 ms. Total relative intensity of 
each emission line was calculated using the integral of the area under each peak. EEDF 
was calculated using a line ratio method (N2 at 337 nm and N2+ at 391 nm) (Begum, 
Laroussi and Pervez, 2013). O3 was sampled using a standard Gastec sampling pump in 
conjunction with a Gastec detection tubes immediately after plasma discharge had ceased. 
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3.2.4 Measurement of Hydrogen Peroxide, Nitrite and Nitrate Concentrations.  
The concentrations of hydrogen peroxide, nitrite and nitrate were quantitatively measured 
in CAP-treated culture medium without phenol red. Concentrations of hydrogen peroxide, 
nitrite and nitrate were determined employing the TiSO4 assay, Griess reagent and 2,6-
dimethylphenol assay, respectively. The quantitative methods have been described in 
detail elsewhere (Lu et al., 2017). To eliminate the effect of the culture medium on 
photometrical measurements, the results of CAP-treated groups were standardised with 
untreated culture medium. 
3.2.5 Lipid Peroxidation.  
For TBARS assay, thiobarbituric acid (TBA), trichloroacetic acid, MDA were purchased 
from Merck. U373MG cells were seeded into TC Dish 150 (Sarstedt) at a density of 1×105 
cells/ml and incubated until confluence. After CAP treatment, cells were further 
incubated for 24 h, and collected by trypsinisation, centrifuged (100 g for 5 min), and 
homogenized by sonication. 100 μl homogenate was mixed with 200 μl ice cold 10% 
trichloroacetic acid and incubated on ice for 15 min to precipitate protein, then 
centrifuged (2200 g for 15 min at 4 ℃). 200 μl of each supernatant was then mixed with 
200 μl 0.67% (w/v) TBA and incubate at 100 ℃ for 10 min. After cooling, samples were 
measured at 532 nm for MDA. 
Lipid peroxidation sensor, C11-BODIPY (581/591) (Thermo Fisher Scientific) was used 
for in-situ detection and localization of the lipid peroxidation induced by CAP treatment. 
Cells were incubated in fresh culture medium containing 5 μM of the probe at 37 ℃ for 
30 min in advance. Then the cells were washed with PBS twice and culture medium once.  
After CAP treatment, cells were further incubated with fresh medium for 30 min at 37 ℃ 
and observed using flow cytometry and confocal microscope as described later.  
3.2.6 Flow Cytometry.  
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BD Accuri™ C6 Plus flow cytometry (BD Bioscience, Allschwil, Switzerland) was used 
in this study. Cells were loaded with C11-BODIPY and treated with CAP as described 
above (Lipid peroxidation). To prepare aliquots, all floating and attaching cells were 
collected by trypsinisation and then washed twice with PBS. For the measurement, a 488 
nm laser was used for excitation, and 10,000 gated events were collected. Green 
fluorescence (oxidised dye) and red fluorescence (non-oxidised dye) was measured using 
an FL1 standard filter (533/30 nm) and FL2 standard filter (585/40 nm), respectively. 
For Propidium iodide (PI) staining, cells were exposed to CAP 75kV for 30s and 
incubated at 37 ℃ for 30 minutes afterwards, then collected by trypsinisation, 
resuspended into 1ml PBS. Resuspended cells were stained with 1µg/ml PI for 5 minutes. 
The fluorescence of PI was then measured at FL2 (585/40nm) standard filter. 
3.2.7 Inhibitor Studies.  
To inhibit various endocytic pathways, cells were pre-incubated with Pitstop (12.5 μM, 
5 min) chlorpromazine (10 μg/ml, 10 min), filipin (5 μg/ml, 30 min), genistein (200 μM, 
30 min), amiloride (50 μM, 30 min) and methyl-β-cyclodextrin (10 mM, 30 min) in 
culture medium for the time indicated, at 37 ℃. After inhibiting treatment, the culture 
medium was removed during CAP treatment, prewarmed fresh culture medium 
containing 100 μg/ml AuNPs was then added immediately to the dishes and incubated 
for 3 h before observing using a Zeiss LSM 510 confocal laser scanning microscope.  
Transferrin conjugated with Alexa Fluor™ 546 was used to determine the change of early 
endosomes induced by CAP combining various endocytosis inhibitors. After the 
inhibiting and CAP treatments indicated above, the cells were incubated in prewarmed 
fresh medium for 0 or 3 h, then incubated with 25 μg/ml transferrin in medium for 5 min. 
Afterwards, cells were fixed with 4% PFA and then observed using confocal microscopy. 
The details of the confocal microscope are described in following section. 
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3.2.8 Clathrin Silencing.  
MISSION® esiRNA (human CLTC) and MISSION® siRNA transfection reagents were 
purchase from Merck. 50,000 U373MG cells were seeded into each 35 mm glass-bottom 
dishes (Greiner Bio-One, Lörrach, Germany) and incubated overnight. 1.2 ul esiRNA 
stock was mixed with 20 ul of transfection reagent in 400 μl serum-free medium and 
incubated for 15 minutes at room temperature. In glass-bottom dishes, previous medium 
was replaced with 1 ml of prewarmed fresh medium with serum. The siRNA/transfection 
reagent solution was then added onto the cells and homogenized to final volume of 1.2 
ml. Afterwards, U373MG cells were incubated at 37 ℃ for 24 h and then incubated with 
fresh medium containing 100 μg/ml AuNPs for 3 h before observing using confocal 
microscopy. 
3.2.9 Endocytosis Tracking and Cell Imaging.  
Early endosomes, late endosomes, lysosomes were demonstrated using the CellLight™ 
Early Endosomes-RFP, BacMam 2.0, the CellLight™ Late Endosomes-RFP, BacMam 
2.0 and the LysoTracker™ Green DND-26, respectively (Thermo Fisher Scientific). 35 
mm glass-bottom dishes (Greiner Bio-One) were used as containers for confocal imaging. 
For early and late endosome marker, 2 μl of BacMan 2.0 reagent per 10,000 cells was 
added in fresh medium and incubated with cells at 37 ℃ for 16 h. Then the cells were 
treated with CAP for 30s and incubated with fresh medium containing 100 μg/ml AuNPs 
for 3 h at 37 ℃. Before observing under a Zeiss LSM 510 confocal laser scanning 
microscope, cells were washed twice with PBS and incubated with fresh medium 
containing 50 nM LysoTracker for 5 min at 37 ℃. The corresponding filter settings were 
as follows. AuNPs, excitation 633 nm, reflection 649-799 nm; Transferrin conjugated 
with Alexa Fluor™ 546, excitation 568 nm, emission 580-630 nm; CellLight™ Early 
Endosomes-RFP, BacMam 2.0, excitation 568 nm, emission 580-630 nm; CellLight™ 
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Late Endosomes-RFP, BacMam 2.0, excitation 568 nm, emission 580-630 nm; 
LysoTracker™ Green DND-26, excitation 488 nm, emission 505-530 nm; C11-BODIPY 
(581/591), excitation 1: 488 nm, emission 1: 500-560 nm; excitation 2: 568 nm, emission 
2: 560-620 nm. Plan-Apochromat 63x/1.4 Oil Ph3 was used as objective for all samples. 
The integrated density of fluorescence in the confocal images was quantified using 
ImageJ software. The confocal images were unscaled, the quantified integrated density 
being the sum of the pixel values in the selection, which is the selected fluorescent area.  
3.2.10 Statistical Analysis.  
At least triplicate independent tests were carried out for each data point, unless indicated 
otherwise. Error bars of all figures are presented using the standard error of the mean 
(S.E.M). Prism 6 (GraphPad Software) was used to carry out curve fitting and statistical 
analysis. Two-tailed P values were used and the Alpha for all experiments is 0.05. The 
significance between data points was verified using one-way ANOVA and two-way 
ANOVA with Tukey’s multiple comparison post-test, as indicated in figures (*P<0.05, 













3.3  Results 
3.3.1 Numerical Modelling of the Uptake of AuNPs by GBM Cells  
Figure 12. Modelling uptake of AuNPs. 
Numerical modelling of experimental data from our previous uptake study (He et al., 
2018) (shown with open circles and dashed lines) was carried out for simulated AuNPs 
uptake (green solid line), AuNPs uptake quenched by incubation of the cells with NaN3 
(blue solid line), AuNPs uptake on application of low dose CAP (red solid line). The 
simulated uptake of AuNPs has been normalised to the maximum calculated value. 
The accumulation of AuNPs inside U373MG cells was monitored using atomic 
absorption spectroscopy and the dose response curve of AuNPs with or without CAP 
treatment has been presented in previous study (He et al., 2018). The experimental results 
reproduced in Figure 12 (open circles/dashed lines) were further analysed according to a 
simulated uptake model to better understand the possible mechanism of CAP-stimulated 
AuNPs uptake. Uptake of nanoparticles by cell populations in vitro has previously been 
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modelled according to a phenomenological rate equation approach (Maher et al., 2014; 
Souto et al., 2016; Byrne and Maher, 2019), which was extended here to further 
investigate the role of CAP in AuNPs uptake.  
The rate of uptake of AuNPs into a cell can be described by the equation: 
dNAuNP/dt= (D-NAuNP) *(1+kdoub) *(N1*R1+N2*R2+N3*R3)     (1) 
where NAuNPs is the number of internalised AuNPs, D is the initial dose of AuNPs, (D-
NAuNP) allows for the depletion of the applied AuNPs dose, and kdoub is the doubling time 
of the cells. N1/R1, N2/R2and N3/R3 allow for three different principle uptake pathways, 
with respective limiting capacities of N and rates R. The first two terms describe 
independent active and passive uptake mechanisms, respectively, with limiting cellular 
capacities N1(0) = N1max and N2(0) = N2max, such that: 
dN1dt= -N1*(D-NAuNP) *R1        (2) 
dN2dt= -N2*(D-NAuNP) *R2        (3) 
Figure 12 (solid green line) shows the simulated uptake of AuNPs, normalised to the 
maximum uptake observed for AuNPs + CAP, for the case of R1 = 3 x 10-3 hr-1, R2 = 2.5 
x 10-5 hr-1, R3 =0, which faithfully reproduces the experimentally observed behaviour. 
Quenching of the active uptake of AuNPs by NaN3 is best simulated by addition of a 
further term in equation 2, such that 
dN1dt= -N1*(D-NAuNP) *R1-N1*NaN3*R4      (4) 
where NaN3 is the effective dose of sodium azide, and R4 allows for the rapid depletion 
of the active uptake pathway. The experimentally observed uptake was well simulated 
(solid blue line) by a value of R4 = 3 x 10-5 hr-1, keeping all other rates as before. 
In simulating the increased uptake of AuNPs upon CAP treatment, it was noted that the 
enhancement of a single pathway described by equations (2-4) by CAP treatment, by 
increasing a single uptake rate, did not faithfully reproduce the experimentally observed 
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behaviour, as the uptakes were limited by the parameters N1max and N2max. Rather, faithful 
reproduction of the observed behaviour required the introduction of independent uptake 
mechanisms for untreated and CAP treated AuNPs uptake, an observation which was 
critical to the interpretation of the effects of CAP treatment on the cells. Such a pathway 
can be represented by: 
dN3/dt = -N3*(D-NAuNP) *R3                                                               (5) 
such that N3(0) = N3max. Upon the application of CAP, the enhanced uptake was well 
fitted (solid red line) by R3 = 2.5 x 10-4 hr-1, keeping all other rates as before. 
The modelling process indicates that CAP treatment increases the capacity of the 
U373MG cells to uptake AuNPs by introducing a third uptake route distinct from passive 
uptake and normal active uptake processes. The modelling parameters employed are 
detailed in Table 1. Note that the parameters relating to the limiting cell uptake, Nnmax, 
were determined by the definition of the dose as 100 mg/mL. Furthermore, the process 
was one of simulation, rather than a mathematical fitting, so the parameters should be 
considered within ~10% confidence. 
Table 2: The modelling parameters employed in Figure 12. 
 N1max N2max N3max NaN3 R1 hr-1 R2 hr-1 R3 hr-1 R4 hr-1 
AuNP 75 150 400 8500 3 x 10-3 2.5 x 10-5 0 0 
AuNPs + 
NaN3 
75 150 400 8500 3 x 10-3 2.5 x 10-5 0 3 x 10-5 
AuNPs + CAP 75 150 400 8500 3 x 10-3 2.5 x 10-5 2.5 x 10-4 0 
 
3.3.2 Reactive Species Generated by CAP Treatment.  
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To identify the possible uptake pathways implicated by the numerical modelling of our 
data, ROS generation of 30 s, 75 kV CAP treatment was first investigated. Several RONS 
were measured using optical emission spectroscopy (OES) and Gastec gas detector tubes, 
including N2, N2+, •OH, and O3. OES emission intensities from the N2 second positive 
system (SPS) were measured at 315, 337, 357, and 377 nm, the N2+ first negative system 
(FNS) at 391 nm, and •OH at 310 nm were measured. The data demonstrated a relatively 
constant RONS production throughout the 30 s treatment (Figure 13a).  
Figure 13. Measurement of reactive species generated by CAP treatment by OES and 
H2DCFDA, TBARS assay and PI staining. 
(a) Emission intensities of excited N2 molecules, N2+ and •OH. (b) Concentration of O3 
measured during CAP treatment. (c) The concentrations of hydrogen peroxide, nitrite 
and nitrate were measured in CAP-treated culture medium. (d) Fluorescence level of 
intracellular oxidised H2DCFDA was measured via Flow cytometry, left curve (green, 
untreated cells), right curve (red, CAP-treated cells). (e) U373MG cells were incubated 
for 24 hours after CAP treatment (0-30 s, 75 kV) and then collected and analysed to detect 
cellular MDA level using TABARS assay. (f) 30 mins after CAP treatment, cells were 
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stained with PI for 5 min, then measured with Flow cytometry. 
The electron energy distribution function (EEDF) of the plasma was also determined. As 
seen in Appendix IV Supplementary Figure S1a, EEDF remained close to a ratio of 7 
during CAP treatment, which indicated that the electron energies were distributed more 
so on the lower end of the energy scale (11 - 12 eV) than the higher energy levels (18.8 
eV). The low variability of the EEDF indicated that the electric field was stable, and that 
the formation of the reactive species was in a steady state manner. Using Gastec ozone 
detector tubes, the concentrations of generated O3 in the extracted gas were measured 
post-discharge of CAP treatment (Figure 13b), revealing significantly increasing levels 
of O3 recorded over the discharge time, which became saturated at the maximum labelled 
value of O3 detection tube after 15 s. High levels of ozone generation may give 
explanation why no detectable or low emission of NO, O, NOx (NO2, NO3, N2O2, N2O3, 
and N2O4), •OH and N2+ were measured in air using OES (Schmidt-Bleker et al., 2015) 
(Appendix IV Supplementary Table S1).  
Hydrogen peroxide (H2O2), nitrite (NO-2) and nitrate (NO-3) were measured and detected 
in culture medium (Figure 13c). Comparing with previous results (Tsoukou, Bourke and 
Boehm, 2018), CAP treatment of culture medium for 30 s generated very low amounts 
of H2O2 (~20 μM), NO2-(~5 μM),  and NO3-(~30 μM) which are at least 15-fold and 200-
fold lower than the IC50 cytotoxicity values we measured previously for U373MG cells 
(315 µM, >1200 µM and >600 µM respectively) and therefore are essentially non-toxic 
(Lu et al., 2017). Intracellular H2O2 was significantly elevated 30 minutes after CAP 
treatment when measured using H2DCFDA by flow cytometry (Figure 13d). Mean 
fluorescence was observed to significantly increase by 4-5-fold above untreated controls 
(Appendix IV Supplementary Figure S1b). 
3.3.3 CAP Treatment Induces Lipid Peroxidation.  
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ROS induces lipid peroxidation of the cell membrane (Leutner, Eckert and Müller, 2001; 
Schuessel et al., 2006). The level of the lipid peroxidation indicator malondialdehyde 
(MDA), measured using the Thiobarbituric acid reactive substances (TBARS) assay, was 
significantly higher in U373MG cells 24 h after CAP treatment compared with the control 
group (Figure 13e), indicating a high level of lipid peroxidation is induced by CAP 
treatment. In our previous study, the IC50 of CAP treatment (75 kV) was determined to 
be 74.26 s (95% confidence range of 47.24–116.8 s) for U373MG cells (Conway et al., 
2016) and we demonstrated that 60 s CAP treatment induces rapid permeabilisation of 
U373MG cell membranes (Conway et al., 2019). Here, we confirm that no significant 
increase of PI uptake is evident following 30 s CAP treatment compared to the control 
(Figure 13f), indicating that membrane integrity was not significantly affected by 30 s 
CAP treatment and CAP-induce lipid peroxidation. This is in agreement with our 
previous findings, where 30 s CAP treatment induces very low, non-significant levels of 
toxicity in U373MG cells 48 hours post treatment (18.52%, SEM=5.41%)(He et al., 
2018). 
CAP induced lipid peroxidation was further analysed and visualised using the lipid 
peroxidation fluorescent sensor C11-BODIPY (581/591). C11-BODIPY (581/591) is a 
lipophilic fluorescent dye that remains membrane bound, can react with various RONS 
and oxidation leads to a shift of the emission peak from around 590 nm (Orange) to 
around 510 nm (Green) (Drummen et al., 2004).  To determine the level of lipid 
peroxidation, more than 60 cells were analysed using ImageJ software for each group. A 
significantly stronger emission of the oxidised green fluorescence was observed in CAP-
treated cells compared to the untreated cells (****p<0.0001, Figure 14a, 2nd panel and 
Figure 14b), which was accompanied by a significant decrease in the non-oxidised orange 
fluorescence (Figure 14a, 1st panel and Appendix IV Supplementary Figure S2). 
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Furthermore, Figure 14c demonstrated a 3-fold significantly greater level of the oxidised 
green fluorescence in CAP-treated cells (****p<0.0001) with a focus on green 
fluorescent vesicle-like structures (Figure 14a, 3rd panel), likely caused by concentrated 
oxidised lipid membranes internalised in endosomes or lysosomes. CAP-induced 
oxidation of lipid membranes was confirmed using flow cytometry (Figure 14d). When 
cells were counterstained with LysoTracker™ Deep Red (red), examples of 
colocalization of oxidised membranes and acidic vesicular organelles (such as lysosomes, 
late endosomes, etc.) were clearly evident in CAP treated cells (Appendix IV 
Supplementary Figure S3, middle& right).  
Figure 14. C11-BODIPY (581/591) staining shows lipid peroxidation and membrane 
trafficking inside the cell to lysosomes. 
(a) Confocal imaging of C11-BODIPY loaded cells, from 1st to 4th panel: Orange, 
reduced form of C11-BODIPY; Green, oxidised form of C11-BODIPY; Red, vesicle-like 
structures was highlighted from green fluorescence using high threshold setting in 
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ImageJ; Merged images (orange and green channels). (b) The total fluorescent 
integrated density of oxidised BODIPY was quantified using ImageJ. (c) With high 
threshold setting, the fluorescence integrated density of oxidised BODIPY was quantified 
with a focus on green fluorescent vesicle-like structures. The statistical significance (b, 
c) assessed by unpaired T-test. (*P<0.05, **P<0.01, ***P<0.001, ****p<0.0001), n≥50, 
see Appendix IV Supplementary Table S2 for original data. (d) Fluorescence level of 
intracellular oxidised BODIPY was measured via Flow cytometry, left curve (green, 
untreated cells), right curve (red, CAP-treated cells).  
3.3.4 Effects of CAP Treatment on Endocytosis of AuNPs.  
A membrane repair mechanism has been described where cells can quickly remove 
damaged regions of membranes from the cell surface through rapid endocytosis (Idone, 
Tam and Andrews, 2008; Andrews and Corrotte, 2018). These impaired membranes can 
be trafficked into endosomes and finally into lysosomes. We wished to determine whether 
rapid endocytosis may contribute to the increased uptake of AuNPs and other materials 
into cells following CAP treatment. To test this hypothesis, CellLight™ Early 
Endosomes-RFP, BacMam 2.0 and CellLight™ Late Endosomes-RFP, BacMam 2.0 
were used to further visualise the route of uptake of AuNPs after CAP treatment. Rab5a 
and Rab7a chimeras tagged with RFP were transfected and expressed inside cells. 
Following overnight incubation, Rab5a-RFP and Rab7a-RFP specifically tracked early 
endosomes and late endosomes, respectively (Dolman, Kilgore and Davidson, 2013). 
Cells were then incubated with AuNPs for 3 h after CAP treatment. In Appendix IV 
Supplementary Figure S4, the white arrows identify examples of co-localisation of 
AuNPs (red) with early (left) and late (right) endosomes (orange). Lysosomes (green) 
were also counterstained. We have previously demonstrated that AuNPs accumulate in 
lysosomes 24 hours after 30 s, 75 kV CAP treatment using confocal imaging and 3D-
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image construction (He et al., 2018). We demonstrate here that that AuNPs enter CAP-
treated U373MG cells mainly through endocytosis and colocalise with Rab5a and Rab7a 
chimeras corresponding to early and late endosomes respectively, eventually 
accumulating in lysosomes (Appendix IV Supplementary Figure S4).  
Transferrin conjugated with Alexa Fluor™ 546, is used as an early endosome marker. To 
investigate the immediate uptake route, CAP treated U373MG cells were incubated with 
Alexa546-Transferrin for 5 min, then fixed with 4% PFA. As seen from confocal imaging, 
within 5 mins after CAP treatment, the number of transferrin-containing endosomes was 
greater compared to the control group (Figure 15a). Quantification of transferrin uptake 
confirmed a significant increase of endosomes 5 min after CAP treatment (Figure 15b, 
p<0.0001). 
Endocytosis is typically subdivided into four types, including clathrin-mediated 
endocytosis (CME), caveolae-mediated endocytosis, macropinocytosis and phagocytosis. 
We used a panel of inhibitors (Iversen, Skotland and Sandvig, 2011) to delineate the 
specific endocytic pathway activated by CAP (see Table 2). Clathrin-inhibitors and 
MβCD-induced cholesterol depletion decreased the number of transferrin labelled 
endosomes and AuNP-uptake 3 h following CAP treatment (Figure 15c, d) whereas 
caveolae-specific inhibitors and an inhibitor of micropinocytosis did not lead to any 
significant inhibition of Transferrin or AuNPs endocytosis in cells 3 h after CAP 
treatment (Figure 15e, f). Original data for quantification can be viewed in Appendix IV 
Supplementary Table S4.   
To further confirm that clathrin-mediated endocytosis played the main role in CAP-
accelerated cellular uptake, MISSION® Endoribonuclease-prepared siRNA (esiRNA) 
against human Clathrin heavy chain 1 (CLTC) was used to disrupting endocytosis 
mediated by clathrin coated pit formation. As seen in Figure 16, AuNPs uptake was much 
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lower in clathrin-silenced cells and no increase in AuNPs uptake was observed 3 h after 
CAP treatment (p<0.0001, see Appendix IV Supplementary Table S5 for original data). 
Together, our data confirms that clathrin-mediated endocytosis played an important role 
in AuNPs uptake, and accelerated endocytosis following CAP treatment was clathrin 
dependent. 
Table 3: Inhibitors used to inhibit endocytosis in this research. 
Agent Effect Targeting endocytosis 
Pitstop 
Small molecular that target and disfunction clathrin 
(Robertson et al., 2014) 
Clathrin-mediated endocytosis 
CPZ 
Inhibits Rho GTPase.  
(Wang, Rothberg and Anderson, 1993) 
Clathrin-mediated endocytosis 
MβCD 
Extracts cholesterol from membrane. (Iversen, 
Skotland and Sandvig, 2011) 
CME, caveolae and 
micropinocytosis 
Filipin 
Interacts with cholesterol  
(Iversen, Skotland and Sandvig, 2011) 
A few caveolae and cholesterol-
dependent mechanisms 
Genistein 
Inhibitor of few tyrosine kinases (Pelkmans, 
Püntener and Helenius, 2002) 
Caveolae pinching 
Amiloride 
Lowers the submembraneous pH and blocks Rac1 


















Figure 15. The CAP-induced endocytosis is clathrin-dependent. 
(a) After CAP treatment (0, 30 s), cells were loaded with transferrin-conjugated with 
Alexa Fluor™ 546 (red) for 5 min and fixed before observing with a confocal microscope. 
(b) The fluorescence level of transferrin was quantified using ImageJ, see Appendix IV 
Supplementary Table S3 for original data. (c, d, e, f) After incubation with various 
inhibitors as indicated, U373MG cells were treated with CAP for 0, 30 s at 75 kV and 
then loaded with transferrin for 5 min or 100 μg/ml AuNPs for 3 h respectively before 
observing using confocal microscopy, with the fluorescence integrated densities 
quantified using ImageJ. The statistical significance in (b, c, d, e, f) was assessed by one-
way ANOVA with Tukey’s multiple comparison post-test (*P<0.05, **P<0.01, 





Figure 16. Clathrin silencing inhibits AuNPs uptake and CAP-induced endocytosis. 
After incubation with esiRNA, targeting expression of clathrin heavy chain, U373MG 
cells were treated with CAP for 0, 30 s at 75 kV and then loaded with 100 μg/ml AuNPs 
for 3 h before observation by confocal microscopy, in comparison with unsilenced groups. 
(a) CAP-untreated cells without silencing, (b) CAP-treated cells without silencing, (c) 
CAP-untreated cells with silencing of clathrin heavy chain, (d) CAP-treated cells with 
silencing of clathrin heavy chain. AuNPs are identifiable as red fluorescence inside cells. 
(e) The fluorescence level was quantified using ImageJ and presented as integrated 
density. The statistical significance was assessed by one-way ANOVA with Tukey’s 
multiple comparison post-test (*P<0.05, **P<0.01, ***P<0.001, ****p<0.0001), n≥50. 
3.4  Discussion 
The cytoplasmic membrane separates and protects the cellular interior from the exterior 
environment and provides specific and efficient exchange channels for the remaining 
intracellular balance and cell viability. Therefore, the integrity of the membrane is vital 
for all cells. Mammalian cells have developed efficient membrane repair mechanisms that 
can recover and reseal an injured cytoplasm membrane quickly to retain cell viability. 
Although investigations of the precise membrane repairing mechanisms have been 
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limited, four possible mechanisms, including patch, tension reduction and 
exocytosis/endocytosis and budding repair mechanisms have been proposed (Andrews 
and Corrotte, 2018). The study of cytoplasmic membrane repair usually employs bacterial 
pore-forming toxins, such as Streptolysin O, to create mechanical injuries on membranes 
(Andrews and Corrotte, 2018). Meanwhile, lipid peroxidation is a complex process that 
damages cellular membrane structure and function, which is believed to link to numerous 
human diseases and aging, including Alzheimer diseases, dementia, Huntington, 
Parkinson, and traumatic injuries, under presence of oxidative stress (Stockwell et al., 
2017; Feng and Stockwell, 2018). Many studies have shown that lipid peroxidation have 
various significant effects to cellular membranes, such as increased membrane 
permeability (Goldstein and Weissmann, 1977; Chatterjee and Agarwal, 1988; Van Der 
Paal et al., 2016), alteration of the lipid order and membrane fluidity (Chatterjee and 
Agarwal, 1988; Borchman et al., 1992; Petrescu et al., 2001; Jacob and Mason, 2005) 
and activity change of membrane proteins (Mattson, 1998; Mattson et al., 1999; Sevanian 
and Ursini, 2000; Jacob and Mason, 2005). However, there remains a paucity of literature 
identifying mechanisms of lipid peroxidation-related membrane damage repair, and the 
mechanisms of oxidised membrane repair remain unknown.  
CAP is known to generate reactive species and thereby cause lipid peroxidation of cells. 
In this research, we explored CAP-induced lipid peroxidation using a low, relatively non-
toxic dose of CAP and studied the possible mechanisms of accelerated cellular uptake of 
AuNPs following CAP-induced oxidative membrane damage.  
As seen in Figure 12, the uptake and accumulation of AuNPs into U373MG cells was 
first modelled. To faithfully reproduce the experimentally observed results in our 
mathematical model, a new independent uptake rate was necessary in the model (equation 
5). This numerical model indicates that CAP treatment may introduce a new uptake route. 
104 
 
Following a detailed experimental analysis, we can confirm this occurs and is due to a 
CAP-triggered, membrane repairing, clathrin-dependent, pathway of endocytosis.  
As seen in Figure 13, we observed a relatively high level of reactive species generated in 
air during CAP treatment such as •OH, ONOO- and O3. This was also evident in medium, 
cells, and ultimately in lipid membranes with the detection of RONS including hydrogen 
peroxide, nitrite and nitrate and detection of peroxidated lipids and by-products. 
Interestingly, the low doses of CAP treatment used generate non-toxic levels of RONS 
but still are induce significant lipid peroxidation.  
CAP treatment has been shown to alter membrane structures, which may be partly due to 
the reactive species-caused lipid peroxidation (Adibhatla and Hatcher, 2010; Cheng et al., 
2014; Recek et al., 2015; Conway et al., 2019). However, in our study, cell membranes 
remain PI impermeable and therefore intact after exposing to 75 kV CAP for 30 s. 
Interestingly, not only did we observe a significant increase in oxidised lipids using C11-
BODIPY following CAP treatment, but there was also a clear and significant increase in 
vesicle-like structures with high levels of oxidised C11-BODIPY, suggesting that 
peroxidised membrane lipids were trafficked inside cells via endocytosis (Figure 14a). 
An immediate (within 5 minutes) increase in endosomes was also confirmed using 
transferrin conjugated with Alexa Fluor™ 546.  
Therefore, we propose that low, sub-toxic doses of CAP can cause cytoplasmic 
membrane oxidation which triggers a rapid membrane repair system. The increased 
endocytosis induced by membrane repair is initiated within 5 minutes and accelerates the 
uptake of AuNPs into U373MG cells.    
To further explore the route of uptake, AuNPs were tracked in cells counterstained with 
Rab5a-RFP, Rab7a-RFP, and LysoTracker™ Green DND-26. Co-localisation of AuNPs 
with early and late endosomes and lysosomes were observed. AuNPs uptake displayed a 
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tendency to enter the periphery region of the cells through endocytosis, then gather at the 
central zone of the cells via endosome trafficking into lysosomes. This demonstrates that 
CAP treatment of U373MG cells triggers uptake and trafficking of AuNPs through early 
endosomes into late endosomes and ultimately accumulation lysosomes. 
Our inhibitor studies and RNA interference studies demonstrate a primary role for 
clathrin-dependent endocytosis of AuNPs, and no other routes of endocytosis in CAP-
triggered uptake. We compared uptake of AuNPs with Transferrin, an essential iron-
binding protein that facilitate iron-uptake in cells via transferrin receptors. Uptake of 
Transferrin is well characterised and involves Clathrin-mediated, receptor dependent 
endocytosis (Lakadamyali, Rust and Zhuang, 2006). Interestingly, Shi et al found that 
CAP treatment decreased transferrin receptor-1 but could induce iron-dependent 
oxidative stress to stimulate significant increase in fluid-phase endocytosis, lysosome 
biogenesis and autophagy in mesothelioma cells (Shi et al., 2017). In contrast to this, as 
seen in Figure 15a, b, our data demonstrates that the uptake of transferrin was 
significantly increased just 5 min after CAP treatment, which may due to the diversity of 
cell lines or CAP generation devices. Similar to AuNPs, formation of transferrin-
trafficking endosomes was inhibited in both groups with 0 and 30 s CAP treatment, after 
exposure to specific/non-specific clathrin inhibitors, including pitstop, CPZ and MβCD. 
Tracking the accumulation of AuNPs demonstrates the long-term CAP-triggered uptake 
via a single, clathrin-dependent endocytosis route are retained for at least 24 hours post 
CAP treatment. Jinno M et al. demonstrated in a CAP-induced gene transfection model 
using mouse fibroblasts that a  clathrin specific inhibitor showed 60% decrease in the 
gene transfection efficiency and that both clathrin-dependent endocytosis and 
electroporation played a role in enhanced transfection efficiency (Jinno et al., 2016). The 
work of Jinno M et al. supports our investigation that clathrin may play key roles in CAP-
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induced cellular uptake mechanisms in response to different materials. 
Our data indicate that oxidised lipids can be seen to colocalise with endosomes and 
lysosomes demonstrating the intracellular sites where the repair of peroxidised lipid 
membranes is taking place. Further investigation of these mechanisms and sites of 
membrane repair following CAP-stimulated oxidative damage is ongoing, to identify 
novel therapeutic targets that can augment CAP cytotoxicity and to fully understand the 
cellular mechanisms governing oxidative membrane repair. 
In summary, we report that the enhanced uptake of AuNPs induced by CAP can be as a 
result of ROS-caused lipid peroxidation, leading to rapid plasma membrane repair via 
clathrin-dependent endocytosis. This contributes to our understanding of the cellular 
effects induced by CAP, especially membrane damage and endocytosis activation, which 
can be employed for efficient uptake of nanomaterials and pharmaceuticals into cells 
when combining CAP with cancer therapies. This mechanism of RONS-induced 
endocytosis will also be of relevance to researchers optimizing other cancer therapies that 













CHAPTER 4. SYNERGISTIC CYTOTOXICITY BETWEEN 
PRO-DRUGS AND CAP AGAINST GLIOBLASTOMA 
CELLS 





Extensive efforts have been made in the war against cancer in the past decades, however, 
the treatment of cancer is challenging due to the tumour heterogeneity and varied patient 
characteristics. Widespread application of advanced stage cancer treatment and early 
diagnosis of cancer are still the highest aspirations.  
Reactive oxygen species (ROS), as natural products generated during normal metabolism 
pathways, play key roles in a variety of cellular activities, but also are considered as 
carcinogenic factors as high levels of ROS are capable of inducing damage and mutation 
of intracellular DNA and therefore cause malignancy (Metelmann et al., 2015). However, 
as understanding deepened, ROS were found to be a double-edged sword to cancer cells 
(von Woedtke et al., 2013).  Evidence showed that higher levels of ROS are generated in 
cancer cells by comparison with normal cells, which is attributed to the higher metabolic 
activities and more rapid proliferation of transformed cells (von Woedtke et al., 2013). 
Hence, the cellular antioxidant system works under heavier load to protect tumour cells 
from oxidative stress, which is a common feature in many types of tumours that can be 
targeted for development of efficient therapies. There have been reported various 
anticancer drugs which can induce extra generation of tumour ROS to kill cancer cells, 
however, they also increase the ROS level in healthy cells, which may induce DNA 
damage and cause secondary malignancies (Peng and Gandhi, 2012). Cold atmospheric 
plasma (CAP) can induce generation of ROS to adjustable levels in controllable area 
(Welz et al., 2015). Meanwhile, prodrugs, which only have cytotoxicity after being 
activated by high level of ROS, have less side effects and are more specific to cancer cells 
(Görmen et al., 2010). Therefore, combining prodrugs with CAP to locally increase 
tumour ROS and activate cytotoxicity only in tumour tissue may provide a novel 
promising combination therapy against most, if not all, cancers.   
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We have acquired in total 47 various types of prodrug candidates from our collaborators, 
who are experts in discovery of novel drugs, including aminoferrocene-based prodrugs 
provided by Prof. Andriy Mokhir (Marzenell et al., 2013), ferrocene, [3] ferrocenophane 
and ferrocifen derivatives provided by Prof. Gérard Jaouen (Jaouen, Vessières and Top, 
2015), matrix metalloproteinase pro-inhibitors and thiazolidinone-based prodrugs 
provided by Prof. Seth M. Cohen (Perez et al., 2015), and a series of pyrazolopyrimidines 
derivatives provided by Prof. John Stephens (Kelada et al., 2018) as described in section 
1.6 (Appendix V Supplementary Table S1, S2, S3, S4 and S5).  
In this chapter, we have screened those 47 candidates for their potential synergistic anti-
cancer effect combined with CAP treatment and identified two leading prodrug 
candidates JW-04-057a and JW-04-061, which were both pyrazolopyrimidine derivates 
provided by Prof. John Stephens. In combination with low dose CAP treatment, which 
had little or no toxicity on cancer cells, the cytotoxicity of leading prodrug candidates 
was synergistically enhanced more than 10 times. The synergistic cytotoxicity between 
JW-04-061 and CAP treatment has been further demonstrated and investigated as 
described in following sections. The ROS generated in culture medium by CAP treatment 
has been determined to play the main role in the activation of prodrug JW-04-061.   
4.2 Methods 
4.2.1 Cell Culture 
U-251 MG (formerly known as U-373 MG) (ECACC 09063001), human brain 
glioblastoma cancer cells (Obtained from Dr Michael Carty, Trinity College Dublin) were 
cultured in DMEM-high glucose medium containing pyruvate (Merck) supplemented 
with 10% FBS (Merck) and maintained in a 37 ℃ incubator within a humidified 5% (v/v) 
CO2 atmosphere. For prodrug treatment, DMEM-high glucose medium without pyruvate 
(Merck) was used to make up culture medium for all groups to avoid the antioxidant 
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effects of pyruvate (O’donnell-Tormey et al., 1987).  
4.2.2 H2DCFDA Assay 
H2DCFDA (Thermo Fisher Scientific, Ballycoolin, Ireland) was used to detect ROS 
induced by CAP treatment. U373MG cells were seeded into the TC dish 35 standard 
(Sarstedt, Belfast, UK) (for flow cytometry) at a density of 2×105 cells/ml, or 35 mm 
glass-bottom dishes (Greiner Bio-One) (for confocal imaging) at a density of 1×105 
cells/ml and incubated overnight to allow adherence. After washing twice with PBS, cells 
were incubated with 25 μM H2DCFDA in serum-free medium for 30 min at 37 ℃. 30 
minutes before measuring the fluorescence of H2DCFDA using flow cytometry, cells 
were then washed with PBS twice, culture medium once and treated with CAP at 75 kV 
for 30s. For confocal imagining, cells were washed with PBS twice, culture medium once 
and treated with CAP at 75 kV for 30s, then were observed under a Zeiss LSM 510 
confocal laser scanning microscope 30 min later (excitation 488 nm, emission 505-530 
nm).  
4.2.3 CAP Configuration and Prodrug Treatment.  
The current research uses an experimental atmospheric dielectric barrier discharge (DBD) 
plasma reactor, which has been described and characterised in detail (Moiseev et al., 2014; 
Conway et al., 2016). Unless otherwise stated, all U373MG cells were treated within 
containers, which were placed in between two electrodes, at a voltage level of 75 kV for 
10-40 s. The culture medium was removed prior to CAP treatment then replaced with 
fresh culture medium afterwards. An optimized prodrug treatment protocol was 
developed and applied in this project as described below. U373MG cells were plated into 
96-well plates (Sarstedt) at a density of 1×104 cells/well (100 μl normal culture medium 
per well) and were incubated overnight to allow a proper adherence. Unless otherwise 
stated, the plating map was 6×10 wells, for 10 different concentrations, negative and 
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positive control groups (5 replicates for each group). All pro-drugs were dissolved and 
prepared in 100% DMSO (Merck) for stock solution, which were then series diluted in 
culture medium to different concentrations as indicated. Afterwards, 10 μl of prodrug 
non-pyruvate culture medium solution was added into each well after fully removing 
previous medium and the rest of prodrug culture medium solution was added into empty 
wells in the plate (300 μl per well). The plate then was treated with CAP at 75 kV for 10-
40 s as indicated. 90 μl of CAP-treated prodrug culture medium solution was then add to 
corresponding wells with cells to final volume 100 μl immediately after CAP treatment. 
Cell viability assays were then carried out after incubation for indicated time.   
4.2.4 Cell Viability Assays. 
Cell viability was analysed using the Alamar blue assay (Thermo Fisher Scientific), 
which used a redox indicator that can generate fluorescent signal by the metabolic 
reduction. After CAP and prodrug treatment, plates were incubated in a 37 ℃ incubator 
within a humidified 5% (v/v) CO2 atmosphere for forty-eight hours. Afterwards, the cells 
were rinsed once with phosphate buffered saline (Sigma-Aldrich), incubated for 3 h at 
37 ℃ with a 10% Alamar blue/90% culture medium solution. The fluorescence was then 
measured (excitation, 530 nm; emission, 595 nm) by a Victor 3V 1420 microplate reader 
(Perkin Elmer). 
4.2.5 CAP-activated medium/prodrug/cells and Inhibitor Study.  
We have investigated the effects of CAP on prodrugs alone to determine the mechanism 
of synergistic cytotoxicity to U373MG cells. Prodrugs were treated with CAP at 75 kV 
for 10 s to 10 min in DMSO stock solution or culture medium solution using 96-well 
plates as container as indicated. The CAP-treated prodrug solution was then added into 
96-well plates to incubate with U373MG cells for 48 hours before cell viability assays. 
For CAP-activated medium, the culture medium was treated with CAP at 75 kV for 30 
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sec in 96-well plate and incubated overnight to remove short-lived reactive species. Then 
prodrug stock solution was series-diluted in the overnight storage CAP-activated medium 
and incubated with U373MG cells in 96-well plates for 48 hours before cell viability 
assays.  
For CAP-activated cells, the U373MG cells were treated with CAP for 30 sec in 96-well 
plates with 10 µl culture medium without pyruvate covered in each well, while culture 
medium was added into empty wells in the plate (300 μl per well). Then the CAP-treated 
culture medium was added to each well to 100 µl. Those CAP-activated cells were then 
incubated in the CAP-activated medium for 0-5 hours as indicated in the figures. 
Afterwards, the previous medium was replaced with fresh medium containing 
corresponding concentrations of prodrugs. The U373MG cells were then further 
incubated for 48 hours before cell viability assays. 
Meanwhile, N-Acetyl Cysteine (NAC) was used as antioxidant to investigate the roles of 
reactive species in activation of prodrugs. 4 M NAC stock solution was prepared in water. 
4 M NAC solution was then diluted in culture medium till final concentration 4 mM 
before adding prodrugs and CAP treatment. The CAP treated culture medium containing 
prodrugs and 4 mM NAC was then added into 96-well plates to incubate with U373MG 
cells for 48 hours before cell viability assays. 
Catalase stock solution (1 mg/ml) was fresh prepared with PBS, then diluted in culture 
medium to 0.1mg/ml for inhibition of H2O2 production. 10 µl of culture medium 
containing 0.1mg/ml catalase and corresponding concentrations of pro-drugs was added 
into each well of 96-well plates to treat U373MG cells with CAP, the rest of culture 
medium containing catalase and pro-drugs was treated in the empty wells of the same 
plates (300 µl per well). After CAP treatment, 90 µl of  CAP-treated culture medium 
containing catalase and  pro-drugs was added into each well and the U373MG cells were 
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then incubated with in total 100 µl of the culture medium containing catalase and pro-
drugs for 48 hours before cell viability assays. 
4.2.6 Statistical Analysis.  
At least triplicate independent tests were carried out for each data point, unless indicated 
otherwise. Error bars of all figures are presented using the standard error of the mean 
(S.E.M). Prism 6 (GraphPad Software) was used to carry out curve fitting and statistical 
analysis. The isobologram and synergistic analysis were carried out using CompuSyn 
software (Available for free download from www.combosyn.com)  according to the detail 
mentioned in Figure 25d legend (Chou and Martin, 2005). Two-tailed P values were used 
and the Alpha for all experiments is 0.05. The significance between data points was 
verified using one-way ANOVA and two-way ANOVA with Tukey’s multiple 
comparison post-test, as indicated in figures (*P<0.05, **P<0.01, ***P<0.001, 
****p<0.0001). 
4.3 Results 
The majority of prodrugs were developed to be activated in cells by oxidation induced by 
ROS. CAP has been well known as inducing generation of ROS (Babington et al., 2015; 
Conway et al., 2016; He et al., 2018). We have demonstrated the generation of ROS by 
CAP in Chapter 3. In Chapter 4, besides flow cytometry, we have used confocal 
microscope and ROS indicator H2DCFDA to demonstrate the ROS generated by 30 s of 




Figure 17. Measurement of reactive species generated by CAP treatment by H2DCFDA. 
Confocal imaging of H2DCFDA loaded cells: (a) untreated U373MG cells; (b) 30 s CAP 
treated U373MG cells. (c) Fluorescence level of intracellular oxidised H2DCFDA was 
measured via Flow cytometry, left curve (green, untreated cells), right curve (red, 30 s 
CAP treated cells). 
As seen in Figure 13 and 14 in Chapter 3, we have also quantified the ROS generation in 
cells and culture medium after 30 s of CAP treatment and measured the level of lipid 
peroxidation in CAP-treated U373MG cells as well. Therefore, 30 s of CAP treatment 
has been demonstrated to be effective on ROS generation and can be used to test the 
synergistic effects with prodrugs. In total four different types of prodrugs have been tested 
in this Chapter, including ferrocene-based prodrugs, pyrimidone bicycle family 
compounds, matrix metalloproteinase pro-inhibitors and thiazolidinone-based prodrugs. 
Due to high amount of work, and to identify leading candidates as soon as possible, all 
compounds were preliminarily tested in CAP-treated and control groups once to acquire 
dose response curves to determine the synergistic cytotoxicity. The relative IC75 values 
of each compounds have been summarised in Figure 18, except low or non-toxic 
compounds (Cmpd1, Cmpd2 and MK2, as seen in Figure 22 and 23, and Table 7 and 8). 
The IC75 values of control groups were separately normalised to 1 together with 
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corresponding CAP-treated groups. The 95% confident ranges were used to present the 
error bars. As see in Figure 18, the difference between control and CAP-treated groups, 
which presents possible synergistic cytotoxicity, was only significant with compounds 1e, 
PY-2-Benzyl, JW-04-057a and JW-04-061. However, according to corresponding dose 
response curves (Figure 19 and 22), there was no significant synergy effect between CAP 
treatment and compounds 1e, PY-2-Benzyl separately. Therefore, JW-04-057a and JW-
04-061 have been determined as the only two leading candidates after repeating the dose 
response curves for two more times. Furthermore, the investigation of the synergistic 
effects between CAP treatment and JW-04-061 and the mechanisms behind it has been 
carried out and presented. 
 
Figure 18. Summary of relative IC75 values of all available compounds.  
The IC75 values were calculated using IC50 values and corresponding hillslopes, and 
then all control groups were normalised to 1 along with corresponding CAP-treated 
groups and 95% confident interval as error bar.  
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4.3.1 Ferrocene-based Prodrugs.  
Figure 19. Dose response curves of compounds 1e and 2a, provided by Prof. Andriy 
Mokhir, Friedrich Alexander University, Germany. 
We have acquired and received a variety of ferrocene-based prodrugs from Prof. Andriy 
Mokhir and Prof. Gérard Jaouen. Two aminoferrocene-based prodrugs were provided by 
Prof. Andriy Mokhir. As seen in Figure 19, compounds 1e and 2a had no significant 
synergistic cytotoxicity but additive cytotoxicity with 30 s CAP treatment. The CAP 
treatment decreased the IC50 values of 1e and 2a (Table 5), but the cell viabilities 
decreased nearly 20% in all CAP treated groups therefore same trends were presented in 
both dose response curves treated with or without CAP. 
Table 4. IC50 values of compounds 1e and 2a, provided by Prof. Andriy Mokhir. 
 
Control CAP 30s  
IC50 (μM) 95% Confidence Intervals IC50 (μM) 95% Confidence Intervals 
1e 153 121.4 to 192.9 63.9 28.42 to 143.7 
2a 80.07 72.40 to 88.55 44.56 23.46 to 84.62 
 
Meanwhile, a series of ferrocene, [3] ferrocenophane and ferrocifen derivatives provided 
by Prof. Gérard Jaouen were tested with U373MG cells (Figure 20 and 21). There was 
no significant synergy observed between those compounds and CAP treatment. Ferrocene, 
[3] ferrocenophane and ferrocifen derivatives usually present strong reaction to ROS. 
They could be already fully activated by the relatively high ROS level in U373MG cells 
instead of CAP treatment, therefore, leading to no synergistic effects with CAP.  
As seen in Table 6, there were highly toxic candidates, P257 (IC50: 62.64 nM, 95% 
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confidence intervals: 20.05 to 195.7 nM), P286 (IC50: 77.75 nM, 95% confidence 
intervals: 39.15 to 154.4 nM), P686 (IC50: 4.1 nM, 95% confidence intervals: 2.134 to 
8.116 nM), P722 (IC50: 29.06 nM, 95% confidence intervals: 8.561 to 98.65 nM), which 
could be further tested both in cancer cell lines with high ROS levels and health cell lines 
with normal ROS levels for drug discovery for GBM treatment as a future project. It is 
interesting that P686 presented significantly lowed cytotoxicity when combining with 
CAP treatment (Figure 21), which might due to chemical or physical effects generated by 
CAP treatment against the structure of P686, thus deactivating the cytotoxicity of P686. 
Table 5. IC50 values of compounds provided by Prof. Gérard Jaouen. 
 











0.233 0.1899 to 0.2859 0.1041 0.08296 to 0.1305 
DP1 0.7197 0.5216 to 0.9929 0.8853 0.6660 to 1.177 
DP6 5.772 4.220 to 7.894 6.697 5.556 to 8.071 
P15 3.188 2.754 to 3.691 2.376 1.928 to 2.927 
P208 5.746 4.991 to 6.614 3.001 1.871 to 4.815 
P228 0.486 0.3139 to 0.7523 0.5175 0.3606 to 0.7426 
P240 1.176 0.8729 to 1.583 1.093 0.8713 to 1.370 
P256 1.626 1.180 to 2.240 1.531 1.253 to 1.872 
P257 0.06264 0.02005 to 0.1957 0.09171 0.03351 to 0.2510 
P258 0.5966 0.4794 to 0.7424 0.5094 0.4016 to 0.6462 
P283 5.303 4.802 to 5.857 5.225 4.679 to 5.835 
P284 1.396 1.073 to 1.817 1.403 1.113 to 1.768 
P286 0.07775 0.03915 to 0.1544 0.07017 0.03573 to 0.1378 
P292 14.56 11.28 to 18.79 18.05 13.15 to 24.77 
P316 4.756 3.796 to 5.957 4.491 3.268 to 6.170 
P388 21.16 18.94 to 23.63 17.17 13.92 to 21.17 
P5 1.739 1.304 to 2.320 2.668 2.096 to 3.396 
P53 0.229 0.1782 to 0.2944 0.2526 0.1895 to 0.3368 
P581 6.813 6.099 to 7.611 8.139 6.512 to 10.17 
P686 0.00416 0.002134 to 0.008116 0.3142 0.1376 to 0.7175 
P721 2.104 1.721 to 2.573 0.8811 0.6000 to 1.294 
P722 0.02906 0.008561 to 0.09865 0.01991 0.005744 to 0.06901 





Figure 20. Dose response curves of compounds provided by Prof. Gérard Jaouen, 











Figure 21. Dose response curves of compounds provided by Prof. Gérard Jaouen, 
Chimie ParisTech, France, Part 2. 
4.3.2 Matrix Metalloproteinase Pro-Inhibitors and Thiazolidinone-Based Prodrugs. 
Several hydrogen peroxides activated matrix metalloproteinase inhibitors and hydrogen 
peroxide responsive thiazolidinone-based compounds were provided by Prof. Seth M. 
Cohen. In our previous study, IC50 value of CAP treatment to U373MG cells was 
determined to be 74.26 s (95% confidence range of 47.24–116.8 s)(Conway et al., 2016). 
The toxicity measured in U373MG cells exposed to 30 s CAP is 18.52%, SEM=5.41% 
(He et al., 2018). As seen from Figure 22, the majority of the compounds presented no 
synergistic effects with CAP treatment. There was only additive decrease of nearly 20% 
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cell viability when U373MG cells were treated with compounds in combination with 30 
s CAP treatment.  
Table 6. IC50 values of compounds provided by Prof. Seth M. Cohen. 
 
Control CAP 30s  












55.39 49.11 to 62.46 36.67 26.32 to 51.08 
PY-2 1008 497.0 to 2045 489.9 71.38 to 3363 
PY-2-
Benzyl 
51.83 43.88 to 61.21 17.07 8.523 to 34.18 
PY-2-
Boronic 
47.41 40.05 to 56.12 29.19 11.60 to 73.44 
Cmpd1 Not 
converged 
Not converged 203.6 141.4 to 293.3 
Cmpd2 Not 
converged 
















Figure 22. Dose response curves of compounds provided by Prof. Seth M. Cohen, 
University of California San Diego, US. 
4.3.3 Pyrimidone Bicycle Family Compounds  
A series of pyrazolopyrimidines derivatives, also as known as compounds from 
pyrimidone bicycle family, provided by Prof. John Stephens were tested using U373MG 
cell line. As seen in Figure 24, the majority of pyrazolopyrimidines derivatives had no 
synergistic cytotoxicity in combination with CAP treatment, the dose response curves of 
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CAP-treated groups presented high comparability and similar trends with untreated 
groups. The CAP treatment didn’t change the IC50 values of the majority of tested 
compounds (Table 8). 
However, the leading candidates of CAP-activated prodrugs were determined in this 
pyrimidone bicycle family. As seen in Figure 23, JW-04-061 and JW-04-057a presented 
great synergistic cytotoxicity with 30 s of CAP treatment. The CAP treatment induced a 
pronounced descent of dose response curves with the increasing of concentrations of 
prodrugs. As seen in Table 8, CAP treatment induced significant decreases of IC50 values 
of JW-04-061 (from 610.8 μM to 55.37 μM) and JW-04-057a (from 940.6 μM to 62.41 
μM) while presenting low cytotoxicity themselves. 
Therefore, among all 47 candidates of prodrugs, JW-04-061 and JW-04-057a were 
determined as the only two leading candidates of CAP-activated prodrugs. The dose 
response curves of JW-04-061 and JW-04-057a with or without 30 s CAP treatment have 
been repeated to further confirm the synergistic cytotoxicity (Appendix V Supplementary 
Figure S2). JW-04-061 has been chosen to be the research focus to save time and budget 
and lay the foundation for future projects.  
Table 7. IC50 values of compounds provided by Prof. John Stephens. 
 











25.51 22.84 to 28.50 12.92 11.53 to 14.48 
JW-01-
033 
11.32 10.09 to 12.70 11.4 10.34 to 12.57 
JW-01-
037 
197 174.3 to 222.7 126.8 113.0 to 142.4 
JW-01-
072 
42.9 37.75 to 48.74 19.04 13.75 to 26.38 
JW-04-
012 
13372 5733 to 31190 5670 1831 to 17555 
JW-04-
017 





366.8 306.1 to 439.5 462.1 197.3 to 1082 
JW-04-
039 
137.2 120.2 to 156.6 86.27 76.20 to 97.68 
JW-04-
057a 
940.6 564.2 to 1568 62.41 49.58 to 78.56 
JW-04-
061 
610.8 523.0 to 713.4 55.37 44.94 to 68.21 
MK2 Not converged Not converged 
MK6 502.2 452.4 to 557.4 608.6 561.0 to 660.2 
MK7 23.34 19.82 to 27.49 38.23 34.96 to 41.80 
MK8 74.59 67.68 to 82.20 44.42 31.39 to 62.85 
MK9 148.1 131.7 to 166.6 86.7 75.02 to 100.2 
Figure 23. Dose response curves of compounds provided by Prof. John Stephens, 
Maynooth University, Ireland, part 1. 
(a) Dose response curves of JW-04-061 with or without CAP treatment. (b) Dose 












Figure 24. Dose response curves of compounds provided by Prof. John Stephens, 
Maynooth University, Ireland, part 2. 
4.3.4 Investigate the Mechanism behind the Synergistic Cytotoxicity Between 
Leading Prodrug Candidate JW-04-061 and CAP Treatment. 
JW-04-061 has been used to further investigate the synergistic anti-cancer effects in 
combination with CAP treatment. To determine the mechanism of CAP activation of JW-
04-061, JW-04-061 was first dissolved in 100% DMSO and then treated with 30 s and 10 
min CAP in DMSO solution. Afterwards, CAP-treated JW-04-061 DMSO solution was 
diluted in culture medium to 1000 μM (DMSO final concentration 1%) and series diluted 
to lower concentrations to incubate with U373MG cells for 48 h before Alamar Blue 
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assay. As seen from Figure 25c, CAP-10 min treated DMSO (series diluted 
concentrations starting from 1%) had no significant cytotoxicity on U373MG cells, and 
untreated JW-04-061, CAP 30s treated JW-04-061 in DMSO, CAP 10 min treated JW-
04-061 in DMSO presented similar dose response curves and IC50 values (Table 9). This 
may due to the lack of ROS generation in 100% DMSO solvent, whereas the generation 
of reactive species relies on the present of reactants in treated liquid (Tanaka et al., 2011), 
and the DMSO may function as scavenger of OH radicals (Eberhardt and Colina, 1988).  
Hence, 30 s and 10 min CAP-treated JW-04-061 DMSO solution demonstrated likely non 
or weak synergistic cytotoxicity in combination with CAP treatment.  
To further confirm the synergistic effects between JW-04-061 and CAP, JW-04-061 was 
diluted in culture medium in different concentration then treated with CAP for 0-40 s. 
The CAP-treated JW-04-61 culture medium solution was subsequently incubated with 
U373MG cells for 48 h before Alamar Blue assay. As seen in Figure 25a, b, CAP 10-40 
s treated JW-04-061 culture medium solution induced a pronounced decreasing of cell 
viability with concentrations higher than 10 μM compared with CAP untreated group, 
when CAP treatment alone had low cytotoxicity (~20% decrease of cell viability). 






061 in DMSO 
CAP 10 min 
treated JW-04-
061 in DMSO 
CAP 10 min 
treated 
DMSO 





85.37 to 169.4 84.72 to 136.8 117.7 to 128.5 1228 to 4233 
 
Meanwhile, NAC was applied as antioxidant to further investigate the mechanism. 4 M 
NAC solution was diluted in culture medium till final concentration 4 mM before adding 
JW-04-061 and 40 s CAP treatment. As seen in Figure 25a, b, the NAC treated group 
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presented much higher cell viability and relatively gentle decrease of dose response curve 
compared to CAP treated group, which demonstrated that ROS generated by CAP 
treatment played key roles in the activation of anti-cancer effects of JW-04-061. The 
normalized isobologram also have been analysed and presented in Figure 25d, which 
further confirm the synergistic effects between CAP treatment and JW-04-061 treated in 
culture medium. Using CompuSyn software, the synergistic analysis was carried out and 
combination index (CI) values have been calculated. The CI values of JW-04-061 with 
10 s CAP were 0.31099, 0.33520 with 20s, 0.47561 with 30s, and 0.57796 with 40 s, 
which were all less than 1.00 and confirmed the significant synergistic cytotoxicity 
between CAP treatment and JW-04-061 (Figure 25d). 
Taken together, we have demonstrated that JW-04-061 was mainly activated by the 
reactive species generated during CAP treatment, therefore presented significant 
synergistic cytotoxicity to U373MG cells in combination with CAP treatment.  
Before the COVID-19 situation and closure of the research buildings, we acquired 
additional preliminary results which have been included in Appendix V, which can be 
used to further determine the detailed mechanism behind the synergistic cytotoxicity 
between CAP treatment and prodrug JW-04-061. Overnight storage CAP-activated 
medium, CAP-activated cells and catalase (hydrogen peroxide decomposition) have been 
used to study the dose response of U373MG cells to JW-04-061. 
As seen in Appendix V Supplementary Figure S3a, when cells were treated with 
overnight storage CAP-activated medium and prodrug, no synergistic cytotoxicity was 
observed. Meanwhile, the U373MG cells have been activated and incubated for 0-5 hours 
after CAP treatment, then incubated with fresh medium containing prodrug. There was 
no significant synergistic cytotoxicity observed between CAP-activated cells and prodrug 
comparing to direct combination of CAP treatment and prodrug, but the CAP-activated 
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cells presented relative lower cell viability at low prodrug concentration comparing to 
direct combination of CAP treatment and prodrug (as seen in Appendix V Supplementary 
Figure S3b). On the other hand, as seen in Appendix V Supplementary Figure S3c, there 
was no significant synergistic effects between CAP treatment and prodrug JW-04-061 to 
catalase treated cells.  
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Figure 25. Dose responses of U373MG cells to JW-04-061 treated by CAP in culture 
medium solution or DMSO stock solution. 
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JW-04-061 has been added into culture medium to corresponding concentrations then 
treated with CAP for 0-40 s with or without NAC. Then the CAP treated medium 
containing JW-04-061 was added in 96-well plates to incubate with U373MG cells for 
48 hours and the dose response was presented using nonlinear regression (a) and bar 
chart (b). (c) JW-04-061 was prepared in DMSO stock solution and treated with CAP for 
30s and 10 min, then series diluted in fresh culture medium and incubated with U373MG 
cells for 48 hours and compared with control groups (Untreated JW-04-061 and vehicle 
(equivalent volume of pure DMSO) treated with CAP for 10 min).(d) Isobologram 
analysis of the combinational effect of JW-04-061 and CAP. The single doses CAP on y-
axis and JW-04061 on x-axis were used to draw the line of additivity. Four combination 
points were indicated in the isobologram (CAP 10-40s and corresponding IC50 values 
of CAP-treated JW-04-061). The localisation of combined JW-04-061 and CAP at 
different time exposures can be translated to synergism CI＜1, additivity CI=1 or 
antagonism CI>1. 
4.4 Discussion 
With development of technique and revolution of knowledge, we are capable of 
performing precise surgery, targeted and focused chemotherapy and radiotherapy after 
quick and accurate diagnosis of tumours. However, current treatments still present several 
side effects, including poor patient experience, secondary malignancy and a variety of 
long-term sequelae (Triesscheijn et al., 2006; Tachibana, Feril and Ikeda-Dantsuji, 2008; 
von Woedtke et al., 2013; Murray and Robinson, 2016). Meanwhile, researchers are 
exploring novel therapies based on different techniques, including sonodynamic therapy 
(Maeda et al., 2017), photodynamic therapy (Kawczyk-Krupka et al., 2015), CAP therapy 
(Ratovitski et al., 2014), gene therapy (Naldini, 2015) and immunotherapy (Pardoll, 2012) 
and some of them have achieved great outcome in clinical trials and even been 
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successfully applied in practice. However, novel therapies are also very limited with the 
high requirement of technique, expensive cost and unknow side effects. In this case, 
combination therapy has been considered as a promising way to solve the problem in a 
short time while generating less side effects. Usually patients are treated with 
combination of surgery, radiotherapy and chemotherapy based on the type and progress 
of the tumours. However, those treatments usually present no synergistic therapeutic 
effects but increase additive anti-cancer effects to improve the survival of patients along 
with more side effects. The purpose of investigating combination therapy in this chapter 
is to improve the anti-cancer effects synergistically and therefore to reduce the dose and 
side effects of the treatment.  
We have tested a total of 47 prodrug candidates from 4 collaborators, including 
aminoferrocene-based prodrugs provided by Prof. Andriy Mokhir (Marzenell et al., 
2013), ferrocene, [3] ferrocenophane and ferrocifen derivatives provided by Prof. Gérard 
Jaouen (Jaouen, Vessières and Top, 2015), matrix metalloproteinase pro-inhibitors and 
thiazolidinone-based prodrugs provided by Prof. Seth M. Cohen (Perez et al., 2015), and 
a series of pyrazolopyrimidines derivatives provided by Prof. John Stephens (Kelada et 
al., 2018), in combination with low dose CAP treatment using culture medium without 
pyruvate. We have identified only two leading candidates with synergistic cytotoxicity in 
combination with CAP treatment, which are JW-04-061 and JW-04-057a provided by 
Prof. Stephens.  
As seen in Figure 19, 20, 21 and 22, all candidates provided by Prof. Andriy Mokhir, Prof. 
Gérard Jaouen and Prof. Seth M. Cohen which contain typical ROS-trigger groups 
presented no significant synergistic cytotoxicity in combination with low dose CAP 
treatment. However, there were few prodrug candidates which presented significant anti-
cancer effects just themselves. This might be due to the relatively high ROS level in 
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U373MG cancer cells caused by their rapid proliferation and altered metabolism. 
Subsequently, the relatively high cellular ROS level in U373MG cells was already rich 
enough to trigger the activation of those prodrug candidates without extra ROS generated 
by low dose CAP treatment. Therefore, the CAP treatment didn't activate those prodrug 
candidates in U373MG cells and thus presented no synergistic cytotoxicity in 
combination with those prodrugs. However, those high cytotoxic prodrug candidates, 
including P286, P686, P53, P722, P258, P257 (as seen IC50 values in Table 6, dose 
response curves in Figure 20 and 21), can be used in future projects to test their 
cytotoxicity and specificity in healthy cells and cancer cells, which may contribute to the 
discovery of novel efficient anti-cancer prodrugs. 
Furthermore, as seen in Figure 25, we have investigated the synergistic effects between 
JW-04-061 and CAP treatment. To distinguish the effects induced by CAP to cells and to 
prodrugs, we have investigated the cytotoxicity of CAP-treated prodrugs without direct 
and immediate effects from CAP treatment to cells. 
To remove the direct and immediate effects from CAP to U373MG cells, we first treated 
JW-04-061 in DMSO for 30 sec or 10 min then series diluted the CAP-treated JW-04-
061 DMSO solution in fresh medium to corresponding final concentrations, subsequently, 
U373MG cells were incubated with CAP treated JW-04-061 culture medium solution 
(from CAP-treated DMSO solution) to investigate if the CAP treatment induced direct 
changes to prodrugs in DMSO solution. However, there's no significant synergistic 
cytotoxicity observed when the CAP treatment was performed to prodrug DMSO solution 
(Figure 25c). We have realized that 100% DMSO contains no H2O in the solution, 
therefore it could be one of the reasons that the CAP treatment could not induce enough 
generation of ROS in JW-04-061 DMSO solution without substrate (Lu et al., 2017). 
DMSO has been demonstrated to be a scavenger of OH radicals (Eberhardt and Colina, 
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1988). Therefore, alternatively, JW-04-061 was first diluted in fresh culture medium to 
corresponding concentrations, then was exposed to CAP treatment for 10-40 s at 75 kV. 
The CAP-treated JW-04-061 culture medium solution was subsequently incubated with 
U373MG cells for 48 h before Alamar Blue assay. As seen in Figure 25a, b, significant 
synergistic effects were observed in combination of CAP treatment and JW-04-061 
treated in culture medium solution. The synergistic cytotoxicity was also analysed using 
isobologram (Figure 25d). Meanwhile, we have applied NAC as antioxidant to 
investigate the roles of ROS. As seen from Figure 25a, b, with protection from NAC, the 
cytotoxicity of CAP-treated JW-04-061 in culture medium was significantly decreased. 
Although, the NAC may decrease the intracellular ROS level of U373MG cells then lead 
to the decreased cytotoxicity. The lower dose of CAP treatment induced less increasement 
of cytotoxicity of JW-04-061, which supported that the ROS generated in culture medium 
played the main role in the activation of drug. Taken together, we can determine that, 
without direct and immediate effects from CAP to U373MG cells, JW-04-061 still has 
significant synergistic cytotoxicity in combination with CAP treatment when there is 
normal generation of ROS in culture medium. However, we could not fully determine the 
roles of CAP-induced ROS played in the synergistic effects yet. The high level of ROS 
in culture medium may affect U373MG cells via a variety of activities, including lipid 
peroxidation, oxidation of protein/DNA/RNA, and intracellular ROS signalling pathways, 
then trigger the synergistic cytotoxicity with JW-04-061. We acquired additional 
preliminary results which may explain more mechanism behind the synergistic 
cytotoxicity between JW-04-061 and CAP treatment. 
Overnight storage CAP-activated medium, CAP-activated cells and catalase (hydrogen 
peroxide decomposition) have been used to study the dose response of U373MG cells to 
JW-04-061 and investigate the mechanism behind the synergistic cytotoxicity between 
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JW-04-06 and CAP treatment. As seen in Appendix V Supplementary Figure S3a, JW-
04-061 was added into overnight storage CAP-activated medium just before incubation 
with cells, no synergistic cytotoxicity was observed when cells were treated with 
overnight storage CAP-activated medium containing JW-04-061 compared to control 
groups. Yan et al. reported that short-lived reactive species were removed by overnight 
storage as well as most of long-lived reactive species, such as hydrogen peroxides in the 
CAP-activated medium (Yan et al., 2016). However, the DIT-120 system investigated in 
this project has been shown to generate high concentrations of hydrogen peroxides which 
were stable in various liquids over storage time (Boehm et al., 2017). Therefore, this is 
yet to be further determined for prodrug treatment. So far, we can determine that the 
oxidised components in CAP-activated medium have no effect on the synergistic 
cytotoxicity between CAP-treatment and prodrug JW-04-061. For the record, the fresh 
CAP-activated medium should have been used to compare with the overnight storage 
CAP-activated medium for prodrug series dilutions and treatment. As seen in Figure 25, 
the fresh CAP-treated medium containing prodrugs presented significant synergy, which 
may be comparable with overnight storage CAP-activated medium. Meanwhile, as seen 
from Appendix V Supplementary Figure S3c, catalase has been used to decompose 
hydrogen peroxides, and the prodrug only has been exposed to other reactive species 
generated by CAP, which demonstrated no significant synergistic cytotoxicity. It 
demonstrated that the hydrogen peroxides generated by CAP in culture medium may play 
a main role in the activation of JW-04-061 during and after CAP treatment. 
On the other hand, CAP-activated U373MG cells have been applied to investigate the 
possible synergy between prodrugs and cellular responses to CAP treatment, such as 
peroxidised cellular membrane, accelerated cellular uptake and oxidation stress response 
(He et al., 2020). U373MG cells were activated together with medium by CAP for 30 sec 
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and then incubated for 0-5 hours. Afterwards, fresh medium containing prodrug JW-04-
061 was used to test cellular dose response and the possible synergistic effects. As we 
can see in Appendix V Supplementary Figure S3b, there was no significant synergistic 
cytotoxicity observed between CAP-activated cells and JW-04-061 compared to direct 
combination of CAP treatment and prodrug. However, it presented lower cell viability 
(around 25% decrease) in CAP-activated cells, which may be due to changing of culture 
medium 0-5 hours after CAP treatment causing extra loss of cells. However, it 
demonstrated that the synergistic cytotoxicity is mainly from CAP-activated prodrug 
instead of CAP-activated cells. The experiments discussed above, including treating cells 
with CAP only, incubating cells with prodrugs only, treating cells and prodrugs with CAP 
at the same time, incubating CAP-untreated cells with CAP-treated prodrugs (prodrugs 
were treated with CPA in culture medium solution or DMSO stock solution), incubating 
CAP-untreated cells with prodrugs dissolved in overnight storage CAP-activated medium, 
incubating CAP-treated cells with CAP-untreated prodrugs, were performed with same 
volumes, same concentrations of prodrugs and same types of culture medium without 
pyruvate. NAC and catalase were used as scavengers of reactive species in inhibiting 
study. The preliminary conclusion is that the JW-04-061 presents significant synergistic 
cytotoxicity against U373MG cells after being activated by low doses of CAP treatment 
in culture medium, whereas the ROS, specifically hydrogen peroxides, may play a main 
role in the activation of JW-04-061. 
All in all, investigating combination therapy is a promising way to develop efficient anti-
cancer therapies with as little as possible side effects, especially if there are significant 
synergistic anti-cancer effects which can be specifically and precisely targeted to tumour 
tissue. Various compounds and nanoparticles were investigated as sensitizers for 
radiotherapy, photodynamic therapy and others. However, the majority of sensitizers only 
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promote the efficiency of the therapy itself or present extra diagnosis function but have 
no extra therapeutic effect. Therefore, in this chapter, we discovered and demonstrated 
new compounds that can synergistically kill cancer cells in combination with low dose 
CAP treatment, which have not been reported before. The JW-04-061 and JW-04-057a 
can be further investigate for future trials. This research has contributed to the foundation 
of CAP/ROS-trigger prodrugs research and will inspire the development of more efficient 

















In the development of successful interventions to cure cancer, nanomaterials have played 
key roles. In last two decades, a variety of nanomaterials have been greatly expanded as 
well as highly diversified and multi-functionalized. Some of these nanomaterials were 
determined as lead candidates to delivery chemotherapeutics to tumours and have passed 
preclinical trials and successfully applied to the clinic. Enhanced permeation and 
retention-based tumour targeting and then, especially, active targeting was introduced, 
which highly increased the efficiency and specificity of drug delivery into tumours. Due 
to the excellent loading capacity of nanocarriers and multifunctionality of their ligand or 
themselves, nanoparticles can be applied in cancer treatments, as both carriers, sensitisers 
and imaging agents, which can provide advanced diagnosis as well as diversified 
treatments.  
AuNPs, as one of the most commonly investigated and used nanomaterials for cancer 
treatment, can be readily manufactured in a variety of specific shapes, size and 
monodispersity with different functions, therefore can be used as diagnostic agents, 
carriers and/or sensitizers for cancer therapy. The AuNPs we used in this project were 
synthesised by trisodium citrate (Na3C6H5O) reduction of auric acid (HAuCl4) and 
therefore were not functionalized and only capped with citrate and manufactured in 
spherical shape and ~20 nm diameter by controlling the ratio between Na3C6H5O and 
HAuCl4. Non-functionalized AuNPs have shown selective cytotoxicity to cancer cells, 
are generally consider nontoxic to healthy cells whereas small AuNPs usually elicit 
higher cytotoxicity than larger AuNPs (Connor et al., 2005; Patra et al., 2007; Alkilany 
and Murphy, 2010). The AuNPs of ~20 nm diameter we used have been demonstrated to 
have elicit relatively low cytotoxicity in both normal and cancer cells and are optimal for 
permitting BBB compared with non-functionalized AuNPs of other sizes (Pan et al., 2007; 
Shilo et al., 2015). Therefore, 20 nm citrated capped spherical AuNPs were applied in 
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this study for investigation of the combination therapy with CAP treatment, which also 
can be the optimal candidate for drug delivery across BBB. 
As emerging technology, it has been clinically shown that cold atmospheric plasma can 
be safely and directly applied on patients for disinfection and promoting the healing of 
wounds and ulcerations (Weltmann et al., 2008; von Woedtke et al., 2013; Mai-Prochnow 
et al., 2014; O’Connor et al., 2014). CAP is showing strong potential in cancer treatment 
as well. Recently, it has been repetitively demonstrated that CAP have significant and 
selective cytotoxicity to multiple tumour lines in vitro and in animal models (Walk et al., 
2013; Ratovitski et al., 2014; Park et al., 2015; Recek et al., 2015; Yan et al., 2015; 
Conway et al., 2016; Zhu et al., 2016). Moreover, as additional treatment, a prospective 
clinical trial for head and neck cancer treatment has been carried out, Metelmann et al. 
presented that CAP treatment not only reduced contamination of ulcerations caused by 
head and neck cancer and may have inhibited tumour growth and caused visible local 
destruction after two weeks of treatment. Meanwhile, during the trial, CAP treatments 
presented low side effects and benefits to patients in various aspects, such as easy to 
handle treatment, easing cancer pain, gain of weight and likely prolonged survival. 
(Metelmann et al., 2015). Most recently, for the first time, a CAP device, Canady 
HeliosTM Cold Plasma Scalpel, has been approved for human clinical cancer treatment 
trials by the FDA to evaluate its safety in patients with solid tumours with carcinomatosis 
scheduled to undergo surgical resection for cytoreduction (‘Canady Helios Cold Plasma 
Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites’, 2020). In this 
study, cold plasma is sprayed in the area of the resected tumour margins after removing 
gross solid tumour via surgery (‘Canady Helios Cold Plasma Scalpel Treatment at the 
Surgical Margin and Macroscopic Tumor Sites’, 2020). Cold plasma also has been 
successfully evaluated in many non-cancer related trials (e.g. Chronic wounds treatment 
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(Isbary et al., 2012), symptomatic knee osteoarthritis treatment (Sánchez et al., 2012), 
herpes treatment (Isbary et al., 2014), treatment of lesions in Hailey-Hailey disease 
(Isbary et al., 2011)). For instance, for chronic wounds treatment, a randomized 
controlled trial presented a significant reduction in bacterial load in plasma-treated 
wounds (Isbary et al., 2012). The CAP treatment for patient with chronic wounds was 
well tolerated and no side-effects occurred (Isbary et al., 2012). 
A promising synergistic anti-cancer effect between CAP and AuNPs which we observed 
was that the uptake of AuNPs into U373MG cells was significantly enhanced with CAP 
treatment, and the cytotoxicity of the AuNPs to U373MG cells was also significantly 
increased combined with CAP treatment. There have been reports that CAP treatment can 
induce pore formation on cell membrane that may increase delivery of agents into cells, 
and had synergistic cytotoxicity combined with nanoparticles especially gold 
nanoparticles. Jinno et al. has described that the electrical effects of CAP combined with 
reactive species helped the gene transfection into L-929, mouse fibroblast cells (Jinno et 
al., 2016). Krassowska et al., simulated that strong electric fields, which exist during CAP 
treatment, can induce formation of large pore in  spherical cell membranes (i.e. 15-25 nm) 
(Krassowska and Filev, 2007). Cheng et al., observed that uneven membrane and 
membrane pores were induced in U87 cells after treatment of CAP (Cheng et al., 2015). 
Nina et al., also described the unrecoverable partial cell membranes and cell components 
damage induced by CAP treatment in U87 cells. The direct membrane damage and pore 
formation induced by CAP treatment described in these studies may explain that we 
observed low levels of non-active uptake of AuNPs during the first few hours after CAP 
treatment, which was not inhibited by NaN3 or low-temperature (4 ℃) incubation. NaN3 
was used as metabolic inhibitor to inhibit the energy-dependent endocytosis, and low-
temperature incubation was used to inhibit endocytosis as a standard experiment. 
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However, we mainly observed that active uptake of AuNPs was stimulated after low dose 
CAP treatment which was inhibited by NaN3 and low-temperature incubation. This has 
not been reported before. Furthermore, we also observed the significant enhancement of 
AuNPs uptake with indirect CAP treatment which removes the direct physical effects. It 
confirmed that pore formation and direct membrane damage plays only a minor role in 
the increased uptake of AuNPs induced by low dose CAP treatment compared to previous 
studies. It should be noted that each of these studies were carried out using different 
cancer cell lines and various dose of CAP generated by different devices with distinct 
input voltage, frequent, current and therefore cause different response of cancer cells to 
CAP treatment.  
On the other hand, several studies to date have reported the synergistic anti-cancer effect 
between CAP treatment and AuNPs. Kim et al., first demonstrated that cytotoxicity of 
CAP to G361 human melanoma skin cancer cells was significantly increased (near five-
fold) by combining with anti-FAK antibody-conjugated AuNPs (FAK-AuNPs) (Kim et 
al., 2008). In this study, the adopted 30nm AuNPs didn’t present any observable cytotoxic 
effect on the proliferation of G361 cells while applied alone, but increased the cell death 
rate from 14% (CAP only) to 36% (CAP and unconjugated AuNPs) and 74% (CAP and 
FAK-AuNPs) (Kim et al., 2008). It is interesting that Kim et al., noted that the cell 
morphology was maintained, even in dead cells, after combination treatment of CAP and 
FAK-AuNPs, whereas cells dying from CAP usually undergo anoikis. (Kim et al., 2008). 
In another study, fluorouracil, a DNA synthesis inhibitor chemotherapeutic that has been 
widely used in clinical treatment of breast, gastrointestinal and gynaecological cancers, 
was loaded in core (gold)-shell (PLGA) nanoparticles for combination treatment with 
CAP against human breast cancer MDA-MB-231 cell line (Zhu et al., 2016). Synergistic 
cytotoxicity between the drug loaded core-shell AuNPs and CAP treatment and enhanced 
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cellular internalization of the drug loaded core-shell AuNPs by CAP treatment were 
observed (Zhu et al., 2016). Similarly, X. Cheng et al., described that 100 nm uncoated 
AuNPs presented synergistic cytotoxicity to U87 cells combined with CAP treatment, 
which was also dose dependent (Cheng et al., 2014). At the optimal concentration, AuNPs 
induced U87 cell death up to a 30% overall increase compared to the control group with 
the same plasma dosage only (Cheng et al., 2014). Highest intracellular ROS intensity 
induced by CAP was measured at this optimal concentration as well (Cheng et al., 2014). 
The exact mechanism has yet to be discovered but they concluded that the AuNPs in the 
medium may accelerate the absorption of exogenous ROS and RNS generated by CAP 
into cells (Cheng et al., 2014). A study was carried out by Irani et al. which demonstrated 
that the cell death of HCT-116 cells (human colorectal cancer cells) was increased 
significantly by CAP treatment in the present of ~55 nm citrate-capped AuNPs (Irani et 
al., 2015). However, despite all the evidences for the synergistic anti-cancer effects 
between CAP treatment and AuNPs, the underlying mechanism of this synergistic 
cytotoxicity was yet to be well understood.  
To date and to the best of our knowledge we are the first to demonstrate the detailed 
mechanism behind the synergistic anti-cancer effects between CAP treatment and AuNPs 
and gave a strong hypothesis with regards to CAP facilitated permeability of drugs. As 
described in Chapter 2, we have successfully determined that CAP treatment promotes 
the uptake of AuNPs into U373MG cells via ATP-dependent active pathway and 
eventually accumulated in lysosomes, and published a peer-reviewed paper based on this 
work (He et al., 2018). The enhanced accumulation of AuNPs in U373MG cells was first 
observed under optical microscope. Then we have tracked the accumulation and uptake 
of AuNPs into cells with or without CAP treatment using a variety of technique and 
devices, including AAS, confocal microscope, flow cytometry, electron microscope and 
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Zetasizer, combined with a panel of inhibitors and fluorescent probes, including ATP 
inhibitor sodium azide, antioxidant NAC, lysosomes tracker. Using AAS, we have 
successfully tracked the accumulation of AuNPs inside U373MG cells and demonstrated 
that the uptake of AuNPs enhanced by CAP treatment was an active pathway. Using 
confocal microscope, the majority of intracellular AuNPs has been confirmed to located 
in lysosomes which presented significant greater accumulation with CAP treatment. It 
should be noted that antioxidant NAC didn’t significantly decrease the stimulated uptake 
of AuNPs by CAP, which may demonstrate that short-lived species or NAC-insensitive 
reactive species played the main role in the stimulation of cellular uptake. Using indirect 
CAP treatment also demonstrated that physical effects induced by CAP also didn’t play 
main role in the increased uptake of AuNPs into U373MG cells. 
However, we didn’t fully answer the questions behind the synergistic cytotoxicity 
between CAP treatment and AuNPs. It is worth to understand the mechanism behind the 
synergy which will be useful for developing more efficient deliveries of nanoparticles 
and pharmaceuticals into cancer cells for tumour therapy and diagnosis and other relevant 
cancer therapies that induce an increase in extracellular ROS. Therefore, we continued 
the investigation of the synergistic effects between CAP treatment and AuNPs and tried 
to precisely identify the CAP-affected cellular pathways involved in the enhanced uptake 
of AuNPs.  
The current study of Chapter 3 demonstrated, for the first time, that the synergistic effects 
of nonfunctionalised AuNPs combined with CAP, to glioblastoma cancer cells, is via the 
clathrin-mediated endocytosis stimulated by CAP-induced membrane repair processes. 
In Chapter 3, numerical modelling of the uptake of gold nanoparticles into U373MG 
glioma cells predicted that CAP may introduce a new uptake route. We have 
demonstrated that cell membrane repair pathways play the main role in the stimulated 
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new uptake route, following non-toxic doses of CAP treatment (30 s, 75 kV). CAP 
treatment induced cellular membrane damage, mainly via lipid peroxidation as a result of 
ROS and RNS generation. Membranes rich in peroxidised lipids were then trafficked into 
cells via membrane repairing endocytosis. We confirmed that the enhanced uptake of 
nanomaterials is clathrin-dependent using a batch of specific chemical inhibitors and 
silencing of gene expression. Therefore, we have hypothesised that CAP-stimulated 
membrane repair increases endocytosis and accelerates the uptake of gold nanoparticles 
into U373MG cells after CAP treatment. In Chapter 3, our data has demonstrated the 
utility of CAP to model membrane oxidative damage in cells and characterised a 
previously unreported mechanism of membrane repair to trigger nanomaterial uptake. 
This research article has been published in the peer-reviewed journal ‘Scientific Report’  
(He et al., 2020). 
Although there has been study hypothesis that after uptake via receptor-mediated 
endocytosis, epidermal growth factor (EGF)-conjugated AuNPs combined with CAP 
induced DNA damage and selective apoptosis of A549 human alveolar basal epithelial 
cancer cells (Kim et al., 2017). This hypothesis was based on the decreased uptake of the 
EGF-conjugated AuNPs when incubated at 29.5 ℃ compared to 37 ℃, and that the EGF 
ligand usually triggers recruitment of the EGF receptor to clathrin-coated pits which has 
been demonstrated to be the endocytosis pathway of uptake of EGFR-ligand complex, as 
well as that AuNPs are mainly internalized via clathrin/ caveolar-mediated endocytosis, 
phagocytosis, macropinocytosis, and pinocytosis (Kim et al., 2017). However, this study 
didn’t directly demonstrate that the increased uptake of AuNPs was via receptor-media 
endocytosis and also used ligand-conjugated nanoparticles which is different compared 
to our study. There is another study demonstrating that iron-dependent cold plasma-
induced oxidative stress can stimulate significant increase in fluid-phase endocytosis, 
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lysosome biogenesis and autophagy, therefore inducing highly selective anti-proliferative 
activity against rat SM2 (sarcomatoid subtype) malignant mesothelioma cells (Shi et al., 
2017). However, the study presented that the CAP treatment decreased transferrin 
receptor-1 which is in contrast with our study. We used transferrin conjugated with Alexa 
Fluor™ 546, an early endosome marker, and confocal microscope to investigate the 
endocytosis enhanced by CAP treatment and demonstrated that the quantification of 
transferrin uptake was significantly increased within 5 min after CAP treatment compared 
to control group. The contrast may be due to the variety of different cell lines and different 
dose of CAP generated from distinct devices. 
As seen in Chapter 2 and 3, the ROS and RNS induced lipid peroxidation played an 
important role in the CAP-induced endocytosis and oxidization stress. It should be noted 
that ROS and RNS play important roles in many other anti-cancer interventions, including  
phototherapy (Zhou et al., 2016), ultrasonic therapy (Yu, Wang and Mason, 2004), as 
well as some types of chemotherapy (Kasiappan and Safe, 2016), as especially in this 
most common cancer treatment, radiotherapy (RT) (Manda, Nechifor and Neagu, 2009). 
As mentioned in Chapter 1, the reactive species is a double-edged sword for cancer cells 
and can be utilised for developing efficient therapeutic strateges against cancer cells. 
ROS-inducing chemotherapy agents and radiation therapy are now the most common 
anti-cancer innovation involved with reactive species. 
Radiation therapy is one of the primary treatments for neoplasm using high-energy 
ionizing radiation (IR). The acting mechanisms of RT include the generation of free 
radicals or the direct deposition of energy by IR. Due to photoelectric effects and 
Compton effects, the energy track of IR is composed by electrons in matters, which 
induce ionization and excitation (Rehman et al., 2015). In cells, the electrons interact with 
water and generate free radicals, including ROS and RNS (Mikkelsen and Wardman, 
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2003). Damage is induced by the ROS/RNS-caused oxidative stress and lesions of 
cellular macromolecules, including DNA, protein and lipids (Nikitaki et al., 2016). 
Meanwhile, the cell killing effect is also related to the direct deposition of energy by IR, 
which is highly penetrating and able to cause irreparable damage to genetic materials 
even at low dose (Rothkamm and Löbrich, 2003). However, due to the high cytotoxicity 
and non-targeted effects of radiation, the radiation must be accurately delivered to tumour 
tissue while sparing normal tissue to improve PFS, OS and life quality of patients 
(Nikitaki et al., 2016). Although ionizing radiation induces the generation of intracellular 
ROS and free radicals (Magné et al., 2006; Graves, 2012), the cytotoxicity of radiation is 
mainly owing to the photons-directly-caused DNA damage (Mikkelsen and Wardman, 
2003; Graves, 2012), even at low doses, resulting in irreparable damage to cellular genetic 
material and cell death (Rothkamm and Löbrich, 2003). Compared to radiation, CAP can 
produce longer lived reactive species, selectively inducing apoptosis to cancer cells 
through signalling pathways, generating low-energy species which is relatively low-toxic 
to normal cells. Due to the regular ROS level in normal cells, the antioxidant system in 
normal cells present higher resistant to CAP treatment compared with cancer cells. 
However, it has been demonstrated that CAP treatment can induce proliferation arrest, 
DNA damage and a senescence phenotype to healthy cells without killing them. 
Therefore, the dose of CAP treatment should be carefully controlled on targeted 
cancerous tissue. 
CAP devices are low cost, easy to control and the field is undergoing a rapid pace of 
innovation and advancement (Ishaq, Evans and Ostrikov, 2014). Therefore, the potential 
of CAP for developing more efficient and lower side-effects human healthcare is 
significant and promising. On the other side, there are many research questions related 
with CAP treatment awaiting to be solved for the clinical application of CAP for cancer 
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therapy. For instance, there are a variety of CAP devices which have been investigated in 
research. Due to high diversity (voltage, currency, frequency, gas types, various 
components and designs of devices),  the comparability between CAP devices is yet to 
be further improved. Meanwhile, the doses of CAP generated from disparate devices are 
difficult to be precisely identified by time of treatment. The identification of exact 
reactive species, especially short-lived reactive species, have not been solved yet. CAP 
only has been investigated for cancer therapy recently, thus the long-term effects of CAP 
treatment are yet to be fully explored. Those are the challenges facing the field of plasma 
medicine and require more efforts to eventually implement the CAP therapy in the clinic.   
In Chapter 2 and 3, the focus of the project was investigation of the synergy between 
AuNPs and CAP to understand the mechanism behind CAP and AuNPs synergy. In 
Chapter 4, the focus was brought to prodrugs and CAP treatment. We first screened all 
prodrug candidates using culture medium with pyruvate but didn’t observed leading 
candidates with significant synergistic cytotoxicity. We have realized that pyruvate, a 
common component of culture medium, may present negative effects in our experiments 
as antioxidant (Ramos-Ibeas et al., 2017). Therefore, in Chapter 4, we screened all 47 
prodrug candidates again and successfully identified that two compounds, JW-04-061 
and JW-04-057a, provided by Prof. John Stephen, have significant synergistic 
cytotoxicity in combination with low dose CAP treatment, using culture medium without 
pyruvate. The synergistic effects between JW-04-061 and CAP treatment was further 
investigated and will be published as peer-reviewed article in collaboration with Prof. 
John Stephen. Other prodrugs, provided by Prof. Andriy Mokhir, Prof. Gérard Jaouen 
and Prof. Seth M. Cohen, all contain typical ROS-trigger groups but presented no 
significant synergistic cytotoxicity in combination with low dose CAP treatment, which 
may be due to  the natural ROS level in U373MG cancer cells being high enough for 
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prodrug activation without CAP treatment. But we still have identified that few prodrug 
candidates, including P286, P686, P53, P722, P258, P257, present high anti-cancer 
effects on their own. Thus, those candidates can be used in future research to test their 
cytotoxicity and specificity in healthy cells and cancer cells to discover new prodrugs.  
In conclusion, we investigated the mechanism behind the synergistic anti-cancer effect 
between CAP and AuNPs and provided solid evidence that the membrane oxidation 
damage induced clathrin-dependent endocytosis played main role in the accelerated 
uptake of AuNPs into U373MG cells by CAP treatment. In Chapter 4, we screened all 
prodrug candidates and have identified two leading candidates that possess most 
significant synergistic cytotoxicity to U373MG cells in combination with CAP treatment. 
We also have provided preliminary evidence that reactive species generated in CAP-
treated culture medium did play the main role in the activation of the leading prodrug 
candidate JW-04-061, which leads to the synergistic cytotoxicity. This thesis provides 
evidence to understand how CAP treatment induces a variety of responses of glioma cells, 
especially stimulated endocytosis, which can be also applied in enhancing permeability 
and tumour accumulation of other therapeutic and diagnostic agents for development of 
efficient cancer therapies and diagnosis. Meanwhile, two novel prodrugs that have 
synergy with CAP treatment have been identified and investigated. However, new 
research questions have been brought to light by this study. Further studies are required 
to fully elucidate what cell death pathways are involved in the synergistic cytotoxicity of 
AuNPs and CAP. Investigation of this novel combination therapy using prodrug-loaded 
AuNPs and CAP treatment in vitro, in 3-dementional cancer sphere model, and in vivo 
also can be investigated in future projects for development of practical innovations in 
clinical therapy. For in vivo treatment, alternative CAP devices, such as plasma jet or 
plasma needle, are required to deliver CAP to targeted area. The cell death pathways 
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involved in the anti-cancer effects of prodrug leading candidates combined with CAP 
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7.3 Appendix III Supplementary Information for Chapter 2 
Figure S1. UV-vis absorption spectrum of 100 μg/ml AuNPs dispersed in water. The 
AuNPs solutions were treated with CAP at 75 kV for 30 s, or untreated. 
 
Table S1. Raw dataset of the Alamar Blue assay. U373MG cells were treated with 
different concentrations of AuNPs (0-800 μg/ml). After incubated for 48 h, cell viability 
was analysed using the Alamar Blue assay. The table presented the raw date produced by 
the Microplate Reader, Synergy HT (BioTek). 
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7.4 Appendix IV Supplementary Information for Chapter 3 
Supplementary Figure S1. (a) Electro energy distribution function (EEDF) of CAP; (b) 
Fluorescence level of intracellular oxidised H2DCFDA was measured via Flow cytometry, 
the analysed average of mean FL1-A value. 
Supplementary Figure S2. The fluorescent integrated density of non-oxidised BODIPY 
was quantified using ImageJ. The statistical significance was assessed by one-way 
ANOVA with Tukey’s multiple comparison post-test (*P<0.05, **P<0.01, ***P<0.001, 
****p<0.0001), n≥50, see Appendix IV Supplementary Table S1 for original data 
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Supplementary Figure S3. The U373MG cells were loaded with C11-BODIPY (green), 
then co-stained with and LysoTracker™ Deep Red (red) after CAP treatment (30 s, 75 
kV) and observed under confocal microscope, three images are presented in the figure. 
White arrows point out examples of co-localisation between oxidised C11-BODIPY and 
lysosomes. 
 
Supplementary Figure S4. After incubation with various inhibitors as indicated, 
U373MG cells were treated CAP for 0, 30 s at 75 kV and then loaded with transferrin for 
5 min or 100 μg/ml AuNPs for 3 h respectively before observing under confocal 
microscope, then the fluorescence integrated densities were quantified using ImageJ. The 
statistical significance was assessed by one-way ANOVA with Tukey’s multiple 
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comparison post-test (*P<0.05, **P<0.01, ***P<0.001, ****p<0.0001), n≥50. 
 
Supplementary Figure S5. Oxidized C11-BODIPY emission was measured with same 
threshold to highlight vesicle-like condensed area. (a) Sample of CAP treated cells; (b) 
Sample of untreated cells; (c) With same threshold, the fluorescence integrated densities 
were quantified using ImageJ. The statistical significance was assessed by unpaired T-











The intensity of O3 production may explain why there was no detectable emission of NO, 
O, NOx and low intensities of •OH and N2+ in Figure 12a, as the free electrons were likely 
quenched before reaching higher energetic states by the interaction and formation of O3. 
Reaction mechanisms (1-4) can further explain how the formation of NO, NOx, and O 
was hindered. In these reactions, M is a third body atom or molecule that, in this case, 
may be N2* or O2. 
O + O2 +  M
∗  → O3 +  M    (1) 
M∗ + NO → M + N + O    (2) 
O + H2O → 2 OH
•      (3) 
2N + M → N2 +  M     (4) 
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Supplementary Figure S6. Uptake and subcellular localization of AuNPs observed by 
confocal microscopy. After CAP treatment (0, 30 s), U373MG cells were incubated with 
100 μg/ml AuNPs for 3 h. Early, late endosomes and lysosomes were stained using 
CellLight™ Early/Late Endosomes-RFP (Marked as orange channel in images) and 
216 
 
LysoTracker™ Green DND-26, respectively. The far-red emission of AuNPs (Red) was 
excited using 633 nm laser. 
Supplementary Table S1. 
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1007005 595270 161873 295272 
982070 610424 155628 306654 
1320705 445595 458594 390399 
946150 1463426 399135 890896 
1342500 708723 462811 741382 
653886 888079 196388 524934 
499775 373856 190853 306468 
875556 1477152 153302 390161 
1037540 653049 163432 651081 
906223 1078557 142877 187065 
1097569 675892 206789 906811 
1207059 402444 37404 312273 
718964 1083730 109317 617780 
559771 930197 236604 468648 
475472 898191 142135 296259 
747381 331716 270552 389688 
807312 532198 82436 195602 
707968 817839 84652 506283 
840742 414865 168778 451699 
777642 749632 364207 303635 
1022745 879071 100734 431292 
1228769 1084756 114519 701205 
2064986 412708 49002 444981 
697882 884861 273032 223330 
1220345 566726 58729 423576 
775782 667011 169249 569403 
1182171 895365 184585 660069 
812884 497905 198073 227918 
940440 603690 154684 478087 
555395 684168 441372 254274 
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1327438 371186 274210 362961 
718786 502118 245082 398478 
642920 415450 228162 325251 
1050097 1489285 437520 346672 
834466 250668 350830 479690 
 247114 199513 1122291 
 460969 184087 191401 
 345379 260743 335414 
 325823 234688 346672 
 342280  303883 
 694899  306629 
 607436  1149608 
 821919  150280 
 1413574  456893 
 729336  283002 
   269830 
   234559 
   524097 
   372300 
   626520 
   889340 
   691489 
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Supplementary Table S3  
Integrated Density of Transferrin  
Untreated CAP30s 
only 
Pitstop Pitstop+CAP CPZ CPZ+CAP 
108598 295322 64736 100433 38802 56788 
43443 108782 38572 31750 24310 83128 
77433 251156 47517 76352 39598 45220 
94477 84583 25591 100240 294486 19690 
86584 65841 35782 71304 68324 13416 
98793 91549 39735 28401 51158 9444 
102070 163102 100772 44936 53180 16446 
129770 156221 40368 22378 72708 29576 
112724 81989 30864 12836 68844 5404 
60643 207294 74733 17119 131656 7596 
70525 80463 76017 26816 72856 4568 
110091 86986 75272 97123 62814 21856 
139093 145578 91199 43380 119252 2280 
98220 63260 29856 83012 26884 7814 
133442 69745 115762 17713 51452 129394 
143649 110816 105188 49522 28458 117634 
75022 123363 43457 54983 71198 30926 
123196 134115 50026 18278 74608 77612 
70338 228112 7877 59622 26936 68470 
55592 140503 69660 29797 3384 88596 
71972 121850 99571 77787 7454 30684 
168227 158303 62211 74743 34034 75958 
93020 121401 89301 78765 19250 95484 
129316 70365 98921 47823 15276 103746 
219 
 
110653 146501 86540 32383 49392 9158 
88591 129369 84316 42288 15354 4520 
122648 82011 80932 52147 19722 25244 
75639 98961 76763 42159 51914 17308 
131539 112977 188739 101745 54704 50974 
157044 76354 30436 28371 41096 16284 
163738 94709 46748 63526 36212 5584 
78925 51942 34317 91475 23016 19136 
111987 177314 59776 41096 19956 7634 
125506 94675 35976 56949 17996 30856 
125495 129185 57772 69132 31342 84574 
120301 127507 56559 99148 19040 30892 
105738 90869 90776 41119 56680 9672 
48458 119518 32429 59855 24088 12082 
68317 113258 58616 47787 42838 37932 
36999 247984 18765 73103 18410 4872 
72117 277862 67164 27352 9752 61354 
89229 184301 72684 37608 22664 29434 
45164 167793 38795 41806 21144 36554 
77146 317787 49816 72871 63528 27876 
88215 213580 12847 87006 15258 69646 
91529 72160 56799 66654 18400 59842 
80253 60324 26547 49931 64260 23916 
63880 97864 15265 46675 20094 14374 
120907 156754 56795 29802 18770 79040 
86245 125687 23657 64467 27556 61076 
   12833 17776 14866 
   28102 69252 85876 
   38183 19000 15354 
   29502 34386 8102 
   37891 8592 38704 
   61498 11670 34414 
   51505 37184 78286 
   35668 8968 16564 
   24266 21180 71468 
   51119 90982 10220 
    22680 19342 
    42116 16544 
    7278 9582 
    6646 77040 
    59824 30404 
    8114 54566 
    19838 48010 
     7918 
     16944 
     6710 
     7116 
     34934 
     7930 
     67322 
     8512 
     5804 
     8342 
     26376 
     33834 
     2612 
     17928 
     20240 
     9364 
     22084 
     53872 
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     38896 
     26456 
     15434 
     43858 
     11738 
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
 












+CAP 131419 66932 97900 163871 101792 133841 196235 124569 
124614 93007 129504 187302 133971 118480 138704 135077 
69503 97275 110897 280194 65462 127431 29079 51297 
75277 46598 90356 105230 147728 283770 72203 88474 
76750 77640 104776 76422 147365 103548 64304 112269 
18178 92103 73574 85766 68864 51402 72146 45995 
81444 24984 159303 113291 72395 55713 83737 14594 
88041 95210 124298 90004 101640 94243 54808 47209 
57794 98855 108271 232008 96453 244560 33708 144728 
51151 89031 72235 76414 174993 104571 31934 49935 
76552 75078 33351 137916 271282 93475 64961 123415 
86342 85701 30163 116268 221595 142366 56665 114787 
40633 59098 62316 77831 83503 113373 48094 163106 
97243 91913 65030 77608 145251 94037 30674 99006 
36007 93666 109848 134224 99669 83792 97877 104122 
79613 93835 95871 82976 72559 161527 99403 145760 
79863 73324 106984 164104 202898 247658 60424 131902 
115776 69286 157208 74697 51052 82664 76203 117916 
47129 35314 109433 78977 58917 65763 37386 43884 
36055 46718 27594 83753 112259 87005 81334 139639 
87390 83701 79618 146374 140919 179148 29538 137618 
62452 56757 89721 152046 163308 75257 65159 73523 
93547 68512 194085 135891 67768 260961 79248 115470 
74815 43701 36909 127681 69400 94462 34570 38530 
65652 38500 50967 92144 52293 252478 101412 214459 
90255 46948 159055 91692 74286 71411 40862 55017 
71303 102306 165479 64158 119649 159244 30034 72765 
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50020 90653 48369 143926 121836 167913 78864 82769 
76361 105447 39814 83297 157275 103238 21499 145664 
61373 48421 82143 93936 100709 117632 87521 103887 
72042 14139 117174 100813 268448 56085 32872 96235 
89546 27184 96452 101386 96458 122851 86774 107471 
94135 58249 61675 144732 200374 244874 108724 73740 
70875 29039 152249 50729 133156 172584 99005 138795 
46285 118411 51630 72558 123251 93479 91400 109758 
74820 60569 178335 116879 66756 99088 162496 97441 
64908 69129 58091 92915 148409 156027 59966 55005 
49964 19395 109739 150147 156027 139595 83504 122417 
25266 97511 122864 126267 116189 127740 79816 96430 
12030 99651 62501 88480 131616 188948 70233 105109 
68275 94682 115067 70907 145548 247489 54977 82412 
24230 53849 89403 87317 64925 129827 20755 137153 
48315 77480 144868 91462 99657 129957 87959 62907 
56293 124595 133432 158029 129320 108170 113851 62485 
46775 125449 143229  126041 113664 9751 139596 
53149 67036 50177  113392 224130 195704  
61754 101836 60733  69885 249655 205460  
18804 127051 147230  81771 112130 71758  
23564 78954 74873  256252 137488 60650  
46598 56597 64963  185763 246213 102646  
  173794  90235 99266 104360  
    87308 88875 72262  
    34485 121148 62646  
    64651 215831 106858  
    116152    
    160153    
 
Integrated Density of AuNPs 
Untreated CAP 30s Pitstop Pitstop+CAP CPZ CPZ+CAP 
5516 22261 6083 3792 7990 8366 
3581 12306 4177 6099 1863 1957 
27847 10762 1746 2099 1486 8966 
15965 3480 3011 1812 1434 6266 
2647 10667 4032 1975 5801 1452 
3198 4966 4808 6106 4778 3468 
6305 8758 3805 2532 7212 2421 
5788 20948 7747 1728 5556 2566 
3919 8903 7417 3160 5631 3101 
17942 10360 1322 3273 4089 4259 
4457 17401 2229 2863 2949 2871 
18099 50518 4509 4671 4297 3558 
5395 21642 5231 5348 2607 3562 
10992 9222 2962 2937 5111 7809 
16843 11587 2971 4733 2967 7133 
7621 14788 2567 3325 8772 4191 
17892 13311 6843 5923 5787 3747 
21501 20808 1608 7813 5110 8074 
2455 12197 10176 2810 3289 5436 
8796 8593 6170 2574 2880 3060 
11688 10932 1970 9692 7444 2601 
3500 15539 3286 2373 9698 3402 
13317 20754 8646 4150 3923 3123 
4841 8846 2766 8823 5399 2857 
2679 4831 1331 4191 2188 5444 
17626 16624 5692 1857 5285 6896 
1669 10846 4185 3482 4443 3207 
8186 16627 5613 4884 4856 4577 
222 
 
9202 19013 6779 10185 3336 3296 
9836 18567 5571 4395 7300 3899 
8877 12700 3958 2648 2034 3728 
10929 10548 3951 1977 2889 2222 
8565 6980 2132 4485 5657 3424 
7736 12991 2702 5126 3539 6041 
2356 15723 1284 4665 3242 3298 
2851 29901 2677 5481 7771 8405 
23594 7900 5960 2430 3372 4964 
14115 24781 4984 4714  4473 
5866 12827 7586 3752  1527 
25137 11509 4864 4573  3776 
11108 31897 9875 1779  4807 
9864 4429 5750 2711  2822 
16203 5919 6359 4560  4205 
11111 7653 6231 3132  3023 
9532 14639 4619 1628  10408 
8395 13590 1388 6677   
11415 8222 4931 12145   
11279 15100 2072 22026   
11099 26498 3939 5527   
13153 14704 3847 2204   
12553 5136 2878 2964   
13217 17050 5958 3948   
17633 9468 6171 7410   
4742 7312 9188 2197   
11052 4848 3643 1465   
15608 13345 1471 5365   
5281 10442 8934 4764   
15270 17738 7551 1713   
12153 10179 2156 2552   
14067 7909 9601 2816   
13005 12894 15586 1916   
6557 10555 7303 6227   
14369 29626 3134 7636   
28194 9385 3070 16947   
4478 13564 6450 2184   
7769 26029 4504 5572   
15100 18355 1676 2971   
14411 8849  4198   
5912 6822  3081   
9159 10362  8244   
10064 12428  6451   
22400 9474  2825   
15100   733   
3145      
5178      
16426      
27029      
8473      
6730      
4345      
9773      
 













14925 45932 7861 8525 10364 5563 4919 12384 
13177 6400 3124 8659 3826 6803 6343 8314 
6253 6224 7004 17234 5294 2748 8187 5489 
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4841 21801 8737 11437 8912 3850 3139 4808 
17947 15017 12423 6792 14276 17048 5059 13403 
4950 6373 6463 11330 9686 4090 1863 8839 
5319 9478 6621 12569 8051 8453 4450 13091 
11753 17365 9855 29753 8871 4153 2650 24387 
8816 10640 9297 5810 5919 5268 2781 14911 
3601 12295 15754 9558 4132 5229 13092 6714 
4623 5898 2416 10012 29822 13267 1360 11432 
14331 6364 8974 12247 9759 8702 1107 7042 
3477 26822 26687 4487 12254 6550 2166 8005 
10509 18101 13251 11413 10175 8515 3635 7039 
6237 15876 3005 24979 4763 9959 5746 10338 
7240 13389 3677 26444 20656 8809 12468 5008 
7500 33586 1610 20449 5935 4552 7872 8225 
3569 10446 21888 11668 8371 3501 2171 8509 
3443 12871 16131 9829 11152 7595 4149 5992 
17505 6565 12798 22269 4376 10268 13666 8063 
11009 10467 10002 7997 12687 6862 4572 9861 
14142 5683 20026 21671 7365 5081 9826 11328 
12541 14049 4944 4504 5930 12182 8787 11552 
10120 17180 8411 10937 17596 7779 5460 13135 
6846 7140 17666 14563 8740 6003 14653 9408 
7556 13706 7391 14822 15900 5778 16330 5093 
8475 14675 9217 19264 4593 18306 7051 12713 
15018 18780 14439 39774 2451 13608 28750 7968 
24729 9029 10800 12115 3554 17698 12822 4766 
6180 9180 10289 9980 3791 2271 7980 5260 
8662 7303 4240 10558 13315 8238 2636 8735 
16450 17269 5030 10707 5436 6113 4535 12229 
9587 5057 5329 7643 10356 3952 4568 7559 
11228 14892 4067 18347 1700 8427 2574 13070 
11317 11273 27835 10790 5436 5052 2969 12427 
5662 3751 21257 9966 3554 11620 2219 15870 
16028 6097 5817 10412 2462 6685 3242 8116 
9972 7096 5579 11849 15179 5245 2159 13472 
9829 14357 19417 11330 6384 5810 5537 6946 
13112 5305 1497 7456 6338  20414 7951 
14690 4870 5149 10368 10377  4421 19438 
14599 6517 6111 8107 4391  9412 9825 
3840 6081 9586 12417 9562  11953 5042 
8961 10141 8745 16088   5431 8533 
7528 14356 9156 18577   2471 24524 
5024 10728 14895 25898   34529  
10471 4837 10299 16529     
4401 12326 10661 9265     
9953 11511 3269 13413     
 8079 3960 7929     
 20982 6973 9668     
 9719 11519 10979     
 6663 6567      
 16067 3955      
 9929       
 26445       
 13543       
 13793       
 12121       
 13008       
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Integrated Density of AuNPs 






540329 172547 71657 81386 
317286 431535 52885 26174 
366683 78334 50113 83853 
118864 227289 98205 62198 
389856 182028 58882 113274 
260748 95261 213664 176140 
255370 67797 32246 90214 
143714 155367 84077 155663 
254835 143994 18060 167904 
241522 409060 130518 52593 
173393 91173 82556 22219 
437882 98606 20741 19181 
301708 372871 42321 16830 
283998 42174 50000 36912 
529897 192966 22797 11897 
132739 43429 32307 67489 
325045 171486 111229 22481 
256487 155863 165385 45392 
225093 218957 243576 12669 
459960 332020 115717 14759 
242832 163495 32769 59857 
102314 178575 134059 29691 
274004 43099 91085 36894 
319820 116779 96918 46448 
144878 33679 42816 24724 
313094 281964 92220 41174 
215681 474462 163157 12320 
426863 78871 107430 42693 
169499 25139 78092 54199 
449778 157231 44965 26720 
207286 25451 46103 68806 
600642 105195 99071 50186 
191247 124412 169342 18736 
175692 128267 80229 16030 
167735 312896 36048 55855 
195195 129867 76657 106951 
195351 127963 117916 17979 
131726 352128 22666 39283 
328548 257630 66817 17452 
212497 116701 53062 34551 
453971 134485 35270 10871 
318022 113204 33485 43176 
335974 203686 37665 6543 
135597 81301 39651 20391 
226104 258075 18179 9906 
136796 117997 56467 43154 
168061 189202 26238 33298 
530325 354143 16544 6978 
310895 179360 42583 10313 
156015 249807 10222 7391 
118700 104282 19974 18762 
122974 189066 53493 56664 
133195 84785 27174 8288 
267536 141462 21953 72528 
200762 345977 148609 24130 
299249 77114 73347 13301 
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94514 47361 62139 18333 
293151 43665 54334 20520 
176776 9389 4625 17705 
 270307 6653 38519 
 31190 46708 28687 
 257884 50733 15938 
 155736 49224  
 345060 17503  
 43585 15541  
 81386 3876  
 23622   
 75993   
 65180   
 568575   
 318601   
 174400   
 52373   
 23718   
 59279   
 38939   
 75419   
 98606   
 24077   
 75776   
 41710   
 22592   
 70125   
 45832   
 98998   
 114681   
 126842   
 72896   





7.5 Appendix V Supplementary Information for Chapter 4 
Supplementary Figure S1. The average reading of Alamar Blue assay performed within 
the plates treated with CAP and Cmpd 6. The control and CAP 30s treated groups 
presented in this figure were incubated with just culture medium without compounds for 
48 h before Alamar Blue assay, demonstrated that this CAP treatment decreased around 
50% of cell viability.  
 
Supplementary Figure S2. The dose response curves of JW-04-061 and JW-04-057a 





Supplementary Figure S3. Determine the synergistic cytotoxicity between CAP 
treatment and prodrug JW-04-061. 
(a) The culture medium was treated with CAP for 30 s and storage overnight. The 
U373MG cells were then incubated with prodrug JW-04-61 in overnight storage CAP-
activated medium for 48 hours. (b) U373MG cells were treated with CAP and then 
incubated in the culture medium that has CAP-treated together for 0-5 h, and then 
incubate with fresh medium containing prodrug JW-04-061. (c) The culture medium was 
228 
 
supplemented with 0.1 mg/ml catalase and then added into the 96-well plate during CAP 
treatment and incubated with U373MG cells for 48 hours. 
Supplementary Table S1. Structures of compunds provided by Prof. Andriy Mokhir, 










Supplementary Table S2. Structures of compunds provided by Prof. Seth M. Cohen, 
























Supplementary Table S3. Structures of compunds provided by Prof. Gérard Jaouen, 
































































Supplementary Table S4. Structures of compunds provided by Prof. John Stephens, 
























































Supplementary Table S5. List of compounds that have been published. 
Code Publication Source 
P5 
1. Metal carbonyl tracers and the ferrocifen family: Two facets 











Synthesis, Cytotoxicity, and COMPARE Analysis of Ferrocene 
and [3] Ferrocenophane Tetrasubstituted Olefin Derivatives 





Comparative toxicity of [3] ferrocenophane and ferrocene 





Synthesis, Cytotoxicity, and COMPARE Analysis of Ferrocene 
and [3] Ferrocenophane Tetrasubstituted Olefin Derivatives 





A ferrocenyl derivative of hydroxytamoxifen elicits an estrogen 






Synthesis, Cytotoxicity, and COMPARE Analysis of Ferrocene 
and [3] Ferrocenophane Tetrasubstituted Olefin Derivatives 







Comparative toxicity of [3] ferrocenophane and ferrocene 









A new series of ferrocifen derivatives, bearing two aminoalkyl 





Phthalimido–ferrocidiphenol cyclodextrin complexes: 





Synthesis, Cytotoxicity, and COMPARE Analysis of Ferrocene 
and [3] Ferrocenophane Tetrasubstituted Olefin Derivatives 





A new series of ferrocifen derivatives, bearing two aminoalkyl 





Comparative toxicity of [3] ferrocenophane and ferrocene 





Comparative toxicity of [3] ferrocenophane and ferrocene 





THE FERROCIFEN FAMILY AS POTENT AND SELECTIVE 






Atypical McMurry Cross-Coupling Reactions Leading to a New 






Comparative toxicity of [3] ferrocenophane and ferrocene 




















Hydrogen Peroxide Activated Matrix Metalloproteinase 












Hydrogen Peroxide Activated Matrix Metalloproteinase 



















Aminoferrocene-based prodrugs and their effects on human 





Aminoferrocene-based prodrugs and their effects on human 





Synthesis of pyrazolopyrimidinones using a “one-pot” approach 






Synthesis of pyrazolopyrimidinones using a “one-pot” approach 
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